CLINICAL STUDY PROTOCOL  
NCT Number:  
Study Title:  
Study Number:  [STUDY_ID_REMOVED]
SHP620-303
Protocol Amendment  and Date: 
Amendment 9  (Version
 10.0): 15 September  2021A Phase 3, Multicenter, Randomized, Double-blind, 
Double-dummy, Active-controlled Study to Assess the 
Efficacy and Safety of Maribavir Compared to Valganciclovir 
for the Treatment of Cytomegalovirus (CMV) Infection in 
Hematopoietic Stem Cell Transplant Recipients
For non-commercial use only
TAKE DA DEVELOPMENT CENTER AMERICAS, INC
TITLE: A Phase 3, Multicenter, Randomized, Double -blind, Double -dummy , 
Active -controlled Study  to Assess the Efficacy  and Safety  of Maribavir 
Compared to Valganciclovir for the Treatment of Cy tomegalovirus 
(CMV)
Infection in Hematopoietic Stem Cell Transplant Recipients
DRUG: SHP620
IND: IND 051001
EUDRACT NO.: 2015-004726-34
SPONSOR: Takeda Development Center Americas, Inc (TDC Americas)
95 Hay den Avenue, Lexington, MA 02421 USA
PRINCIPAL/
COORDINATING
INVESTIGATOR:Multicenter
PROTOCOL 
HISTORY:Amendment 9 (Version 10.0): 15September 2021
Amendment 8 (Version 9.0): 02 July  2021
Amendment 7 (Version 8.0): 25 March 2021
Amendment 6 (Version 7.0): 07 December 2020
Amendment 5 (Version 6.0): 12 February 2020
Amendment 4 (Version 5.0): 05 February 2019
Amendment 3 (Version 4.0): 01 September 2017
Amendment 2 (Version 3.0): 01 June 2017
Amendment 1 (Version 2.0): 02 March 2017
Original Protocol (Version 1.0): 04 August 2016
This document contains confidential and proprietary information of Takeda and is disclosed pursuant to 
confidentiality and nondisclosure obligations. This information should be used solely for the purposes for which it 
was provided and should not be copied, shared w ith, or disclosed to any third party without the express w ritten 
consent of Takeda.
PROTOCOL: SHP620 -302
For non-commercial use only
Takeda CONFIDENTIAL Page2 
Maribavir 
Clinical Study Protocol: SHP620-302 Protocol Amendment 9 15 Sep 2021 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Takeda) Approval 
, MD 
Investigator's Acknowledgement 
I have read this protocol for Takeda Study SHP620-302. 
Title: A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled 
Study to Assess the Efficacy and Safety ofMaribavir Compared to Valganciclovir for the 
Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant 
Recipients 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonisation guidelines on Good Clinical 
Practice and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: The investigator completes the bottom section of the 
(please hand print or type) protocol signature page 
Signature: Date: 
For non-commercial use only
Takeda CONFIDENTIAL Page 3
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
(AMENDMENT 8)
Noteworth y changes to the protocol are captured in the table below. The protocol has been 
amended to update the information on drug interactions and contraindications, consistent with 
the current Investigator’s Brochure .
Other minor editorial revisions (including changes for consistency  and clarity ) are not described 
in this table.
Protocol Am endment
Summary of Changes Since Protocol Version 8.0 (Protocol Am endment 7)
Amendment Number
9Amendment Date
15Septem ber2021Global
Description and Rationale for Change Section(s) Affected by Change
Updated description of drug interactions consistent with the 
latest Investigator’s BrochureSection 1.2.1 Pharmacokinetics, Metabolism, and 
Drug -Drug Interactions
Section 4.5.1 Reasons for Discontinuation and/or 
Withdraw al
Section 5.2.1 Permitted Treatment 
Section 5.2.2 Prohibited Treatment
For non-commercial use only
Takeda CONFIDENTIAL Page 4
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
EMERGENCY  CONT ACT IN FORMA TION
Please refer to Section 8.2.2 for information on serious adverse event reporting procedures.
For protocol -or safety- related issues (but with no information that would unblind the 
study treatment assignment) during normal business hours 8:00am - 5:00pm (local time 
per region) , the investigator must contact the PPD blinded medical monitor:
Hotline numbers (24 hours a day /7days a week):
North America: 
Europe, Middle East, Africa (EMEA)/Asia- Pacific (APAC): 
Fax numbers:
North America:  and 
EMEA/APAC: 
Email:
North America: RTP Safety  Mailbox (SM) –
EMEA/ASI A: Safet y Central Mailbox (SM) –
For protocol -or safet y-related issues outside of normal business hour s, the Investigator must 
contact:
Hotline numbers (24 hours a day /7days a week):
North America: 
EMEA/APAC: 
For non-commercial use only
Takeda CONFIDENTIAL Page 5
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
PRODUCT QUALITY  COMP LAINTS
Investigators are required to report investigational product quality  complaints to Takeda within 
24hours. This includes any  instances wherein the quality  or performance of a Takeda product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet t he specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use PQC@shire.com to report the Product Quality  Complaint.
Telephone number and address (provided for reference if needed):
95 Hayden Avenue, Lexington, MA 02421 USA
1-800-828-2088
For non-commercial use only
Takeda CONFIDENTIAL Page 6
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
TABLE OF  CONTENTS
PROTOCOL SIGNATURE PAGE..............................................................................................2
SUMMARY OF CHANGES F ROM PREVIOUS VERSION (AMENDMENT 8).................3
EMERGENCY CONTACT IN FORMATION ...........................................................................4
PRODUCT QUALITY COMP LAINTS ................................
......................................................5
TABLE OF CONTENTS ..............................................................................................................6
LIST OF TABLES .......................................................................................................................10
LIST OF FIGURES .....................................................................................................................10
LIST OF APPENDICES .............................................................................................................10
ABBREVIATIONS ......................................................................................................................11
DEFINITIONS .............................................................................................................................14
STUDY SYNOPSIS .....................................................................................................................15
STUDY SCHEDULES .................................................................................................................30
1. BACKGROUND INFORM ATION .......................................................................................37
1.1 Indication and Current Treatment Options ...................................................................37
1.2 Maribavir Background and Clinical Information .........................................................38
1.2.1 Pharmacokinetics, Metabolism, and Drug -Drug Interactions...............................39
1.2.2 Efficacy ................................
........................................................................................40
1.2.3 Safety ...........................................................................................................................43
2. STUDY OBJECTIVES AND PURPOSE ..............................................................................45
2.1 Rationale for the Study .....................................................................................................45
2.2 Rationale for the Study Design ................................ ................................ ........................ 46
2.3 Rationale for Dose Selection ................................ ................................ ............................. 47
2.4 Study Objectives................................................................................................................48
2.4.1 Primary Objective ......................................................................................................48
2.4.2 Key Secondary Objective ...........................................................................................48
2.4.3 Secondary Objectives ................................................................
.................................48
2.4.4 Exploratory Objectives ..............................................................................................49
3. STUDY DESIGN ......................................................................................................................50
3.1 Study Design and Flow Chart ..........................................................................................50
3.2Duration and Study Completion Definition ................................
......................................54
For non-commercial use only
Takeda CONFIDENTIAL Page 7
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
3.3 Sites and Regions ...............................................................................................................55
3.4 Changes to Study Procedures Due to COVID- 19 Pandemic .........................................55
4. STUDY POPULATION ................................................................
..........................................57
4.1 Inclusion Criteria ................................................................
..............................................57
4.2 Exclus ion Criteria .............................................................................................................59
4.3 Restrictions ................................................................
........................................................60
4.4 Reproductive Potential ................................................................
.....................................60
4.4.1 Female Contraception................................................................
................................60
4.4.2 Male Contraception ....................................................................................................62
4.5 Discontinuation an d/or Withdrawal of Subjects ............................................................62
4.5.1 Reasons for Discontinuation and/or Withdrawal ....................................................63
4.5.2 Subjects “Lost to Follow -up” Prior to Last Scheduled Visit ..................................64
5. PRIOR AND CONCOMI TANT MEDICATIONS, TH ERAPIES, AND 
PROCEDURES .......................................................................................................................65
5.1 Prior Medications, Therapies, and Procedures ..............................................................65
5.2 Concomitant Medications, Therapies, and Procedures .................................................66
5.2.1 Permitted Treatment ................................
..................................................................67
5.2.2 Pr ohibited Treatment .................................................................................................68
5.2.3 Treatments Taken During the Follow- up Phase ......................................................69
6. IDENTITY OF INVES TIGATIONAL PRODUCTS ...........................................................70
6.1 Identity of Investigational Product ..................................................................................70
6.2 Administration of Investigational Product(s)
.................................................................70
6.2.1 Interactive Response Technology for Investigational Product Manageme nt.......70
6.2.2 Allocation of Subjects to Treatment ................................
.........................................70
6.2.3 Dosing ..........................................................................................................................71
6.2.4 Blinding Proce dures ...................................................................................................76
6.3 Labeling, Packaging, Storage, and Handling .................................................................77
6.3.1 Packaging and Labeling .............................................................................................77
6.3.2 Storage .........................................................................................................................78
6.4 Drug Accountabil ity..........................................................................................................79
6.5 Subject Compliance ................................................................
..........................................80
7. STUDY PROCEDURES .........................................................................................................81
7.1 Study Schedule ..................................................................................................................81
7.1.1 Screening Period .........................................................................................................81
7.1.2 Study Drug Administration Period ...........................................................................83
7.1.3 Follow -up Period ........................................................................................................85
7.1.4 Additional Care of Subjects after the Study ............................................................87
7.2 Study Evaluations and Procedures ..................................................................................87
7.2.1 Demographic and Other Baseline Characteristics ..................................................87
7.2.2 Efficacy ................................
........................................................................................87
7.2.2.1 CMV DNA Quantitation .....................................................................................87
For non-commercial use only
Takeda CONFIDENTIAL Page 8
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
7.2.2.2 CMV Genotyping and Phenotyping ...................................................................87
7.2.2.3 88
7.2.2.4 89
7.2.2.5 Underlying Disease Assessment ................................
..........................................89
7.2.2.6 Graft -versus- host-disease Assessments..............................................................
89
7.2.2.7 Comorbidity Status..............................................................................................90
7.2.2.8 Medical History ................................
....................................................................90
7.2.2.9 Subject Survival ...................................................................................................91
7.2.3 Safety ................................................................
...........................................................91
7.2.3.1 Physical Examination (Including Weight) .........................................................91
7.2.3.2 Vital Signs .............................................................................................................92
7.2.3.3 Electrocardiogram ...............................................................................................92
7.2.3.4 Clinical Laboratory Evaluations ........................................................................92
7.2.3.5 Adverse Event Collection ....................................................................................95
7.2.4 Others ..........................................................................................................................95
7.2.4.1 Clinical Pharmacology Assessments ..................................................................95
7.2.4.2 97
7.2.4.3 98
7.2.5 Volume of Blood to Be Drawn from Each Subject..................................................99
8. ADVERSE AND SERIO US ADVERSE EVENTS AS SESSMENT ..................................100
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events ...............................................................................................................................
100
8.1.1 Severity Categorization ............................................................................................100
8.1.2 Relationship Categorization ....................................................................................101
8.1.3 Outcome Categorization ..........................................................................................102
8.1.4 Adverse Events of Special Interest ..........................................................................102
8.1.5 Disease Under Study.................................................................................................103
8.1.6 Clinical Laboratory and Other Safety Evaluations
..............................................105
8.1.7 Pregnancy ..................................................................................................................105
8.1.8 Abuse, Misuse, Overdose, and Medication Error
.................................................106
8.2 Serious Adverse Event Procedures ................................................................................107
8.2.1 Reference Safety Information .................................................................................107
8.2.2 Reporting Procedures ................................
..............................................................107
8.2.3 Serious Adverse Event Definition ...........................................................................108
8.2.4 Serious Adverse Event Collection Time Frame ................................ ..................... 109
8.2.5 Serious Adverse Event Onset and Resolution Dates .............................................109
8.2.6 Fatal Outcome ...........................................................................................................109
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting ..................................................................................................................109
9. DATA MANAGEMENT AND STATISTICAL METHO DS............................................111
9.1 Data Collection ................................
................................................................................111
9.2 Clinical Data Management .............................................................................................111
9.3 Data Handling Considerations .......................................................................................111
For non-commercial use only
Takeda CONFIDENTIAL Page 9
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
9.4 Statistical Analysis Process .............................................................................................111
9.5 Data Monitoring Committee ..........................................................................................112
9.6 Sample Size Calculation and Power Considerations ...................................................112
9.7 Study Population ................................................................
.............................................114
9.8 Efficacy Analyses .............................................................................................................114
9.8.1 Prim ary Efficacy Endpoint ......................................................................................114
9.8.2 Key Secondary Efficacy Endpoint ..........................................................................117
9.8.3 Multiplicity Adjustment ...........................................................................................118
9.8.4 Subgroup Analyses ...................................................................................................119
9.8.5 Secondary Efficacy Endpoints .................................................................................119
9.8.6 Exploratory Efficacy Endpoints ..............................................................................121
9.9Safety Analyses .................................................................................................................121
9.10 Other Analyses ..............................................................................................................124
9.10.1 124
9.10.2 124
9.10.3 Pharmacokinetic and Pharmacokinetic/pharmacodynamic Analyse s ..............124
10. SPONSOR’S AND INVESTIGATOR’S RESPONSIBI LITIES .....................................126
10.1 Sponsor’s Responsibilities ............................................................................................126
10.1.1 Good Clinical Practice Compliance ................................
......................................126
10.1.2 Indemnity/Liability and Insurance.......................................................................126
10.1.3 Public Posting of Study Information ....................................................................127
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees .........................................127
10.1.5 Reporting of COVID -19 Cases During the Study ...............................................127
10.1.6 Study Suspension, Termination, and Completion ...............................................127
10.2 Investigator’s Responsibilities
......................................................................................127
10.2.1 Good Clinical Practice Compliance ......................................................................127
10.2.2 Protocol Adherence and Investigator Agreement ...............................................128
10.2.3 Documentation and Retention o f Records ...........................................................129
10.2.3.1 Case Report Forms
..........................................................................................129
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents .129
10.2.3.3 Audit/Inspection ...............................................................................................130
10.2.3.4 Financial Disclosure
................................ ................................ ......................... 130
10.2.4 Compliance to all Local, State, and National Controlled- substance 
Biohazard and Infectious Disease Regulations and Legislation ..........................130
10.3 Ethical Considerations ..................................................................................................130
10.3.1 Informed Consent ................................
...................................................................130
10.3.2 I nstitutional Review Board or Ethics Committee ................................................131
10.4 Privacy and Confidentiality .........................................................................................132
10.5 Study Results/Publication Policy .................................................................................132
11. REFERENCES .....................................................................................................................135
For non-commercial use only
Takeda CONFIDENTIAL Page 10
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
LIST OF TABLES
Table 1. Schedule of Assessment 1: Screening Phase and Study Treatment Phase ...............30
Table 2. Schedule of A ssessment 2: Follow- up Phase ...............................................................35
Table 3. Prior Medications, Therapies, and Procedures ..........................................................65
Table 4. Common Excluded Treatments and Associated Washout Period ............................68
Table 5. Study Treatment Dosing – Standard Regimen ...........................................................72
Table 6. Valganciclovir Dosing –Adjustment for Renal Function .........................................73
Table 7. Valganciclovir Dose Adjustment Based on ANC Level and CMV DNA 
Clearance ................................
................................................................
.................................74
Table 8. Subjects ≥18Years Sparse PK Schedule .....................................................................96
Table 9. Subjects ≥16 to <18 Years Including Intensive PK (Week 1) Schedule ...................96
Table 10. Volume of Blood Drawn Per Study Visit ..................................................................99
Table 11. 104
Table 12. Assessments of Virological Responders at Study Week 8 .....................................115
Table 13. Assessments of Responders for Key Secondary Endpoint ....................................117
LIST OF FIGURES
Figure 1. Study Design Flow Chart ............................................................................................51
LIST OF APPENDICES
Appendix 1 Protocol History ................................................................
.....................................141
Appendix 2 Child -Pugh Classification of Chronic Liver Disease ..........................................162
Appendix 3 CMV Genetic Mutations Associated with Resistance to Anti CMV Drugs .....163
Appendix 4 169
Appendix 5 Karnofsky Performance Status Scale ..................................................................172
Appendix 6 173
Appendix 7 Acute Graft -Versus
-Host Disease: Clinical Staging and Grading ....................174
Appendix 8 Recommendations for Chronic GVHD Diagnosis and Grading .......................176
Appendix 9 Diagnostic Criteria for Chronic GVHD ..............................................................181
Appendix 10 Bacterial and Fungal Infections As sessment ....................................................187
For non-commercial use only
Takeda CONFIDENTIAL Page 11
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
ABBREVIA TIONS
AAG alpha -1-1acid -glycoprotein
AE adverse event
AESI adverse events of special interest
AIDS acquired immune deficiency  syndrome
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the plasma concentration versus time curve
-hCG beta-human chorionic gonadotropin
BAL bronchoalveolar lavage
BID twice dail y
CI confidence interval
Cmax maximum observed plasma concentration
Cmin minimum observed plasma concentration
CMH Cochran -Mantel -Haenszel
CMV cytomegalovirus
CNS central nervous s ystem
CoD Certificates of Destruction
COVID -19 Coronavirus Disease 2019
CRA clinical research associate
CrCl creatinine clearance
CRF case report form
CRO contract research organization
CT computerized tomography
CTCAE Common Terminology  Criteria for Adverse Events
Ctrough trough concentration
DDI drug-drug interaction
DMC Data Monitoring Committee
DNA deox yribonucleic acid
DTP direct -to-patient
For non-commercial use only
Takeda CONFIDENTIAL Page 12
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
EC ethics committee
ECG/EKG electrocardiogram
eIC electronic informed consent
EIND emergency  investigational new drug
EMA European Medicines Agency
EU European Union
FDA Food and Drug Administration
FU follow -up
GCP Good Clinical Practice
GGT gamma -glutamy ltransferase
GI gastrointestinal
GVHD graft -versus- host disease
HBV hepatitis B virus
HCMV human cy tomegalovirus
HCV hepatitis C virus
HHC home healthcare
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HLA human leukocy te antigen
HSA human serum albumin
HSCT hematopoietic stem cell transplant
HSV herpes simplex virus
ICH International Conference on Harmonisation
INR international normalized ratio
IRB Institutional Review Board
IRT interactive response technology
IV intravenous
IVIg intravenous immunoglobulin
KPS Karnofsk y Performance Status
LAR legally  authorized representative
LLOQ lower limit of quantification
MMF mycophenolate mofetil
NCI National Cancer Institute
For non-commercial use only
Takeda CONFIDENTIAL Page 13
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
NI noninferiority
NIH National Institutes of Health
NPP named patient program
OTC over-the-counter
PBPK physiologicall y-based pharmacokinetics
PCR polymerase chain reaction
P-gp P-glycoprotein
PK pharmacokinetic(s)
PI Principal Investigator
PO per os (oral)
PT preferred term
QD once dail y
qPCR quantitative poly merase chain reaction
QTc corrected QT interval
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analy sis plan
SMQ standardized MedDRA queries
SOC system organ class
SOT solid organ transplant
TEAE treatment -emergent adverse event
TID 3 times daily
ULN upper limit of normal
US United States
VZV varicella zoster virus
WBC white blood cell
For non-commercial use only
Takeda CONFIDENTIAL Page 14
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
DEFINITIONS
Term Definition
Confirmed viremia 
clearanceDefined as plasma cy tomegalovirus (CMV) DNA concentration 
below the lower limit of quantification (<LLOQ; ie, <137 IU/mL ]), 
when assessed b y COBAS®AmpliPrep/COBAS®TaqMan®CMV 
Test at a central specialty laboratory ,in 2consecutive postbaseline 
samples, separated b y at least 5 days.
Recurrence of CMV 
viremiaDefined as plasma CMV DNA concentration ≥LLOQ when 
assessed b y COBAS®AmpliPrep/COBAS®TaqMan®CMV Test in 
2 consecutive plasma samples at least 5 days apart, after being 
unquantifiable (<LLOQ) for at least 5 days in 2 consecutive 
samples.
Rebound of CMV 
viremiaDefined as increase in viral DNA load for >1 log 10above nadir 
without prior clearance of viremia.
Recurrence of the CMV 
diseaseDefined as the presence of signs or s ymptoms of the tissue invasive 
CMV disease (same or new s ymptomatology ) confirmed as per 
Ljungman et al. ( 2017), after the period of resolution of the disease 
in subjects sy mptomatic at baseline .
Refractory Documented failure to achieve >1 log 10(common logarithm to 
base 10) decrease in CMV DNA level in whole blood or plasma 
after 2 or more weeks of treatment with IV ganciclovir, oral 
valganciclovir, IV foscarnet, or IV cidofovir (or any  combination 
thereof) .
Resistant Documentation of 1 or more CMV genetic mutations associated 
with resistance to ganciclovir, valganciclovir, foscarnet, and/or 
cidofovir.
Symptomatic subjects HSCT recipients who have tissue -invasive CMV disease as 
determined b y the investigator according to the criteria specified b y 
Ljungman et al. 
(2017).
Asymptomatic subjects HSCT recipients who do not have tissue -invasive CMV disease as 
determined b y the investigator accor ding to the criteria specified by  
Ljungman et al. ( 2017
).
For non-commercial use only
Takeda CONFIDENTIAL Page 15
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
STUDY  SYNOPSIS
Protocol num ber: SHP620 -302 Drug: Maribavir
Title of the study: A Phase 3, multicenter, randomized, double -blind, double- dummy, active -controlled study to 
assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus 
(CMV) infection in hematopoietic stem cell transplant recipients
Number of subjects (total and for each treatm ent arm): Approximately 612 subjects will be screened to 
randomize approximately 550 subjects in the study, allowing for a 10% screen failure rate. Approximately 
550subjects will be randomized in a 1:1 ratio to a double -blind treatment with maribavir or valganciclovir. 
Assuming a 10% dropout rate during the double -blind phase, approximately 494 subjects (247 each in the 
maribavir and valganciclovir arms) are required to provide 90% p ower to assess the noninferiority of maribavir 
to valganciclovir.
Investigator(s): A multicenter study to be conducted at approximately 105 sites worldw ide.
Site(s) and Region(s): Approximately 105 sites in North America, Europe, and Asia Pacific.
Study periods (planned ): 2017 -2022 Clinical phase: 3
Prim ary Objective:
Tocompare the efficacy of maribavir to valganciclovir in CMV viremia clearance at the end of Study Week 8 in 
asymptomatic CMV infection in hematopoietic stem cell transplant (HSCT) recipients .
Key Secondary Objective:
To compare the efficacy of maribavir and valganciclovir on maintenance of CMV viremia clearance , achieved 
at the end of Study Week 8 through Study Week 16 (8 weeks of post -treatment/follow -up Phase) .
Secondary Objective s:
To compare the efficacy of maribavir to valganciclovir in CMV viremia clearance after completion of 
8weeks of treatment for asymptomatic CMV infection in HSCT recipients .
To compare the efficacy of maribavir and valganciclovir on maintenance of CMV viremia clearance, 
achieved after completion of 8 w eeks of treatment, through Study Weeks 12 (4 weeks of post -treatment 
period), 16 (8 weeks of post -treatm ent/follow -up phase), and 20 (12 weeks post -treatment).
To assess the maintenance of CMV viremia clea rance achieved at the end of Study Week 8, through 
Weeks 12 (4 w eeks post -treatment), and 20 (12 weeks post -treatment).
To evaluate the incidence of recurrence of confirmed CMV viremia in the 2 study treatment arms 
during the first 8 weeks of the study, du ring the 12 -weeks of the follow -up study phase, and at any time 
during the study.
To evaluate the incidence of recurrence of confirmed CMV viremia in the 2 study treatment arms when 
subjects are on treatment and off treatment.
To evaluate the incidence of grade 3 or 4 neutropenia (defined as absolute neutrophil count [ANC] 
<1000/mm3or ANC<500/mm3) while on treatment.
To assess the safety and tolerability of maribavir compared to valganciclovir.
To characterize the pharmacokinetics (PK) of maribavir.
Exploratory Objectives :
 
For non-commercial use only
Takeda CONFIDENTIAL Page 16
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
 
Rationale:
There are no anti- viral drugs specifically approved for treatment of CMV infection in transplant recipients. Both 
(IV) ganciclovir, approved for the treatment of CMV retinitis in immunocompromised patients including 
patients with HIV/AIDS and prevention of CMV disease in transplant recipients at risk for CMV disease, and 
oral valganciclovir approved for treatment of CMV retinitis in patients with HIV/AIDS and prevention of CMV 
disease in solid organ transplant recipient are widely used in clinical practice to treat CMV infection. The most 
common adverse effect of this treatment is bone marrow suppression, which is of particular concern for HSCT 
recipients whose marrow has been ablated and who are significantly immunosuppressed to prevent 
graft -versus -host disease (GVHD). The rates of valganciclovir -related neutropenia in HSCT range from 19% 
(Barkam et al., 2012) and 33% (Takahata et al., 2015) to 55% (Boeckh et al., 2015).
Maribavir is an anti -CMV agent that may be of particular benefit to HSCT patients as it does not app ear to cause 
bone marrow  suppression. In addition to the favorable safety profile of maribavir observed in earlier Phase 1-3 
studies (studies evaluating prophylactic administration of maribavir), results from a recent large Phase 2 
randomized trial (Study 1263- 203) support the safety, tolerability, as well as anti -viral activity of maribavir as a 
potential option for the treatment of CMV infections in transplant recipients. Study 1263 -203 w as a multicenter, 
randomized, dose- ranging, parallel -group study of maribavir versus valganciclovir for the treatment of CMV 
infections in HSCT or solid organ transplant (SOT) recipients. Eligible subjects w ere randomized in a 1:1:1:1 
allocation ratio (40 subjects per group) to receive oral maribavir at 400 mg, 800 mg, or 1200 mg twice daily 
(BID); or valganciclovir (900 mg BID for 3 weeks, 900 mg once daily (QD) after 3 weeks) for up to 12 weeks. 
Maribavir, at doses 400 mg BID, had comparable efficacy to valganciclovir at clearing CMV viremia and was 
generally well tolerat ed across the dose range studied. In the subgroup of subjects whose transplant type was 
HSCT, a numerically higher percentage of subjects in the overall maribavir group (75%) than the valganciclovir 
group (48%) achieved confirmed undetectable plasma CMV DN A within 6 weeks of treatment. There w as a 
higher incidence of neutropenia through Week 12 for valganciclovir -treated subjects compared with maribavir-
treated subjects. This w as evident for both measured degrees of neutropenia: 18% versus 5% (ANC<1000/mm3), 
and 5% versus 2% (ANC<500/mm3) through Week 12 for the valganciclovir and overall maribavir groups, 
respectively.
This Phase 3 study is designed to further assess and demonstrate the efficacy and safety of maribavir, 
administered at 400 mg BID, compared to valganciclovir administered at 900 mg BID for the treatment of 
asymptomatic CMV infection in HSCT recipients.
Study treatm ent, dose, and mode of administration
Investigational product:
The sponsor w ill provide maribavir 200 mg strength tablets, which will be administered orally (PO) at 400 mg 
BID w ith food. Administration with food is not required for maribavir however it is required for valganciclovir 
(as per valganciclovir label), therefore same administration conditions (ie, with food) w ill be used to protect the 
blind.
Active control:
Valganciclovir will be provided in 450 mg strength tablets, which will be administered PO at 900 mg BID 
(oradjusted dosage, as required) with food.
For non-commercial use only
Takeda CONFIDENTIAL Page 17
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Placebo:
To protect the study blind, maribavir and valganciclovir ta blets will each have matching placebo tablets w ith 
same mode of administration.
Methodology:
This is a multicenter, randomized, double- blind, double- dummy, active -controlled study of maribavir compared 
to valganciclovir for the treatment of asymptomatic CMV infection in HSCT recipients. “ Asymptomatic 
subjects ” at baseline will be defined as HSCT recipients who do not have tissue -invasive CMV disease as 
diagnosed by the investigator. The study will assess the efficacy of maribavir by measuring the plasma C MV 
DNA clearance. To be eligible for the study, subjects must have a documented asymptomatic CMV infection 
with a screening value of CMV DNA ≥1365 IU/m L to ≤273000 IU/mL in whole blood or ≥455 IU/m L to 
≤91000 IU/ml in plasma in 2 consecutive assessments, s eparated by at least 1 day, as determined by local or 
central specialty laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV 
DNA results. Results should be available before the subject is randomized to verify subject elig ibility for the 
study. Both samples should be taken within 14 days prior to randomization with the second sample obtained 
within 5 days before randomization. The same laboratory and sample type should be used for these assessments. 
Subjects must not have C MV tissue invasive disease (symptomatic CMV infection) and must not have a CMV 
infection that is known to be genotypically resistant to anti -CMV drugs and must meet the remaining specified 
eligibility criteria.
All eligible subjects will be stratified base d on the last prebaseline whole blood or plasma CMV DNA 
concentration as determined by the local or central specialty laboratory qPCR and acute GVHD (presence or 
absence at baseline):
High viral load with CMV DNA ≥27300 IU/mL in whole blood or ≥9100 IU/mL in plasma;
Low viral load with CMV DNA ≥2730 IU/mL to <27300 IU/mL in whole blood or ≥910 IU/mL to 
<9100 IU/mL in plasma, and
Very  low viral load and high -risk infection with CMV DNA >1365 IU/mL to <2730 IU/mL in whole 
blood or >455 IU/mL to <910 IU/mL in plasm a
Subjects in each stratum will then be randomized in a 1:1 allocation ratio to receive double -blind maribavir 
400mgBID or valganciclovir 900 mgBID (w ith dose adjustment for renal function or neutropenia) for 
8weeks.
As shown in the study schemati c in Study Design Flow  Chart below , the study will have 3 phases: (1) Up to a 
2-week screening phase; (2) 8 -week double -blind study treatment phase; and (3) 12 -week follow -up phase. 
Subjects will be required to visit the site up to 18 times for up to a 22 -week period.
Screening Phase
Approximately 612 subjects will be screened during an approximate 2 -week screening phase to establish 
eligibility for study participation. If applicable, those subjects who meet eligibility requirements will undergo 
washout of any prohibited medications, the length of which will be specified in the eligibility criteria. Subjects 
treated w ith ganciclovir, valganciclovir, foscarnet, or letermovir for the current CMV infection must not be 
treated w ith these anti -CMV agents for long er than 72 hours prior to enrolling in the study. Subjects who 
discontinue from screening due to COVID -19-related factors but are otherw ise qualified to participate in the 
trial may be rescreened at any time if the Takeda medical monitor agrees.
Study Trea tment Phase
Approximately 550 subjects with an asymptomatic CMV infection who meet eligibility requirements during the 
screening phase, including the presence of quantifiable (local or central specialty laboratory) whole blood or 
plasma CMV DNA levels as specified, w ill be stratified based on their CMV viral load and GVHD status, and 
then randomized at Visit 2/Day 0 to receive either double -blind maribavir/placebo or valganciclovir/placebo 
(collectively, the study treatment) for 8 weeks.
For non-commercial use only
Takeda CONFIDENTIAL Page 18
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Historical labora tory results for tests specified in the Schedule of Assessment 1 may be used for eligibility 
assessment ( HIV test results, relevant hematology, and chemistry results) as long as those are obtained w ithin 
the specified time period. The Screening and Visit 2/Day 0 visits can occur on the same day, if laboratory results 
are available for the determination of eligibility.
All Visit 2/Day 0 procedures and screening laboratory results needed to confirm eligibility must be completed 
and documented prior to randomi zation and study treatment administration and all clinical laboratory results 
required for eligibility verification must be available prior to randomization, including two separate CMV DNA 
assessments. Initiation of study treatment (ie, first dose) w ill on ly occur after completion of all required 
Visit 2/Day 0 procedures, confirmation of eligibility, and completion of randomization. This will be done under 
the supervision of investigator site personnel.
Subjects randomized to receive maribavir will take the 400mg BID dose for the 8 weeks of the study treatment 
phase . Maribavir 200 mg strength tablets will be utilized for the daily dosing.
Although typically valganciclovir treatment in HSCT patients is started as an induction dose of 900 mg BID for 
up to 14 days and then reduced to a maintenance dose of 900 mg QD for a further 2 weeks or until CMV viral 
load clearance (Tomblyn et al., 2009), a different dosing strategy was selected for this study based on input from 
regulatory authorities. Treatment with valg anciclovir 900 mg BID for the duration of 8 weeks was chosen in 
order to eliminate a potential bias for efficacy in favor of the investigational treatment (maribavir) by 
administering the comparator (valganciclovir) at a low er dose. Dosage for valganciclov ir (450 mg QD up to 
900mg BID, as adjusted for renal function) will utilize 450 mg strength tablets.
Depending on the time of the first dose of study treatment on Visit 2/Day 0, a second dose should be 
administered on Visit 2/Day 0 provided that doses can be separated by a minimum of 8 hours; otherwise, 
only 1dose should be administered on Visit 2/Day 0. Study treatment will then be administered (preferably) 
every 12 hours (q12h). When q12h dosing is not feasible, the doses should be separated by a minimu m of 
8hours.
To protect the study blind, subjects w ill be required to take 2 tablets of their assigned study treatment and 
2tablets of the placebo q12h in a double -dummy format as shown in the table below .
Study Treatment Dosing –Standard Regim en
Regim en AM PM
maribavir
400mg BIDmaribavir active 400mg (2 tablets) 400mg (2 tablets)
valganciclovir placebo placebo (2 tablets) placebo (2 tablets)
valganciclovir
900mg BIDavalganciclovir active 900mg (2 tablets) 900mg (2 tablets)
maribavir placebo placebo (2 tablets) placebo (2 tablets)
BID: tw ice daily
aStarting dose for valganciclovir could be low er based on renal function results at screening (refer to dose 
adjustment tables for renal function).
Subjects randomized to receive valganciclovir will follow  the 900 mg BID dosing regimen for the 8 weeks of 
the study treatment phase, with the exception of a permitted dose adjustment based on renal function and/or 
neutropenia. Subjects with estimated CrCl of ≥30mL/min will be enrolled ; adjustment of the valganciclovir 
dose for renal function will be allow ed at study entry and during the study treatment phase consistent with 
valganciclovir label, as indicated in the table below . Placebo tablets will be assigned to make up for adjusted 
dose and decrease in valganciclovir tablets.
For non-commercial use only
Takeda CONFIDENTIAL Page 19
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Valganciclovir Dosing –Adjustment for Renal Function
Valganciclovir 450 m g Tablets
CrCla(mL/min) Dose
≥60 900mg (2 tablets) BID
40 –59 450mg (1 tablet) BID
25 –39 450mg (1 tablet) QD
10 –24 450mg every 2 days
BID: twice daily; CrCl: creatinine clearance; QD: once daily
aAn estimated creatinine clearance in adults is calculated from serum creatinine by the following formulas: 
For Males = (140 –age [years]) × (body weight [kg]) / [(72) × (serum creatinine [mg/dL])]
For Females = 0.85 × male value.
Valganciclovir administration is not recommended below CrCl of 10 mL/min.
In addition, as shown in the table below , predefined criteria for valganciclovir dose adjustment based on ANC 
level and CMV DNA clearance may be used to manage subjects that experience neutropenia.
Valganciclovir Dose Adjustment Based on ANC level and CMV DNA Clearance
ANC >1000/mm3
[1.0×109/L]
ANC based on local 
or central 
laboratory resultsANC 500/mm3[0.5×109/L] 
to 1000/mm3[1.0×109/L]
ANC based on local or 
central laboratory resultsANC<500/mm3[0.5×109/L]
ANC based on local or central 
laboratory results
CMV DNA ≤ LLOQ 
(based on local or 
central specialty 
laboratory, most 
recent result prior to 
dose assessment 
shou ld be considered)Continue 
valganciclovir 
900mg BID
Hematopoietic 
growth factors may 
be used at 
investigator’s 
discretionMay adjust valganciclovir 
dose to 450 mg BID or 
interrupt the dose and resume 
at 450 mg BID or 900 mg 
BID (dose choice at 
investigato r’s discretion) once 
ANC >1000/mm3[1.0×109/L]
Hematopoietic growth factors 
may be used at investigator’s 
discretionMay interrupt valganciclovir dose 
and resume at 450 mg BID or 
900mg BID (dose choice at 
investigator’s discretion) once ANC 
>1000/mm3[1.0×109/L]
Permanent valganciclovir 
discontinuation and alternative 
anti-CMV treatment may be 
considered at investigator’s 
discretion
Hematopoietic growth factors should 
be strongly considered
CMV DNA ≥LLOQ 
(based on local or 
central specialty 
laboratory, most 
recent result prior to 
dose assessment 
should be considered)Continue 
valganciclovir 
900mg BID
Hematopoietic 
growth factors may 
be used at 
investigator’s 
discretionMay adjust valganciclovir 
dose to 450 mg BID
Hematopoietic growth factors
may be used at investigator’s 
discretionMay interrupt valganciclovir dose 
and resume at resume at 450 mg BID 
or 900 mg BID (dose choice at 
investigator’s discretion) once ANC 
>1000/mm3[1.0×109/L]
Permanent valganciclovir 
discontinuation and alternative 
anti-CMV treatment may be 
considered at investigator’s 
discretion
Hematopoietic growth factors should 
be strongly considered
ANC=absolute neutrophil count; BID=twice daily; CMV=cytomegalovirus; DNA=deoxyribonucleic acid; LLOQ=lower 
limit of quantitation; QD=once daily
For non-commercial use only
Takeda CONFIDENTIAL Page 20
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Various clinical scenarios of neutropenia will be programmed in the interactive response technology (IRT) and 
appropriate options w ill be selected by the investigator. Interruptions and discontinuation of study treatment will 
be conducted i n a blinded manner; therefore, it is possible that treatment with either valganciclovir or maribavir 
will be interrupted or discontinued for neutropenia presence. The investigator may also select to interrupt study 
treatment, for other adverse events, rega rdless of the treatment assignment (maribavir or valganciclovir). The 
interruption for a maximum of 7 consecutive days will not result in permanent study treatment discontinuation. 
Up to 2 study treatment interruptions for a total of up to 7 days will be a llowed. If study drug is interrupted for 
any reason and subsequently resumed, the end of the study drug administration period w ould remain fixed at a 
maximum of 8 weeks after the date of the start of treatment. A third study treatment interruption w ill lea d to 
permanent study treatment discontinuation ; the subject w ill com plete the end of treatment procedures described 
for Visit 10/Study Week 8 in the Schedule of Assessment 1, and will follow a modified schedule of assessments 
through the remaining weekly v isits scheduled for the study treatment phase and the regular schedule of 
assessments through the 12 -week follow -up phase.
All subjects will undergo study -specific evaluations weekly during the study treatment phase. All subjects who 
complete the study treatment phase through Visit 10/Week 8 will enter the 12 -week follow -up phase.
Subjects who permanently discontinue study treatment will complete the end of treatment procedures described 
for Visit 10/Study Week 8 in the Schedule of Assessment 1;these subjects will follow  a modified schedule of 
assessments through the remaining weekly visits of the study treatment phase and the regular sch edule of 
assessments through the 12 -week follow -up phase. The end of treatment sample for immunosuppressant drug 
concentration will be collected at the next visit scheduled 1 week after the treatment discontinuation. Subjects 
who discontinue study treatmen t early will not be asked to complete the following procedures for subsequent 
visits in the treatment phase: the use of the diary for study treatment compliance, dispense or use of any study 
treatment, and PK sample collection. After completing the 8 -weeks specified for the study treatment phase, 
subjects will enter the 12 -week follow -up phase. After the permanent discontinuation of study treatment and 
until the end of the study, subjects might be administered other anti -CMV treatment as deemed necessary by the 
investigator. Subjects who withdraw  from  the study during the follow -up phase will perform the end of study 
evaluations and procedures for Visit 18/Week 20 (Follow -up Week 12) as soon as possible.
Subjects who withdraw  consent during the study treatme nt phase will be asked to undergo all end of treatment 
evaluations and procedures listed for Visit 10/Week 8, if they agree; subjects who withdraw from the study 
during the follow -up phase will undergo all end of study evaluations and procedures listed for Visit 18/Week 20 
(Follow -up Week 12) as soon as possible and, whenever possible, if they agree, prior to initiation of any 
nonstudy anti -CMV treatment (as deemed necessary by the investigator); no further follow -up will be 
performed.
Follow -up Phase
Study -specific evaluations including central specialty laboratory CMV testing and safety assessments will occur 
weekly for the first 4 weeks, then every 2 weeks for the final 8 weeks of the 12 -Week Follow -up Phase. Refer to 
Study Schedule 2 for a complete list of the evaluations.
Study Design Flow Chart
Visit 1
Wks -2 to -1Screenin g
PhaseDouble- blind
Phase
Follow-up
Phase
Visits 11-18
Wks 9-20
Every 2 Weeks
(last 8 wks)Weekly
(first 4 weeks)Visit 2
Wk 0SHP620 400mg BID OR
ValG CV 900mg BIDa
BL/
RandVisits 3-10
Wks 1-8
Double- blind
Study Drug Adm inistration
Visit
2Ab
BID=twice daily; BL=baseline; Rand=randomized; wks=weeks
aUnless dose adjustment is required for moderate renal impairment.
bVisit 2A is required only for subjects receiving tacrolimus, cyclosporine, everolimus, or sirolimus at baseline.
For non-commercial use only
Takeda CONFIDENTIAL Page 21
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Notable Study Evaluations during Study Treatment Phase and Follow -up Phase
CMV DNA Quantitation
Blood samples will be assessed at a central specialty laboratory for the quantification of CMV DNA in plasma 
using the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test. Central specialty laboratory plasma CMV 
DNA results will be reported to the investigator site as available. Additional CMV DNA testing at local 
specialty laboratories may be performed at mor e frequent intervals or using additional assay methods at the 
discretion of the investigator.
Confirmed CMV viremia clearance will be defined as plasma CMV DNA concentration below  the lower limit 
of quantification (<LLOQ; ie, <137 IU/mL]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® 
CMV Test at a central specialty laboratory, in tw o consecutive postbaseline samples, separat ed by at least 
5days.
Confirmed Recurrence or the confirmed CMV viremia recurrence will be defined as plasma CMV DNA 
concentration ≥LLOQ when assessed by COBAS®AmpliPrep/COBAS®TaqMan®CMV Test in 2 consecutive 
plasma samples at least 5 days apart, after being unquantifiable (<LLOQ) for at least 5 days in 2 consecutive 
samples.
CMV Genotyping and Phenotyping
Subjects with known resistance to anti -CMV agents as determined by site local specialty laboratory (testing will 
be done as directed by the investigator) w ill be excluded from the study. At Visit 2/Day 0 plasm a samples will 
be obtained and tested by the central specialty laboratory to identify mutations in the viral UL97 and UL54 
genes known to confer resistance to anti -CMV agents. In addition , UL 27 will be tested. Given the urgency to 
treat the subjects, it is not possible to w ait for this central specialty laboratory assessment prior to a subject’s 
randomization to confirm lack of resistance to any previously used agents. In instances when a mutation will be 
reported in the baseline sample analyzed by the central specialty laboratory these subjects will be excluded from 
the Per Protocol Set for analysis. Subjects will be managed based on investigator clinical judgments, and if 
resistance is s uspected genotyping may be conducted by a local specialty laboratory at investigator discretion. It 
is not expected that the genotyping results from central specialty laboratory will be available in time to direct 
patient management.
 
 
Rebound is defined as increase in viral DNA load w ithout prior clearance of viremia. The entire UL97, UL54, 
and UL27 CMV genes will be sequenced in every sam ple that meets the criteria for genotyping, including the 
baseline samples.
 
 
PK Assessment
Pharm acokinetic samples will be obtained for all subjects as in the Schedule of A ssessments 1, but analyzed for 
only those subjects who are taking maribavir. Bioanalysis of PK samples will be conducted w hile the study is 
ongoing. The analysis will be conducted by unblinded staff from the bioanalysis lab/contract research 
organization ( CRO) to allow for the identification of the PK samples from the subjects randomized to the 
maribavir treatment arm.
For non-commercial use only
Takeda CONFIDENTIAL Page 22
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Inclusion and exclusion criteria:
Approximately 550 subjects, ≥16years of age, who are HSCT recipients w ith asymptomatic CMV infections 
will be enrolled.
Inclusion Criteria:
Subjects must:
1.Be able to provide w ritten, personally signed, and dated informed consent to participate in the study 
before completing any study -related procedures. As applicable, a parent/both parents or legally 
autho rized representative (LAR) must provide signature of informed consent and there must be 
documentation of assent by the subject before completing any study -related procedures. During the 
COVID -19 public health emergency, informed consent from a potential or current trial participant 
may, if permitted by local laws and regulations, be obtained via electronic informed consent (eIC) 
capabilities or an electronic face- to-face consent interview when these individuals are unable to travel 
to the site (Food and Dru g Administration [FDA] COVID -19 Guidance, 27 Jan2021, Q11).
2.Be ≥16years of age at the time of consent.
3.Be a recipient of hematopoietic stem cell transplant.
4.Have a documented asymptomatic CMV infection, with a screening value of CMV DNA 
≥1365 IU/mL to ≤273000 IU/mL in whole blood or ≥455 IU/mL to ≤ 91000 IU/mL in plasma in 
2consecutive assessments, separated by at least 1 day, as determined by local or central specialty 
laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative C MV DNA 
results. Both samples should be taken within 14 days prior to randomization with second sample 
obtained w ithin 5 days prior to randomization. Same laboratory and same sample type (whole blood or 
plasma) should be used for these assessments. Asymptom atic CMV infection is defined as an infection 
that does not present with tissue invasive CMV disease, as assessed by the investigator. Subjects with 
CMV DNA <910 and ≥455 IU/mL in plasma or <2730 and ≥1365 IU/mL in whole blood will also 
need to meet at lea st 1 of the follow ing criteria for high -risk CMV infection to be eligible:
Human leukocyte antigen (HLA) -related (sibling) donor w ith at least 1 mismatch at 1 of the 
following 3 HLA -gene loci: HLA -A, -B or -DR,
Haploidentical donor,
Unrelated donor w ith at least 1 mismatch at 1 of the following 4 HLA -gene loci: HLA -A, -B, -C 
and -DRB1,
Use of umbilical cord blood as stem cell source,
Use of ex vivo T -cell-depleted grafts,
Grade 2 or greater GVHD, requiring the use of systemic corticosteroids (defined as the use of 
≥1mg/kg/day of prednisone or equivalent dose of another corticosteroid).
5.Have the current CMV infection as the first episode of CMV viremia after HSCT, either primary or 
reactivation , which, in the investigator’s opinion, requires treatment .
6.Per investigator’s judgment, be eligible for treatment with valganciclovir.
7.Have all of the following results as part of screening laboratory assessments (results from either the 
central laboratory or a local laboratory can be used for qualification):
a.Absolu te neutrophil count ≥1000/mm3[1.0 x 109/L]
b.Platelet count ≥25,000/mm3[25 x 109/L]
c.Hem oglobin ≥8g/dL
d.Estimated creatinine clearance ≥30 mL/min
8.Have a negative serum beta human chorionic gonadotropin (β -hCG) pregnancy test at screening, if a 
female of childbearing potential. Urine pregnancy tests may be done per institutional requirements; 
however, they are not sufficient for eligibility determination. Sexually active females of childbearing 
potential must agree to comply with any applicable contracepti ve requirements of the protocol. If 
male, must agree to use an acceptable method of birth control, as defined in the protocol, during the 
study treatment administration period and for 90 days afterward the last dose of study treatment.
For non-commercial use only
Takeda CONFIDENTIAL Page 23
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
9.Be able to sw allow  tablets.
10.Have life expectancy of ≥8weeks.
11.Weigh ≥40kg.
12.Be w illing and have an understanding and ability to fully comply with study procedures and 
restrictions defined in the protocol.
Exclusion Criteria:
Subjects must not:
1.Have CMV tissue invasive disease as assessed by the investigator at the time of screening and 
randomization at Visit 2/Day 0.
2.Have a CMV infection that is known to be genotypically resistant to ganciclovir, valganciclovir, 
foscarnet, or cidofovir based on documented evidence.
3.Be presenti ng with recurrent CMV infection (defined as a new  detection of CMV infection in a 
subject who had at least one previously documented episode of CMV infection post -transplant, and 
who has had at least 2 weeks of undetectable CMV DNA betw een the episodes dur ing active 
surveillance, based on same local laboratory and same sample type). The subject must also have been 
off any anti -CMV treatment betw een the current and prior infection. Otherwise, the current infection 
may be considered continuation of the prior infection.
4.Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions other than 
CMV when study treatment is initiated (example: herpes simplex virus [HSV] co -infection requiring 
use of any of these agents after the randomiz ation) or w ould need a co -administration with maribavir 
for CMV infection.
5.Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated. NOTE: Subjects 
who may be receiving leflunomide must discontinue the use at least 14 days prior to randomization at 
Visit 2/Day 0 and the first dose of study treatmen t. Subjects receiving letermovir must discontinue 
3days prior to first dose of study treatment. Subject s receiving artesunate must discontinue the use 
prior to the first dose of s tudy treatment.
6.Be on treatment with anti -CMV agents (ganciclovir, valganciclovir, foscarnet, or letermovir) for the 
current CMV infection for longer than 72 hours.
7.Have known hypersensitivity to the active substance or to an excipient of the study treatme nts.
8.Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the 
first dose of study treatment that w ould preclude administration of oral medication.
9.Require mechanical ventilation or vasopressors for hemodynamic s upport at the time of 
randomization.
10.Be female and pregnant or nursing.
11.Have previously completed, discontinued, or have been withdraw n from this study.
12.Have received any investigational agent with known anti -CMV activity within 30 days before 
initiation o f study treatment or CMV vaccine at any time.
13.Have received any unapproved agent or device within 30 days before initiation of study treatment.
14.Have any clinically significant medical or surgical condition that, in the investigator’s opinion, could 
interfe re with interpretation of study results, contraindicate the administration of the assigned study 
treatment, or compromise the safety or w ell-being of the subject.
15.Have previously received maribavir.
16.Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at screening, or 
serum alanine aminotransferase (ALT) >5 times ULN at screening, or total bilirubin ≥3.0 x ULN at 
screening (except for documented Gilbert’s syndrome), as analyzed by local or central lab.
17.Have known (previously docu mented) positive results for human immunodeficiency virus (HIV). 
Subjects must have a confirmed negative HIV test result within 3 months of study entry or, if 
unavailable, be tested by a local laboratory during the screening period.
For non-commercial use only
Takeda CONFIDENTIAL Page 24
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
18.Have active malignancy with the exception of nonmelanoma skin cancer, as determined by the 
investigator. Subjects who experience relapse or progression of their underlying malignancy (for 
which HSCT w as performed), as determined by the investigator, are not to be enrolled.
19.Be un dergoing treatment for acute or chronic hepatitis C.
Maximum duration of subject involvem ent in the study:
Planned duration of Screening Phase: Up to 2 weeks
Planned duration of Study Treatment Phase: 8 weeks
Planned duration of Follow -up Phase: 12 weeks
Endpoints and statistical analysis:
Subject Populations:
The Enrolled Set w ill consist of all subjects who have signed an informed consent and have begun 
some study procedures.
The Randomized Set will consist of all subjects in the Enrolled Set for whom a randomization number 
has been assigned.
The Modified Randomized Set w ill consist of all subjects in the Randomized Set who have taken at 
least 1 dose of assigned study treatment.
The Safety Set will consist of all subjects who have taken at least 1 dose o f study treatment.
The Per Protocol (PP) Set w ill consist of all subjects in the Randomized Set who do not have major 
predefined protocol deviations that may affect the primary efficacy assessment.
The Pharmacokinetic Set will consist of all subjects in th e Safety Set who had plasma samples draw n 
and tested for maribavir concentrations.
oThe adolescent pharmacokinetic set will consist of a subset of the PK set of subjects 
of≥16- <18years of age who had plasma samples drawn and tested for maribavir 
concentra tions.
The Modified Randomized Set and PP Set w ill be used for efficacy analyses. Pharmacokinetic data w ill be 
analyzed using the Pharmacokinetic Set.
Prim ary Efficacy Endpoint:
The primary efficacy endpoint of this study is confirmed clearance of plasma CMV DNA (CMV viremia 
clearance) at the end of Study Week 8.
For clearance of CMV viremia at the end of Study Week 8, the subject must have received exclusively a 
study -assigned treatment.
Key Secondary Efficacy Endpoint:
The key secondary efficacy endpoint is defined as t he maintenance of confirmed CMV viremia clearance 
achieved at the end of Study Week 8 through Week 16.
For clearance of CMV viremia achieved at the end of Study Week 8, and maintenance of such effect through 
Week 16, the subject must have r eceived exclusively a study -assigned treatment and must also have symptom 
control.
Secondary Efficacy Endpoints:
The achievement of the confirmed CMV viremia clearance after 8 w eeks of receiving study -assigned 
treatment.
The maintenance of the confirmed CM V viremia clearance achieved after completion of 8 weeks of 
study -assigned treatment, through Study Weeks 12 (4 weeks of post -treatment period), 16 (8 w eeks of 
post-treatment/follow -up phase), and 20 (12 w eeks post -treatment).
For non-commercial use only
Takeda CONFIDENTIAL Page 25
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The maintenance of confirmed CMV viremia clearance achieved at the end of Study Week 8 through 
Weeks 12 and 20, regardless of whether either study -assigned treatment was discontinued before the 
end of the stipulated 8 weeks of therapy. For maintenance effe ct to be achieved at a time point, the 
subject must have received exclusively study -assigned treatments up to that time point and also must 
have symptom control.
The recurrence of confirmed CMV viremia in the 2 study treatment arms during the first 8 w eeks of the 
study, during the 12 w eeks of the follow -up study phase, and at any time during the study, regardless of 
whether either study -assigned treatment was discontinued before the end of the stipulated 8 w eeks of 
therapy.
The recurrence of confirmed CMV v iremia in the 2 study treatment arms when subjects are on 
treatment and off treatment.
The incidence of grade 3 or 4 neutropenia (defined as ANC <1,000/mm3[1.0×109/L] or ANC 
<500/mm3[0.5×109/L], respectively) while receiving study treatment, time to first neutropenia 
development while receiving study treatment.
Exploratory Efficacy Endpoints :
 
 
Safety Endpoints (Secondary):
Treatment- emergent AEs and treatment -emergent SAEs, overall study AEs and overall study SAEs
Clinical laboratory evaluations (including incidence of neutropenia defined as ANC <500/mm3
[0.5×109/L] or ANC <1,000/mm3[1.0×109/L] at any time during the study (on treatment and overall 
study period), time to neutropenia development).
Pharm acokinetic endpoints for m aribavir treatm ent
Pharm acokinetic samples will be obtained for all subjects as in the Schedule of Assessment 1, but analyzed for 
only those subjects who are taking maribavir.
Maribavir C min(predose maribavir concentration)
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:
AUC (0-tau): area under the concentration time curve over the 12 -hour dosing interval at steady state
Cmax: maximum concentration
Tmax: time when maximum concentration is observed
CL/F: apparent oral clearance
Vz/F: apparent volume of distribution
For non-commercial use only
Takeda CONFIDENTIAL Page 26
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Exploratory endpoints:
 
Statistical Methodology for Prim ary Efficacy Endpoint:
Confirmed CMV viremia clearance at the end of Study Week 8, irrespective of treatment duration is defined as 
plasma CMV DNA concentrations <LLOQ (ie, <137 IU/mL), w hen assessed by COBAS®AmpliPrep/COBAS®
TaqMan®CMV Test at a central specialty laboratory, in 2 consecutive postbaseline samples separated by at 
least 5 days at the end of Study Week 8.
Assessments of Virological Responders at Study Week 8
ScenarioCMV DNA Weeks on StudyResponse RationaleWeek 6 Week 7 Week 8 Week 9a
1 + / - - - +/-/NA Yes2 consecutive “ -” at Week 7 and 
Week 8
2 + / - - + +/-/NA NoNot 2 consecutive “ -” at Week 7 and 
Week 8
3 + / - + - +/-/NA NoNot 2 consecutive “ -” at Week 7 and 
Week 8
4 + / - - NA - Yes2 consecutive “ -” as shown by 
available data and both “ -”at Week 7 
and Week 9 for missing Week 8, 
otherwise nonresponder
5 - NA - +/-/NA Yes2 consecutive “ -” as shown by 
available data and both “ -” at Week 6 
and Week 8 for missing Week 7, 
otherwise nonresponder
6 - NA NA - Yes2 consecutive “ -” as shown by 
available data at Week 6 and Week 9 
and both “ -”, otherwise nonresponder
NA = not available for evaluation of study drug effect; reason could be starting alternative anti-CMV treatment, withdrawal 
from study etc.
aWeek 9 data, if available to evaluate effect of study drug, to be used only if Week 8 data is unavailable or missing.
Notes: Scenarios in the table above are provided as examples and may not be inclusive of all possibilities. Only CMV DNA 
data evaluable for assessment of effect of study drug will be included (ie, prior to the start of alternative anti -CMV treatment 
if any).
"-" = CMV DNA concentration <LLOQ (< 137IU/mL)
"+" = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Confirmed clearance of plasma CMV DNA (CMV viremia clearance) = 2 consecutive postbaseline assessments of CMV 
DNA target <LLOQ, separated by at least 5 days.
Statistical Methodology for Prim ary Efficacy Endpoint:
The difference in proportion of subjects w ith confirmed CMV viremia clearance, at the end of Study Week 8, 
irrespective of treatment duration, betw een treatment groups (maribavir and valganciclovir) w ill be obtained 
using Cochran -Mante l-Haenszel (CMH) w eighted average across strata with baseline plasma CMV DNA 
concentration levels and presence or absence of acute GVHD as the stratification factors. The baseline plasma 
CMV DNA concentration will be the last central laboratory assessment before the first dose of study treatment. 
For non-commercial use only
Takeda CONFIDENTIAL Page 27
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The 2 -sided 95% confidence interval (CI) of the weighted average of difference across strata w ill be calculated 
using the normal approximation method. If the lower limit of the 95% CI is greater than -7%, it w illbe 
concluded that maribavir is as efficacious as valganciclovir. The noninferiority analysis will be performed on 
the PP Set as the primary analysis and on the Modified Randomized Set as a secondary analysis.
Sensitivity and supportive analyses of the pri mary endpoint of confirmed CMV viremia clearance at Week 8 
will be conducted to evaluate the robustness of the results from the primary method.
Subject to the multiplicity adjustment method, the superiority will be tested by comparing the lower limit of th e 
95% CI of the difference in proportion of subjects with confirmed CMV viremia clearance betw een m aribavir 
and valganciclovir with 0. The superiority testing will be performed on the Modified Randomized Set.
Analyses will be conducted for the following su bgroups (inclusive, but not limited to):
Cytomegalovirus DNA viral load (high, low, very low/high -risk)
Acute GVHD presence/absence at baseline
Adolescents ≥16 to <18 years of age (exploratory analysis: may be conducted if sample size is 
adequate)
Statistical Methodology for Key Secondary Efficacy Endpoint:
The difference in proportion of subjects who achieve response as defined for the key secondary efficacy 
endpoint betw een treatment groups (maribavir and valganciclovir) w ill be obtained using CMH weighted 
average across strata with baseline plasma CMV DNA concentration (based on the last central laboratory 
assessment before the first dose of study treatment) and presence or absence of acute GVHD as the stratification 
factors. The 2 -sided 95% CI of the weighted average of difference across strata will be calculated using the 
norm al approximation method. Sensitivity analyses for the key secondary endpoint will also be conducted.
Subject to the multiplicity adjustment method, the noninferiority testin g will be done using the same NI margin 
as the primary efficacy endpoint. If the low er limit of the 95% CI is greater than -7%, it will be concluded that 
maribavir is as efficacious as valganciclovir in maintaining treatment effect. The noninferiority anal ysis will be 
performed on the PP Set as the primary analysis and on the Modified Randomized Set as a secondary analysis.
Subject to the multiplicity adjustment method, the superiority in key secondary efficacy endpoint w ill be tested 
by comparing the lower limit of the 95% CI of the difference in proportion of subjects who achieve response as 
defined for the key secondary efficacy endpoint between maribavir and valganciclovir with 0. The superiority 
testing will be performed on the Modified Randomized Set.
Multiplicity Adjustm ent:
The hypothesis testing of the primary and key secondary efficacy endpoints will be adjusted for multiple 
comparisons following the gatekeeping strategy as described below  to control the family -wise Type 1 error rate 
at α=5% level. The testing will be done in the order of primary efficacy endpoint NI hypothesis testing (H11) 
first, the superiority hypothesis testing for primary efficacy endpoint (H12) and the key secondary efficacy 
endpoint NI hypothesis testing (H21) second, and las tly the superiority testing for key secondary efficacy 
endpoint (H22).
First, the NI hypothesis of the primary efficacy endpoint will be tested based on the 2 -sided 95% CI of 
the adjusted difference in proportion of subjects who have CMV viremia clearance at the end of Study 
Week 8 stratified by baseline CMV DNA concentration level and presence/absence of acute GVHD at 
baseline. This analysis will be conducted using PP Set as the primary and Modified Randomized Set as 
secondary. If the low er limit of the 95 % CI is above -7%, NI of the primary efficacy endpoint is 
considered established.
If and only after the NI of the primary efficacy endpoint is established, the superiority hypothesis of the 
primary efficacy endpoint and the NI hypothesis of the key seconda ry endpoint will be tested in 
parallel. Hochberg procedure will be used to control family -wise Type 1 error rate at α=5% level.
If and only if the superiority of the primary efficacy endpoint and NI of key secondary efficacy 
endpoint are established, the s uperiority hypothesis of the key secondary efficacy endpoint will be 
tested.
For non-commercial use only
Takeda CONFIDENTIAL Page 28
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Statistical Methodology for Safety Endpoints:
The safety analyses will include evaluation and procedures to meet the secondary objective of assessing the 
safety and tolerability o f study treatments.
Safety evaluation will be made during the periods as illustrated in the Study Design Flow  Chart, (ie, Screening 
Phase, Treatment Phase, and Follow -up Phase).
Two observation periods are defined for the purpose of analyses:
1) The on -treatment observation period starts at the time of study treatment initiation through 7 days after
the last dose of study treatment. For subjects who transfer from the study treatment to a nonstudy
anti-CMV treatment, the on -treatment observation period st arts at the time of the study treatment
initiation through 7 days after the last dose of study treatment, or until the nonstudy anti -CMV
treatment initiation, whichever is earlier.
2) The overall -study observation period starts at the time of the start of the study treatment through the
end of the study.
Treatm ent-emergent AEs (TEAEs) are defined as those with a start date on or after the first dose of study 
treatm ent, or with a start date before the date of first dose of study treatm ent, but increasing in severity 
after the first dose of study treatm ent.
The overall study AEs are those occurring during the overall- study observation period.
Safety endpoints will be summarized descriptively for the on- treatm ent period, and overall -study period, 
as appropriate. Baseline assessments will be the last assessment before the first dose of study treatm ent.
The number of events, incidence, and percentage of TEAEs and overall -study AEs will be displayed for each 
treatment group by preferred terms using the Medical Dict ionary for Regulatory Activities (MedDRA®). 
Summaries in terms of severity and relationship to study medication will also be provided. Treatment -emergent 
SAEs will be summarized separately in a similar fashion. Summaries of AEs causing discontinuation of s tudy 
medication, withdrawals, AEs leading to death, SAEs, and adverse events of special interest (AESI) w ill be 
provided.
Adverse events of special interest (AESIs) will be analyzed according to prim ary system organ classes 
(SOCs) and preferred terms (PTs) . Standardized MedDRA queries (SMQs) may be used, as applicable. 
Summary tables with SOCs and PTs will be generated presenting the number and percentage of subjects 
by AE, severity, seriousness, and relationship to study medication. Invasive bacterial and fungal 
infections, if any, will be noted.
Usage of concom itant medications will be summarized descriptively for each of the treatm ent groups for 
the on -treatm ent period and overall -study period. Additionally, adm inistration of hematopoietic growth 
factors, blood, and blood products will be summarized.
Change from  Baseline in vital signs and clinical laboratory tests will be summarized for each treatm ent 
group with descriptive statistics at each assessment visit. Additional shift tables m ay be produced for 
selected laboratory param eters using severity grades based on National Cancer Institute (NCI) comm on 
term inology criteria for adverse events (CTCAE v4.0) or using normal/above norm al/below norm al 
range. Analyses of shifts in NCI CTC toxicity grades from bas eline to maximum  grade postbaseline for 
the on -treatm ent period and the overall -study period will be analyzed. Potentially clinically important 
findings will also be summarized.
Treatment- emergent grade 3 or 4 neutropenia (defined respectively as ANC <1,00 0/mm3[1.0 x 109/L]) or ANC 
<500/mm3[0.5 x 109/L]) w ill be summarized as shifts in laboratory results from lower grade to maximum grade 
of either 3 or 4 postbaseline for the on -treatment period and the overall -study period. Time to neutropenia 
development will be evaluated.
Study treatm ent dose adjustment, specifically valganciclovir dose adjustm ent, and interruptions for 
neutropenia or renal function impairment or other AE, and maribavir dose interruptions for any AE, will 
be summarized.
Abnormal physical examination findings will be listed.
For non-commercial use only
Takeda CONFIDENTIAL Page 29
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Summary of ECG findings will be provided by treatm ent groups.
An independent Data Monitoring Committee (DMC) will be established to assess the data for safety and 
to ensure the validity and scientific m erit of the tria l. Detailed plans for the DMC’s purpose and 
responsibilities will be described in the DMC charter and the statistical analysis plan.
PK Analysis:
In order to maintain the study blind, if needed, an interim population PK analysis of maribavir PK data obtained 
from the study subjects will be performed by an independent unblinded team.
Sample Size Justification:
The primary testing is to establish that maribavir is not inferior to valganciclovir in treatment of CMV infection 
in HSCT recipients. For ethical reasons it would not be possible to conduct a study of maribavir versus placebo 
since different treatment strategies are already used and well established in clinical practice to treat CMV 
infection. Valganciclovir has been selected as the active c ontrol because of its documented effectiveness for the 
treatment of CMV infection, including in patients after hematopoietic stem cell transplantation. While clinical 
trials of ganciclovir and valganciclovir versus placebo have been conducted for CMV proph ylaxis, no 
placebo -controlled studies have been done to date for the treatment of CMV infection or disease. Therefore, the 
effect size of valganciclovir against placebo is not available, and treatment effect estimate had to be derived 
indirectly. Literatur e reports viremia clearance rate for valganciclovir at 70% to 100%. In the VICTOR study, a 
randomized controlled study to compare valganciclovir with ganciclovir for the treatment of CMV disease in 
SOT subjects (Asberg et al., 2007 ), the Week 7 viremia clearance rate w as reported at 67% and the derived 
lower limit of the 95% CI was 60% for valganciclovir treatment group (n=164). In Phase 2 treatment 
SHP620 -203 study, 75% of HSCT subjects (n=61 across 3 dose groups) in the maribavir group and 48% in 
valganci clovir group (n=21) had confirmed CMV viremia clearance within 6 weeks. Based on these available 
data, the proportion of subjects who achieve viremia clearance after 8 weeks of treatment in the current study is 
assumed at 60% for the valganciclovir treatme nt group.
A 7% NI margin is chosen for the current study based on the following considerations. First, a 7% of margin 
preserves at least 85% of the effect size assumed for the valganciclovir treatment group. Secondly, a 7% margin 
is less than half of 15%, a common NI margin used in antiviral trials and is considered very conservative. 
TwoNI studies on comparing valganciclovir with ganciclovir in CMV treatment were identified after a 
thorough literature research. One study was reported by Chawla et al. 2011 , and the other is VICTOR study 
(Asberg et al., 2007); both used a NI margin of 15%. Discussions with clinical experts confirmed that a 7% NI 
margin is considered a conservative choice and in clinical practice, a low er response rate might even be 
considere d given the favorable safety profile of the test drug and where toxicities of available treatments such as 
valganciclovir limit their use.
Based on SHP620 -203 study reporting 75% of HSCT subjects in the maribavir group and 48% in valganciclovir 
group havin g confirmed CMV viremia clearance within 6 weeks, it could be expected that maribavir may be 
superior to valganciclovir in the treatment setting in the HSCT population. However, given the uncertainties 
from the differences in this study design from that of SHP620 -203, literature reported treatment effect for 
valganciclovir, and practical consideration for enrollment of sufficient number of patients in this orphan patient 
population, the primary objective of this study is testing for noninferiority, with tes ting for superiority to be 
conducted only after non inferiority is established.
For sample size calculation, to be conservative, it is assumed that 68% and 60% subjects will achieve confirmed 
CMV viremia clearance for the primary efficacy endpoint, in the maribavir and valganciclovir groups, 
respectively. Using the normal approximation method, a 2 -sided 95% confidence interval (CI) of the difference 
in the proportions of subjects with the confirmed CMV viremia clearance will be calculated. If the low er limi t of 
the CI is greater than the predefined NI of 7%, the noninferiority will be assumed. The sample size is estimated 
based on a 2 -group test of equivalence in proportions by using nQuery Advisor 7.0. Based on the above 
assumptions, 494 eligible subjects ( 247 per treatment group) w ill result in a >90% pow er to declare 
noninferiority of maribavir to valganciclovir for the primary efficacy endpoint. Considering 10% subjects who 
are not in the PP Set due to dropout, 550 subjects (275 subjects per treatment arm ) will be enrolled and 
randomized.
For non-commercial use only
Takeda CONFIDENTIAL Page 30
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
STUDY  SCHEDULES
Table 1. Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
Phasea Double -blind Study Treatm ent Phasea,b
Study Visit 1c2 2Ad3 4 5 6 7 8 9 10 (End of 
Treatm ent)
Study Weeke-2 to 0 0 1 1 2 3 4 5 6 7 8
Study Day (perm itted window) -14 to 0 0f4 (±1) 7 (+2) 14 (±2) 21 (±2) 28 (±2) 35 (±3) 42 (±3) 49 (±3) 56
Informed consentgX
Inclusion/exclusion criteria X X
Randomization X
Physical examination (including weight)hX X X
Height X
Weight X X X
Vital signs X X X X X X
Medical history X Xi
Prior medications, therapies, and procedures X X
12-lead ECGjX X
Hem atology/ChemistrykX X X X X X X X X X X
UrinalysiskX X X X X
Pregnancy testlX X X X
HIV statusmX
HBV, HCV test Xn
CMV DNA testoXpX X X X X X X X X
Immunosuppressant drug concentration levelsdXsXsXsX
PK samplestX XsX
Interactive Response TechnologyuX X X X X X X X X
Study treatment dispensedvX X X X X X X X
For non-commercial use only
Takeda CONFIDENTIAL Page 31
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 1. Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
Phasea Double -blind Study Treatm ent Phasea,b
Study Visit 1c2 2Ad3 4 5 6 7 8 9 10 (End of 
Treatm ent)
Study Weeke-2 to 0 0 1 1 2 3 4 5 6 7 8
Study Day (perm itted window) -14 to 0 0f4 (±1) 7 (+2) 14 (±2) 21 (±2) 28 (±2) 35 (±3) 42 (±3) 49 (±3) 56
Study diarywX X X X X X X X X X
Underlying disease assessmentxX X X X X X X X X X
Invasive bacterial and fungal 
infection/transplant relevant infections 
assessmentX X X X X X X X X X
GVHD assessmentyX X X X X X X X X X
Liver function assessment by Child -Pugh 
classificationX
Com orbidity status evaluation X X X
Concomitant medications, therapies, and 
procedureszX X X X X X X X X X
AE/SAE monitoring X X X X X X X X X X
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; ; GVHD=graft -versus -host -disease; 
HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; hx=history; IRT=interactive response technology PK=pharmacokinetic; 
SAE=serio usadverse event; 
aStudy Visit 1 (Screening) and Study Visit 2 (Randomization) must be done with the subject present at the investigative site. Study Visits 2A through 10 may be conducted at 
the clinic or by optional home healthcare visits to extend flexibility to subjects d uring the COVID -19 public health emergency, although it is preferable to conduct Study 
Visit 10 (End of Treatment) with the subject present at the investigative site. Home healthcare visits will be documented in the st udy records and eCRF. 
bSubjects who permanently discontinue study treatment will complete the end- of-treatment procedures described for Visit 10/Study Week 8; these subjects will continue a 
modified schedule of assessments through the remaining weekly visits scheduled for the study treatment phase and the regular schedule of assessments through the 12-week 
follow -up phase. The end of treatment sample for immunosuppressant drug concentration level will be collected at the next visit sche duled one week after the treatment 
discontinuation. Subje cts who discontinue study treatment early will not be asked to complete the following procedures after the end of treatment v isit for subsequent visits in 
the study treatment phase: the use of the diary for study treatment compliance, dispense or use of an y study treatment, and PK sample collection. After completing the 8 -week 
duration specified for the study treatment phase, subjects will enter the 12 -week follow -up phase.
For non-commercial use only
Takeda CONFIDENTIAL Page 32
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 1. Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
Phasea Double -blind Study Treatm ent Phasea,b
Study Visit 1c2 2Ad3 4 5 6 7 8 9 10 (End of 
Treatm ent)
Study Weeke-2 to 0 0 1 1 2 3 4 5 6 7 8
Study Day (perm itted window) -14 to 0 0f4 (±1) 7 (+2) 14 (±2) 21 (±2) 28 (±2) 35 (±3) 42 (±3) 49 (±3) 56
cObtaining Informed Consent is not restricted to Study Visit 1 but can be obtained during the course of the screening phase (Study Weeks -2 to 0) as long as it is obtained 
before any study -specific procedures are performed. During the COVID -19 public health emergency, informed consent from a potential or current trial participant may be
obtained via electronic informed consent (eIC) capabilities or an electronic face -to-face consent interview when these individuals are unable to travel to the site (FDA 
COVID -19 Guidance, 27 Jan 2021, Q11), if permitted by local laws and regulations. All other assessments must be done at the investigative site. 
dImmunosuppressant drug concentration testing and Visit 2A are solely for subjects receiving immunosuppressive therapy with tacrolimus, cyclosporine, everolimus, or 
sirolimus. Visit 2A will occur at Day 4±1day for subjects receiving immunosuppressive agent at baseline; or 4±1 days after initiating one of these immunosuppressive 
treatments for subjects who start during the study.
ePermissible assessment windows: Study Visit 2A, ±1 day, Study Visit 3 (Week 1) +2 days, Study Weeks 2-4, ±2 days; Study Weeks 5-8, ±3 days.
fScreening and Visit 2/Day 0 visits can occur on the same day in the case when historical laboratory values are available for determination of the eligi bility. All Visit 2/Day 0 
procedures and screening laboratory results needed to confirm eligibility must be completed and documented prior to randomization and initiation of study treatment. The test 
results for the samples taken at Visit 2, from central laboratory or central specialty laboratory, will not be available to be used for the screening. Initiation of study treatment 
(ie,first dose) will only occur after completion of all required Visit 2/Day 0 procedures, confirmation of eligibility, and completion of randomization. This wi ll be done under 
the supervision of investigator site personnel.
gInformed consent must be obtained before any study -specific procedures are performed. All screening procedures will be completed within 14 days prior to initiation of study 
treatment, with the exception of: 1) screening clinical laboratory tests (hematology, chemistry, pregnancy), which must be performed and veri fied within 3 days prior to 
initiation of study treatment; either central or local laboratory results for hematology/chemistry/preg nancy testing can be used for qualification, and 2) documentation of CMV 
infection in whole blood or plasma, with a screening value of ≥1365 IU/mL to <273000 IU/mL in whole blood or ≥455 IU/mL to <91000 IU/mL in plasma in 2 assessments, 
separated by at lea st one day, as determined by local or central specialty laboratory quantitative polymerase chain reaction (qPCR) or comparabl e quantitative CMV DNA 
results. Results should be available before the subject is randomized to verify subject eligibility for the study. Both samples should be taken within 14 days of randomization 
with second sample obtained within 5 days before randomization. Same laboratory and sample type (whole blood or plasma) should be used for these assessments.
hSymptom -oriented physical ex aminations other than protocol -specified examinations will be performed when clinically indicated.
iUpdated medical history on Visit 2/Day 0 (Section 5.1).
jECGs other than protocol -specified ECGs will be performed when clinically indicated. For home healthcare visits, ECGs may be performed by a qualified healthcare 
professional who is certified/authorized by the Principal Investigator to perform such tests routinely.
kClinical laboratory tests will be performed at a central laboratory for all specified time points during the study with the exception of Visit 2A (for subjects receiving 
tacrolimus, cyclosporine, everolimus, or sirolimus); a local lab will assess potassium and magnesium at Visit 2A for these subjects. Central or local laboratory results for 
hematology/chemistry/ pregnancy testing can be used for eligibility and their results must be available prior to randomizatio n. Local laboratory beta human chronic 
gonadotropin test results can be used for the assessment of pregnancy on Visit 2/Day 0/Week 0, prior to study drug administration. Sample for 
hematology/chemistry/pregnancy will be taken for analyses by the central laboratory before study drug administration at baseline. For subsequent visits, in addition to 
samples taken for central laboratory analysis at the visit, samples for complete blood count with differential and serum crea tinine should be drawn and analyzed by a local
laboratory within 2 days prior to study treatment dispensation. These local laboratory results should be available and reviewed, to ascertain any dose adjustment of study drug 
(valganciclovir dose adjustment for renal function and/or neutropenia) can be c onducted, if needed, prior to each study treatment dispensation during the treatment phase. For 
home healthcare visits, collection of clinical laboratory samples (blood specimen collection or other diagnostic tests) may b e performed by the investigator or qualified site 
staff who can visit the trial participant’s residence.
For non-commercial use only
Takeda CONFIDENTIAL Page 33
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 1. Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
Phasea Double -blind Study Treatm ent Phasea,b
Study Visit 1c2 2Ad3 4 5 6 7 8 9 10 (End of 
Treatm ent)
Study Weeke-2 to 0 0 1 1 2 3 4 5 6 7 8
Study Day (perm itted window) -14 to 0 0f4 (±1) 7 (+2) 14 (±2) 21 (±2) 28 (±2) 35 (±3) 42 (±3) 49 (±3) 56
lFemale subjects of childbearing potential will have serum pregnancy testing performed at a central or local laboratory. Urine test results may be performed to accommodate 
institutional requirements, however, are not sufficient for eligibility determination.
mHIV status confirmed within 3 months prior to randomization will be used for the evaluation of this criterion. If a subject is known (previously documented ) to be HIV 
positive, thi s information will be used in the eligibility assessment. Local testing during screening will be required for the eligibility assessment for subjects for whose HIV 
status within the 3 months prior to study entry is unknown; negative results must be confirm ed prior to randomization.
nHBV and HCV historical results available within 3 months prior to study treatment initiation will be accepted. If historical values are not available then the test will be 
performed at Visit 2/Day 0. The results of test do not have to be available prior to start of dosing.
oBlood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping) will b e tested in the central specialty laboratory. 
During screening period, local speci alty laboratory results for CMV DNA quantitation (from whole blood or plasma as per site’s standard practice) could be used f or 
eligibility assessment; in this case CMV DNA results from central laboratory are not required. At baseline (Visit 2/Day 0/Week 0) a sample for the CMV DNA quantification 
will be taken and tested at the central specialty lab. At all other visits CMV DNA tests will be conducted at a central specialty laboratory, local specialty laboratory testing 
will be done at the investigator’s di scretion. The screening results, regardless whether from the local or central specialty laboratory, will be utilized for stra tification for 
randomization.
pTo be eligible for randomization, both CMV DNA results must be ≥455 IU/mL in plasma or ≥1365 IU/mL in whole blood.
qSubjects with CMV disease at screening/baseline will be excluded. Subjects will be assessed at subsequent visits during the s tudy for the development of new tissue invasive 
CMV disease, and disease outcome (no change, improvement, resolution).
 
sIf the subject is receiving immunosuppressant drugs (cyclosporine, tacrolimus, sirolimus, or everolimus), as mentioned in Sec tion7.2.3.4 , on Study Day 0, then a blood 
sample to measure immunosuppressant drug concentration will be obtained on Visit Day 0 prior to study treatment administration, at Visit 2A (Day 4 ±1 day), and on Visit 
Day 7 (+2day). If the subject is not receiving immunosuppressant drugs at Day 0, but starts any time after Day 0 while still receiving study treatment, then a blood sample to 
measure immunosuppressant drug concentration will be obtained 4 days±1 day after initiating the immunosuppressant), and at the next scheduled study visit. Tests will be 
performed at a local laboratory. For more details see Section 7.2.3.4 .
tPharmacokinetic (PK) samples should be obtained for all subjects and analyzed for only those subjects who are taking maribavi r. A PK sample will be taken before the 
morning dose of study drug at all 3 PK visits. A PK sample will also be taken 2 -4 hour after the morning dose of study at Visit 3/Week 1 and Visit 10/Week 8. There will be 
no postdose PK sample collected for Visit 6/Week 4. At Visit 3/Week 1 an intensive PK sampling for children ≥16 and <18 years of age will be performed as follows: 
prem orning dose, 1, 2, 3, 4, 6, 8 (all ±5 min), and 12 hours (±15 min) postmorning dose. PK sample collection for children ≥16 and <18 years of age will also be performed at 
Visit 6/Week 4 (one premorning dose PK sample) and at Visit 10/Week 8 (one premorning dose and one between 2-4 hours postmorning dose PK samples). Additional PK 
samples will be collected from the subjects with biopsy proven GI graft -versus host -disease (GVHD) with diarrhea (>300 ml/day) or biopsy proven GI GVHD with nausea 
and vomiting or d ocumented acute GVHD of liver (Stage II), total bilirubin >3 mg/dL or biopsy -proven) with diarrhea (>500 ml/day) or biopsy proven acute GVHD of the 
skin with diarrhea (>500 mL/day) per Boeckh et al. ( 1998 ). See Section 7.2.4.1 for more details.
uThe IRT system will be used for stratification and randomization of eligible subjects at baseline. IRT will be used for dispe nsing study treatment.
vAll dispensed study treatments will be documented on the CRFs a nd/or other investigational product records, and may include additional information as required per 
applicable regulations. The disposition of unused supply of dispensed study treatment that has been prescribed to the subject will be documented in the acco untability log.
For non-commercial use only
Takeda CONFIDENTIAL Page 34
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 1. Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
Phasea Double -blind Study Treatm ent Phasea,b
Study Visit 1c2 2Ad3 4 5 6 7 8 9 10 (End of 
Treatm ent)
Study Weeke-2 to 0 0 1 1 2 3 4 5 6 7 8
Study Day (perm itted window) -14 to 0 0f4 (±1) 7 (+2) 14 (±2) 21 (±2) 28 (±2) 35 (±3) 42 (±3) 49 (±3) 56
wThe study diary will be dispensed at baseline and will be collected at the last follow -up visit. 
 
xUnderlying disease that led to HSCT, including relapse/progression, will be assessed at all visits throughout the study treatment phase.
ySubjects will be stratified at baseline according to presence/absence of acute GVHD.
zIncludes recording of medications and transfusions of blood products. Changes in immunosuppression regimens will also be reco rded.
For non-commercial use only
Takeda CONFIDENTIAL Page 35
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 2. Schedule of Assessment 2: Follow -up Phase
Phase Follow -up Phasea,b
Visit11 12 13 14 15 16 1718 (End of 
Study)
Study Week (Follow -up Week)c9 (1) 10 (2) 11 (3) 12 (4) 14(6) 16 (8) 18 (10) 20 (12)
Study Day (Follow -up Day) 63 (7) 70 (14) 77 (21) 84 (28) 98(42) 112 (56) 126 (70) 140 (84)
Physical examination (including weight) X
Vital signs X
12-lead ECGdX
Hem atology/ChemistryeX X X X
UrinalysiseX
Immunosuppressant drug concentration levelfX
Underlying disease assessmentgX X X X X X X X
Invasive bacterial and fungal infection(s) assessment X X X X X X X X
CMV DNA testhX X X X X X X X
GVHD assessment X X X X X X X X
Com orbidity status evaluation X X X
AE monitoringkX X X X X X X X
SAE monitoringkX X X X X X X X
Concomitant medications, therapies, and procedureslX X X X X X X X
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; GVHD=graft -versus -host -disease; HBV=hepatitis B virus; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IRT=interactive response system; SAE=serious adverse event; 
aSubjects who withdraw from the study during the follow-up phase will perform the Visit 18/Week 20 (Follow -up Week 12) end -of-study procedures.
bIf the subject is unable to or unwilling to travel to the site for the follow -up visits, these visits may be performed remot ely (ie, at the subject’s home) by a qualified and 
authorized Principal Investigator’s designee, and only if permitted by local laws and regulations. However, it is preferable to conduct Study Visit 18 (End of Study) with the 
subject present at the investi gative site. Blood sample for CMV DNA quantitation and clinical laboratory assessments will be collected. AE and SAE collection may be 
completed by telephone follow -up call on the day of the scheduled visit.
For non-commercial use only
Takeda CONFIDENTIAL Page 36
Maribavir
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 2. Schedule of Assessment 2: Follow- up Phase
Phase Follow -up Phasea,b
Visit11 12 13 14 15 16 1718 (End of 
Study)
Study Week (Follow -up Week)c9 (1) 10 (2) 11 (3) 12 (4) 14(6) 16 (8) 18 (10) 20 (12)
Study Day (Follow -up Day) 63 (7) 70 (14) 77 (21) 84 (28) 98(42) 112 (56) 126 (70) 140 (84)
cPermissible assessment windows: Study Weeks 9-12 (Follow -up Weeks 1-4) ±2 days; Study Weeks 14-20 (Follow -up Weeks 6-12) ±3 days.
dECGs other than protocol -specified ECGs will be performed when clinically indicated. For home healthcare visits, ECGs may be performed by a qualified healthcare 
p
rofessional who is certified/authorized by the Principal Investigator to perform such tests routinely.
eClinical laboratory testing performed at a central laboratory for all specified time points during the follow -up phase.
fSee Section 7.2.3.4 for more details.
gUnderlying disease that led to HSCT, including relapse/progression, will be assessed at all visits throughout the follow -up phase.
 
kSAEs and nonserious AEs deemed related to stu dy drug will be monitored and recorded through Visit 18/Week 20/Follow -up Week 12 (end of study). Nonserious AEs will 
be recorded through 30 days after the last dose of study medication.
lAll medications, therapies, and procedures used to treat AEs will b e recorded through Visit 18/Week 20 (Follow -up Week 12/end of study).
For non-commercial use only
Take da CONFIDENTIAL Page 37
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
1.BACKGROUND INFORMATI ON
1.1Indication and Current Treatment Options
Cytomegalovirus (CMV) is a beta herpesvirus that commonly  infects humans; serologic 
evidence of prior infec tion can be found in 40- 100% of various adult populations 
(de la Hoz et al., 2002 ). It is one of the most important complications associated with 
significant morbidit y and mortality in the individuals with compromised immune systems af ter 
allogenic hematopoietic stem cell transplantation (HSCT) ( de la Hoz et al., 2002; 
Razonable and Emery , 2004 ; Maffini et al., 2016 ). Cy tomegalovirus can cause multiorgan 
disease in recipients of stem cell transplants, including pneumonia, hepatitis, gastroenteritis, 
retinitis, and encephalitis, and the disease can develop both earl y and late after the 
transplantation p rocedure ( Boeckh et al., 2003 ; Boeckh and Ljungman, 20 09;Krause et al., 1997 ; 
Zaia et al., 1997 ). In addition to the direct effects that manifest as CMV orga n disease or 
symptomatic infection, CMV also is known to have several potential indirect effects. These 
indirect effects include an increased incidence of opportunistic infections, an association between 
CMV and graft -versus- host disease (GVHD), and reduce d survival in HSCT patients 
(Boeckh and Ljungman, 2009). These effects are believed to be mediated by  the virus’s ability  to 
modulate the immune system, either directl y or secondary  to the host antiviral response through 
regulation of cy tokine, chemokine, and/or growth factor production.
Prevention strategies based on proph ylactic antiviral th erapy have not been common in HSCT in 
contrast with solid organ transplant (SOT). Before the introduction of ganciclovir (one of the 
available anti- CMV agents), the vast majority  of CMV infections occurred in the time period 
between engraftment and day 100 after hematopoietic SCT, with sporadic occurrences before 
engraftment 
(Bueno et al., 2002 ). However, whereas the prevalence of earl y CMV disease 
declined with intense antiviral drug use, the incidence of bacterial and fungal infections as well 
as late CMV disease increased, without an impact on the mortality  rate 
(Ariza -Heredia et al., 2014 ; Boeckh et al., 2003 ; Zaia et al., 1997 ).
Although currentl y available systemic anti -CMV agents, intravenous (IV) or oral ganciclovir, 
oral valganciclovir (a prodrug of ganciclovir with improved bioavailability ), IV foscarnet, and 
IVcidofovir are generally  effective, however, their use is limited by  their respective toxicities; 
bone marrow suppression caused b y ganciclovir/valganciclovir and renal impairment caused b y 
foscarnet or cidofovir ( Boeckh et al., 2003 ; Ljungman et al., 2001 ; Maffin i et al., 2016 ;
Reusser et al., 2002; Salzberger et al., 1997). These toxicities are of particular concern in HSCT 
recipients, in whom the bone marrow has been ablated or significantl y suppressed, who receive 
ongoing immunosuppressants to prevent GVHD, or who may  require the use of other therapies 
that are potentiall y toxic to the kidney s or other organs.
For non-commercial use only
Take da CONFIDENTIAL Page 38
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Regardless of currently  available antiviral strategies that exist for various high- risk transplant 
subjects, the adverse effects of these strategies have led to low use of prophylaxis in the HSCT 
recipients who continue to remain at risk for CMV infection within the early  (initial ~3months) 
or later post -transplantation time periods ( Boeckh et al., 2003 ; Legendre and Pascual, 2008 ).
In contrast, pre -emptive strategies are widel y preferred as a prevention method by transplant 
centers and include close surveillance of target viral DNA concentration (CMV viremia), which 
varies depending on host’s risk for CMV disease, current immunosuppression, and treatment 
center practice. Cy tomegalovirus viremia is considered one of the most important predictors of 
development of CMV disease ( Emery  et al., 2000 ; Humar et al., 1999).
The currently  available anti- CMV agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) 
albeit extensively  used in preemptive and treatment setting for CMV infection are not approved 
for this indication, and their use is limited by  their toxicities. Also, development of anti- viral 
resistance to these anti-CMV agents is an ongoing clinical problem leading to graft loss and even 
mortality  for some transplant patients, including HSCT pati ents.
Maribavir is currently under development for the treatment of CMV infection or disease, 
including those resistant or refractory  to ganciclovir, valganciclovir, foscarnet, or cidofovir, in 
transplant recipients (HSCT and SOT). Based on clinical studie s completed to date, maribavir 
does not appear to cause bone marrow suppression or renal toxicities and therefore may  offer a 
safer option for CMV treatment in HSCT patients.
1.2Maribavir Background and Clinical Information
Maribavir is a potent and selective , orally  bioavailable antiviral drug with a novel mechanism of 
action against CMV ( Chulay  et al., 1999) and a favorable nonclinical and clinical safet y profile. 
It is a potent member of a new class of drugs, the benzimidazole ribosides 
(Williams et al., 2003 ). In side -by-side in vitro assay s it is 3 -to 20 -fold more potent than 
ganciclovir and cidofovir, and at least 100 -fold more potent than foscarnet 
(Biron et al., 2002 ; Drew et al., 2006 ). Unlike currently  available anti- CMV agents that inhibit 
CMV deox yribonucleic acid (DNA) pol ymerase, maribavir inhibits the CMV UL 97 
serine/threonine kinase by  competitively  inhibiting the binding of adenosine triphosphate (ATP) 
to the kinase ATP -binding site ( Biron et al., 2002 ; Williams et al., 2003 ;
 Krosky et al., 2003 ; 
Wolf et al., 2001; Kern et al., 2004 ); the dominant phenoty pic inhibi tory effect of maribavir is on 
viral DNA assembly  and egress of viral capsids from the nucleus of infected cells 
(Biron et al., 2002 ). Except for ganciclovir, maribavir does not antagonize the effects of other 
anti-viral (anti -CMV) agents. Since ganc iclovir is dependent on its initial phosphory lation by  the 
viral UL97 kinase, maribavir may  antagonize its clinical efficacy . Maribavir is active in vitro 
against strains of CMV that are resistant to ganciclovir, foscarnet, or cidofovir.
For non-commercial use only
Take da CONFIDENTIAL Page 39
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
1.2.1 Pharmacokinetics, Metabolism, and Drug -Drug Interactions
Following oral administration, maribavir was rapidly  and well absorbed with mean peak plasma 
concentrations generally  achieved between 1 and 3 hours postdose. Total exposure to maribavir, 
as measured b y area under the curve (AUC), was approximately  dose -proportional following a 
single dose from 50 to 1600 mg, or multiple doses from 300 to 2400 mg per day . Maribavir 
demonstrates time independent pharmacokinetics (PK). When coadministered with a moderate 
fat meal, mariba vir AUC was not changed, while the maximum observed plasma concentration 
(Cmax) was reduced b y 28%. Maribavir can be taken with or without food, as the slight to 
moderate decrease in exposure is not considered clinically  significant based on the accumulate d 
efficacy  and safet y data. Bioavailability  of a 100 mg tablet was unaffected by  crushing the tablet 
or changes in gastric pH. Maribavir is highl y bound to plasma proteins (98.0% in vitro and 
98.5% to 99.0% ex vivo), and binding appears to be independent o f maribavir plasma 
concentrations at the therapeutic doses and populations (healthy  subjects, subjects with renal or 
hepatic impairment, and transplant patients). Maribavir can penetrate the blood -retinal barrier, 
with the ratio of vitreous humor to plasma maribavir concentrations ranging from 0.026 to 0.281, 
which is greater than the free fraction in plasma. Maribavir is not expected to cross the blood 
brain barrier in human based on the nonclinical data. Following 400 mg BID doses, the 
elimination half -life (t1/2) of maribavir was estimated to be 4.32 hours in adult transplant 
patients. Due to the relatively  short t1/2, steady  state was reached within 2 day s of dosing, with 
the accumulation ratio ranging from 1.24 to 1.49 for AUC after BID dosing. Maribavi r is 
metabolized primarily  in the liver through cy tochrome P450 (CYP) 3A4 (primary ) and CYP1A2 
(secondary ) pathway s with the formation of the primary  metabolite, VP44469. Renal clearance is 
a minor route of elimination of maribavir.
Based on in vivo data a nd population PK analy sis, no maribavir dose adjustment is needed based 
on transplant ty pe, age, gender, race, in patients with mild or moderate hepatic impairment, or in 
patients with mild, moderate, or severe renal impairment.
Maribavir is contraindicate d with valganciclovir/ganciclovir as it may  antagonize ganciclovir’s 
antiviral effects due to maribavir’s inhibitory  effect on UL97 serine/threonine kinase, which is 
required for activation/phosphorylation of ganciclovir. Maribavir can be administered with other 
anti-CMV drugs, including letermovir, foscarnet, and cidofovir as clinically significant PK -or 
pharmacod ynamic -based drug -drug interactions (DDIs) are not expected. Based on extensive in 
vitro and in vivo data, maribavir has a low propensity  to cau se, or be the victim of DDIs. Dose 
adjustment of maribavir is only  needed when maribavir is coadministered with a strong or 
moderate CYP3A4 inducer. With the exceptions of selected immunosuppressants and 
rosuvastatin, coadministration with maribavir does n ot impact the use or outcomes of a wide 
range of other drugs commonly  used in the target patient population.
For non-commercial use only
Take da CONFIDENTIAL Page 40
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Strong or moderate CYP3A inducers may  significantly  decrease the plasma exposure to 
maribavir. Coadministration with rifampin (a strong inducer of CYP3A and moderate inducer of 
CYP1A2) decreased Cmax, AUC and predose trough concentration (C trough) by 39%, 60% and 
82%, respectively , and therefore, is not recommended due to the potential for a decrease in 
efficacy  of maribavir based on the magnitude of the reduction in maribavir C trough. Alternative 
antimicrobial or antituberculosis therap y with a lower CYP3A induction potential (eg, 
pyrazinamide, ethionamide) should be considered.
Strong CYP3A4 inhibitors may  increase the plasma exposure to maribavir. Coadministration 
with ketoconazole (a strong CYP3A and P -glycoprotein [P -gp] inhibitor) increased Cmax and 
AUC by  10% and 53%, respectivel y. Based on the less than 3-fold increase in maribavir 
exposure expected, lack of dose- limiting toxicity  and a wide therapeutic window, maribavir can 
be coadministered with a strong CYP3A4 inhibitor (eg, clarithrom ycin, ketoconazole, 
itraconazole, posaconazole, and voriconazole) without dose adjustment.
Coadministration of 400 mg BID maribavir with tacrolimus (an immunosu ppressant and a 
CYP3A4 and P -gp substrate) increased the tacrolimus whole blood Cmax, AUC, and Ctrough b y 
38%, 51%, and 57%, respectivel y. When immunosuppressants tacrolimus, cyclosporine, 
everolimus, or sirolimus are coadministered with maribavir, their w hole blood concentrations 
should be frequently  monitored during treatment and after discontinuation of maribavir.
Maribavir is an in vitro inhibitor of breast cancer resistance protein (BCRP). To be cautious, it is 
recommended that when initiating maribavi r dosing in patients who are taking rosuvastatin (a 
sensitive BCRP substrate), patients should be closely  monitored for rosuvastatin -related events, 
especiall y the occurrence of my opathy  and rhabdomy olysis.
1.2.2 Efficacy
Once the safet y and tolerability  of mari bavir was established across a wide range of doses (up to 
2400 mg/day  for 28 days) in 17 Phase 1 studies, the clinical development plan focused on 
maribavir as an anti-CMV agent for the prevention of CMV disease in transplant patients. 
Results from the Pha se3 trials for CMV prevention, where maribavir was administered at 
100mg BID for up to 12 weeks in HSCT recipients and up to 14 weeks in liver transplant 
recipients, failed to show reduction in the incidence of endpoint adjudication committee 
confirmed C MV disease within 6 months following HSCT when compared with placebo 
(Study 1263-300), and failed to show noninferiority  to ganciclovir with respect to the incidence 
of endpoint adjudication committee confirmed CMV disease within 6 months following liver 
transplantation (Study  1263 -301).
For non-commercial use only
Take da CONFIDENTIAL Page 41
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Maribavir was used for treatment of CMV infections in 6 transplant recipients (5 SOT, 1 HSCT) 
under individual emergency  investigational new drug (EIND) applications in the 
United States (US) ( Avery  et al., 2010 ).
All patients had previously  been treated with multiple other anti -CMV drugs, and 4 out of 6 had 
known genoty pic CMV resistance to 1 or more of those CMV drugs. For all 6 patients, oral 
maribavir treatment was initiated at a dose of 400 mg BID. In 2 patients, the dose was increased 
to 800 mg BID. The duration of treatment was individualized for each patient based o n response. 
Maribavir appeared to be safe and well- tolerated, as it was administered for prolonged periods of 
time (4 out of 6 patients were dosed >6 months). Three patients reported 7 serious adverse events 
(SAEs), all of which were considered to be unrel ated to maribavir.
Within 6 weeks of starting maribavir treatment, all subjects had a >1 log decrease in blood CMV 
DNA, and 4 of the 6 patients had no detectable CMV. Cy tomegalovirus viremia persisted in 
2patients despite dosing >6 months; 1 of these pati ents had unusually  low exposure to maribavir 
based on trough blood levels. The other patient in whom CMV viremia persisted had a very  high 
baseline CMV DNA level. The genoty pic anal ysis for this patient revealed the presence of 
UL97maribavir -resistance mu tations T409M and H411Y ( Strasfeld et al., 2010).
Subsequently , in Europe, more than 200 patients received maribavir through a named patient 
program (NPP), and in France, t hrough the authorized therapeutic -use procedure. Data from onl y 
a small subset of the French NPP were reported. These data were consistent with the US EI ND 
experience. Additional details regarding these patients are available in the maribavir 
investigator’ s brochure.
The data obtained from the small number of patients in EI ND and NPP, suggested that maribavir 
was associated with a reduction in CMV DNA in the blood in the majority  of subjects, and could 
be useful for the treatment of CMV infections including these that are resistant or refractory  to 
currentl y available anti -CMV therapies. As a result, two Phase 2 studies were conducted to 
assess the safety , tolerability , and anti -CMV activity  of maribavir for treatment of CMV 
infections: Study SHP620 -202 in t ransplant recipients with CMV infections or disease that are 
resistant or refractory  to treatment with anti -CMV agents conducted in the US and 
Study 1263- 203 (SHP620- 203) in transplant recipients with wild -type CMV infections who do 
not have CMV organ dise ase (as ymptomatic) conducted in Europe. In these studies subjects 
received maribavir at 1 of 3 dose strengths: 400, 800, or 1200 mg BID. Both studies 
demonstrated favorable anti -CMV activity  of maribavir and showed that maribavir was 
well-tolerated with no safety  concerns at all doses evaluated.
For non-commercial use only
Take da CONFIDENTIAL Page 42
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The primary  efficacy  endpoint for Study  SHP620- 202 was confirmed undetectable plasma CMV 
DNA within the 6 weeks after starting stud y drug treatment, defined as 2 consecutive 
postbaseline, on treatment undetectable r esults (<200 copies/mL ) separated by  at least 5 days. 
Overall, 67% of subjects achieved confirmed undetectable plasma CMV DNA within 6 weeks. 
Among maribavir groups, there was no strong evidence of dose strength differentiation in the 
proportion of subject s achieving the endpoint. Among subjects with ≥1investigator -reported 
CMV genetic mutation associated with resistance to ganciclovir/valganciclovir or foscarnet at 
baseline, 43/71 (61%) achieved confirmed undetectable plasma CMV DNA within 6 weeks after 
starting treatment with maribavir.
Secondary  efficacy  endpoints for Study  SHP620-202 included CMV recurrence, defined as 
achievement of undetectable plasma CMV DNA in at least 2 consecutive samples separated b y at 
least 5 days at an y time after Day 1, follo wed b y detectable plasma CMV DNA in at least 
2consecutive samples separated b y at least 5 days. Overall, 30/86 (35%) maribavir subjects had 
a CMV recurrence at an y time during the stud y (Note: Percentage is based on the number of 
subjects achieving undete ctable CMV DNA). Twenty -four of the 30 subjects had a CMV 
recurrence while on study  drug. Thirteen of these 24 subjects developed UL97 mutations 
previously  described to confer resistance to maribavir that were not present prior to study  drug 
dosing. The re maining 6 maribavir subjects had a CMV recurrence after the end of treatment 
with study  drug.
The primary  efficacy  endpoint for Study  SHP620- 203 was confirmed undetectable plasma 
CMV DNA within 3 and 6 weeks after starting study  drug treatment, defined as 2consecutive 
postbaseline, on treatment undetectable results (<200 copies/mL ) separated by  at least 5 days. 
The proportion of subjects with undetectable plasma CMV DNA within 3 and 6 weeks 
after starting study  drug treatment was numerically  higher in the maribavir group than the 
valganciclovir group. Among the 3 maribavir dose strength groups, there was no difference 
inthe proportion of subjects achieving the endpoint. I n the subgroup of subjects whose 
transplant type was HSCT, a numerically  higher percentage of subjects in the overall 
maribavir group (75%) than the valganciclovir group (48%) achieved confirmed undetectable 
plasma CMV DNA within 6 weeks. Although the percentage of subjects with high baseline 
plasma CMV DNA ( ≥10000 copies/mL ) was simi lar between the overall maribavir and 
valganciclovir groups (34% vs. 33%), a numerically  higher percentage of maribavir subjects 
(77%) achieved confirmed undetectable plasma CMV DNA within 6 weeks compared with 
valganciclovir (65%).
Secondary  efficacy  endp oints for Study  SHP620- 203 included CMV recurrence; this was 
assessed within 6 weeks after starting stud y drug treatment and within the study  participation 
period. 
For non-commercial use only
Take da CONFIDENTIAL Page 43
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Overall, 22/98 (22%) maribavir subjects and5/28 (18%) valganciclovir subjects experienced a
CMV recurrence within the study  participation period (Note: Percentages are based on the 
number of subjects achieving undetectable CMV DNA). Four of the 22 maribavir subjects 
recurred while on stud y drug (2 subjects each in the 400 mgBID and 800 mgBID groups). All 
4of these subjects developed UL97 mutations previously  described to confer resistance to 
maribavir that were not present prior to stud y drug dosing. The remaining 18 maribavir subjects 
and all 5 valganciclovir subjects experienced a CMV recurr ence after the end of study  drug 
treatment.
Phase 3 registration trials have been planned based on the results from these Phase 2 studies for 
CMV treatment.
1.2.3 Safety
Maribavir has been administered across a broad range of oral doses from 50 -2400 mg/day . 
Clinical safety experience has been obtained from 17 Phase 1 studies in adult healthy  volunteers, 
special populations (subjects with renal and hepatic impairment, and stable renal transplant 
recipients), and HIV -infected subjects.
Maribavir had a favorable saf ety and tolerability  profile in both the Phase 2 and Phase 3 trials for 
CMV prophy laxis. Adverse events (AEs) were most commonly  associated with gastrointestinal 
(GI) disorders (eg, diarrhea, d ysgeusia, nausea, and vomiting). These events were generally  of
mild or moderate intensity. There were no signals of clinically significant effects of maribavir on 
vital signs, electrocardiogram (ECG) parameters, or laboratory findings in the studies conducted 
for CMV proph ylaxis.
In both Phase 2 studies for treatment of CMV infection (Studies SHP620 -202 and SHP620 -303), 
subjects received maribavir at 1 of 3 dose strengths: 400, 800, or 1200 mg BID, and both 
studies demonstrated that maribavir was well- tolerated with no safet y concerns at all doses 
evaluated. In Stud ySHP620 -202, treatment -emergent AEs (TEAEs) that occurred were events 
alread y observed in previous studies (ie, dysgeusia, GI events, elevated immunosuppressant drug 
levels, and rash) and there were no additional safety  concerns raised from this study . In 
Study SHP620 -203, TEAEs that occurred at a higher frequency  in maribavir subjects compared 
with valganciclovir were events alread y observed in previous studies with maribavir 
(ie,dysgeusia, GI events, and elevated immunosuppressant drug levels). Analy ses o f clinical 
laboratory , vital signs, and ECG data did not identify  any clinicall y meaningful differences 
across the maribavir treatment groups.
For non-commercial use only
Take da CONFIDENTIAL Page 44
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Based on the Phase 2 CMV treatment and Phase 3 CMV prophy laxis studies, the adverse drug 
reactions (ADRs) associa ted with maribavir use are: abdominal pain, abdominal pain upper, 
decreased appetite, diarrhea, dizziness, dy sgeusia, fatigue, headache, immunosuppressant drug 
level increased, nausea, and vomiting.
To date, maribavir has shown an overall favorable safet y profile in placebo -controlled studies, 
open -label studies, and in studies that compared maribavir with other CMV therapies 
(ganciclovir, valganciclovir) for proph ylaxis and for CMV treatment in HSCT and SOT patients. 
Treatment effect on viral load reduction (confirmed undetectable plasma CMV DNA: 67% of 
subjects within 6 weeks in Study  SHP620- 202; 60.5% of subjects in 3 weeks and 77.3% of 
subjects in 6 weeks in Study  SHP620- 203) seen in Phase 2 treatment studies coupled with 
acceptable safet y and tolerabili ty establish the positive benefit -risk profile and warrant further 
investigation of maribavir in the treatment of CMV infections in transplant recipients.
Refer to the latest version of the maribavir investigator’s brochure for the most detailed and most 
current information regarding the drug metabolism, pharmacokinetics, efficacy ,and safety  of 
maribavir.
For non-commercial use only
Take da CONFIDENTIAL Page 45
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
2. STUDY OBJECTIVES AND PURPOSE
2.1Rationale for the Study
There are no anti -viral drugs specificall y approved for treatment of CMV infection in transplant 
recipients, including in pediatric populations. However, both (IV) ganciclovir, approved for the 
treatment of CMV retinitis in immunocompromised patients including patients with AI DS and 
prevention of CMV disease in transplant recipients at risk for CMV disea se, and oral 
valganciclovir approved for treatment of CMV retinitis in patients with AIDS and prevention of 
CMV disease in solid organ transplant recipient are widel y used in clinical practice to treat CMV 
infection. The most common adverse effect of both treatments is bone marrow suppression, 
which is of particular concern for HSCT recipients whose marrow has been ablated or who are 
significantl y immunosuppressed to prevent GVHD. Contributing factors for development of 
cytopenias include viral infection, septicemia, GVHD, and m yelotoxic drugs in addition to 
valganciclovir. Of the commonly  used drugs with my elotoxic potential, ganciclovir is 
particularl y prone to cause neutropenia. The underly ing mechanism of ganciclovir -related 
neutropenia is a dose -depende nt inhibition of DNA -polymerase in hematopoietic progenitor cells 
(Sommadossi and Carlisle, 1987). The rates of valganciclovir -related neutropenia in HSCT range 
from 19% ( Barkam et al., 2012) and 33% ( Takahata et al., 2015 ) to 55% ( Boeckh et al., 2015 ) . In 
the study  by Salzberger et al. (1997), a clear trend was observed between the degree of 
neutropenia and the rate of bacterial infections while an increased incidence of fungal infecti ons 
was present only  in patients with an absolute neutrophil count (ANC) of less than 200/μL , 
whereas there was no significant trend over the different degrees of neutropenia. In the same 
study  neutropenia was found to be an independent risk factor for poo r long -term outcome. This 
was shown as a negative effect on overall survival and nonrelapse mortality.
Maribavir is an anti -CMV agent that may  be of particular benefit to transplant patients as it does 
not appear to cause bone marrow suppression. In additi on to the favorable safet y profile of 
maribavir observed in earlier Phase 1-3 studies (studies evaluating prophy lactic administration of 
maribavir), results from a recent large Phase 2 randomized trial (Study 1263 -203) support the 
safet y, tolerabilit y, as well as anti -viral activity  of maribavir as a potential option for the 
treatment of CMV infections in transplant recipients. Study 1263- 203 was a multicenter, 
randomized, dose- ranging, parallel- group stud y of maribavir versus valganciclovir for the 
treatme nt of CMV infections in HSCT or SOT recipients. Eligible subjects were randomized in a 
1:1:1:1 allocation ratio (40 subjects per group) to receive oral maribavir at 400 mg, 800 mg, or 
1200 mg BID; or valganciclovir (900 mg BID for 3 weeks, 900 mg once dail y (QD) after 
3weeks) for up to 12 weeks. Maribavir, at doses ≥400 mgBID, had comparable efficacy  to 
valganciclovir at clearing CMV viremia and was generall y well tolerated across the dose range 
studied. 
For non-commercial use only
Take da CONFIDENTIAL Page 46
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Inthesubgroup ofsubjects whose transplant typewasHSCT, anumerically higher percentage 
of subjects in the overall maribavir group (75%) than the valganciclovir group (48%) achieved 
confirmed undetectable plasma CMV DNA within 6 weeks of treatment. There was a 
higher incidence of neutropenia through Week 12 for valganciclovir -treated subjects 
compared with maribavir -treated subjects. This was evident for both measured degrees of 
neutropenia: 18% versus 5% (absolute neutrophil count [ANC] <1000/mm3), and 5% versus 
2%(ANC<500/mm3) through Week 12 for t he valganciclovir and overall maribavir groups, 
respectivel y.
This Phase 3 study  is designed to further assess and demonstrate the efficacy  and safet y of 
maribavir, administered at 400 mg BID, compared to valganciclovir administered at 900 mg BID 
for the t reatment of as ymptomatic CMV infection in HSCT recipients.
2.2Rationale for the Study Design
This Phase 3 study  will be conducted in HSCT recipients due to the relatively  high risk for 
CMV infection resulting from ongoing immunosuppression to prevent GVHD. Ga nciclovir and 
valganciclovir are commonly  used to treat CMV infection in HSCT recipients and are generally  
considered effective, but present toxicity  issues with respect to bone marrow suppression which 
may require management with hematopoietic growth factors, discontinuation of treatment, 
andmay increase risk for opportunistic infections ( Busca et al., 2007; Reusser et al., 2002 ). 
Additional constraints are present if treatment initiation is required in the pr e-engraftment period. 
Alternative treatment by  foscarnet or cidofovir is limited by  nephrotoxicity  of these medications 
(Reusser et al., 2002; Tombly n et al., 2009). Maribavir may  address safety  limitations of 
currentl y available treatment.
Oral valganciclovir is the active control for this study  to allow for the interpretation of 
virologic response to maribavir. While I V ganciclovir may  be appropriate for certain 
patients, itpresents the challenges inherently  associated with administration of an y IV 
medication, particularl y when treatment may  last longer. Oral valganciclovir (Valcy te®) 
900mgprovides ganciclovir exposure comparable to that of IV ganciclovir 5 mg/kg 
(refer totheValcy tePrescribing Information as documented in the Study Pharmacy Manual; 
Winston et al., 2006) and the VI CTOR study  provided evidence that valganciclovir has 
comparable safet y and is not inferior to standard IVganciclovi r treatment for eradication of 
viremia and clinical success in solid organ transplant recipients with CMV disease ( Asberg et al., 
2007; Tombly n et al., 2009 ).
For non-commercial use only
Take da CONFIDENTIAL Page 47
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Study  subjects will be randomized to receive either maribavir or valganciclovir for 8 weeks 
during the double -blind treatment phase. In the SHP620 -203 study  (HSCT and SOT recipients 
with asy mptomatic CMV infection), the majorit y of maribavir and valganciclovir subjects 
achieved confirmed undetectable plasma CMV DNA levels b y Week 6 of study  drug treatment, 
while CMV recurrence occurred at rates expected for such a population with continued 
immu nosuppression. Maribavir administered at 400 mg, 800 mg, and 1200 mg BID achieved 
CMV viremia clearance within 3 weeks to 6 weeks after starting the stud y drug treatment. 
Therefore, an 8 -week treatment regimen will be administered in this Phase 3 study  to account for 
maximum treatment period of 6 weeks where maribavir demonstrated a comparable efficacy  to 
valganciclovir (900 mg BID from Weeks 1-3, and 900 mg QD after Week 3) in 
Study SHP620 -203, adding 2 weeks for secondary prophy laxis.
As there are current ly no approved therapies for the treatment of CMV infections in the pediatric 
transplant recipient population, this study  will initiate the assessment of maribavir use in the 
pediatric population b y enrolling adolescent subjects ≥16 to <18 years of age.
2.3Rationale for Dose Selection
Results from the Phase 2 studies SHP620-202 (HSCT and SOT recipients with resistant or 
refractory  CMV infections) and SHP620
-203 (HSCT and SOT recipients with asy mptomatic 
CMV infection) demonstrated comparable efficacy across th e 400 mgBID, 800 mgBID, 
and1200 mgBID maribavir dose groups in the clearance of CMV viremia within up to 
6weeks after starting study  drug treatment. In both Phase 2 studies, the most common 
treatment -emergent adverse events included d ysgeusia, nausea, vomiting, and diarrhea, and 
elevated immunosuppressant drug concentration levels. There was a dose -dependence for 
dysgeusia and elevated immunosuppressant drug concentration levels. These findings 
(comparable efficacy and better safety  profile with the 40 0mg dose) support the further 
evaluation of 400 mg BID maribavir for the treatment of CMV.
Currently  available maribavir pharmacokinetics, PK modeling and extrapolation of sy stemic 
exposure from adults, and safet y and tolerability data in adults support t he administration of the 
400mg BID dose in adolescents who weigh ≥35kg and are able to swallow tablets. Per L u and 
Rosenbaum ( 2014), the expression of CYP3A4 and CYP 2C19, which are primary  enzy mes for 
maribavir metabolism in the liver, occurs during the first weeks of life. The expression of 
CYP1A2, which is also involved with maribavi r metabolism, the last enzy me to develop, is 
present b y 1 to 3 months of life. By  1 to 2 years of age, all the isoenzy me activities are similar to 
those of adults. Therefore, the bioavailability  and sy stemic exposure of maribavir in adolescent 
subjects ( ≥16 and <18 years of age) is not expected to be different from adults at the same oral 
dose.
For non-commercial use only
Take da CONFIDENTIAL Page 48
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Although t ypicall y valganciclovir treatment in HSCT patients is started as an induction dose of 
900mg BID for up to 14 days and then reduced to a maintenance dose o f 900 mg QD for a 
further 2 weeks or until CMV viral load clearance ( Tombly n et al., 2009 ), a different dosing 
strategy  was selected for this study  based on input from regulatory  authorities. Treatment with 
valganciclovir 900 mg BID for the duration of 8 weeks was chosen in order to eliminate a 
potential bias for efficacy  in favor of the investigational treatment (maribavir) by  administering 
the comparator (valganciclovir) at the higher dosage throughout. Treatment with valganciclovir 
at a lower dosage based on CrCl would be allowed to ensure comp arable exposures in renally  
impaired subjects.
2.4 Study Objectives
2.4.1 Primary Objective
The primary  objective of the study  is to compare the efficacy  of maribavir to valganciclovir in 
CMV viremia clearance at the end of Study  Week 8 in asy mptomatic CMV infection in HSCT 
recipients.
2.4.2 Key Secondary Objective
The key  secondary  objective of this study  is to compare the efficacy  of maribavir and 
valganciclovir on maintenance of CMV viremia clearance, achieved at the end of Study  Week 8 
through Stud y Week 16 (8 weeks of post-treatment/follow -up phase).
2.4.3 Secondary Objectives
The secondary  objectives of this study  are:
To compare the efficacy  of maribavir to valganciclovir in CMV viremia clearance after 
completion of 8 weeks of treatment for as ymptomatic CMV infection in HSCT recipients .
To compare the efficacy  of maribavir and valganciclovir on maintenance of CMV viremia 
clearance, achieved after completion of 8 weeks of treatment, through Study Weeks 12 
(4weeks of post -treatment period), 16 (8 weeks of post -treatment/fo llow-up phase), and 
20(12weeks post -treatment).
To assess the maintenance of CMV viremia clearance, achieved at the end of Study  Week 8, 
through Weeks 12 (4 weeks of post -
treatment period), and 20 (12 weeks post -treatment).
To evaluate the incidence of r ecurrence of confirmed CMV viremia in the 2 study  treatment 
arms during the first 8 weeks of the stud y, during the 12 weeks of the follow -up study  phase, 
and at an y time during the study .
For non-commercial use only
Take da CONFIDENTIAL Page 49
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
To evaluate the incidence of recurrence of confirmed CMV viremia in the 2 study  treatment
arms when subjects are on treatment and off treatment.
To evaluate the incidence of treatment -emergent grade 3 or 4 neutropenia (defined as
ANC<1000/mm3or ANC<500/mm3) while on treatment.
To assess the safet y and tolerability of mari bavir compared to valganciclovir.
To characterize the PK of maribavir.
2.4.4 Exploratory Objectives
For non-commercial use only
Take da CONFIDENTIAL Page 50
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
3.STUDY DESIGN
3.1Study Design and Flow Chart
This is a multicenter, randomized, double -blind, double -dummy , active -controlled study  of 
maribavir compared to valganciclovir for the treatment of as ymptomatic CM V infection in 
HSCT recipients. “ Asymptomatic subjects” at baseline will be defined as HSCT recipients who 
do not have tissue- invasive CMV disease as determined by  the investigator according to the 
criteria specified b y Ljungman et al. ( 2017 ). The study  will assess the efficacy  of maribavir by  
measuring the plasma CMV DNA clearance. To be eligible for the study , subjects must have a 
documented as ymptomatic CMV infection with a screening value of CMV DNA ≥1365 IU/mL 
to ≤273000 IU/mL in whole blood or ≥455 IU/mL to ≤91000 IU/mL in plasma in 2 consecutive 
assessments, separated by  at least 1 day, as determined by  local or central specialty  laboratory  
quantitative poly merase chain reaction (qPCR) or comparabl e quantitative CMV DNA results.
Results for CMV and, in subjects with very  low viral load, evaluations for high- risk CMV 
infection (Section 7.1.1) should be available before the subject is randomized to verify  subject 
eligibility  for the study . Both samples should be taken within 14 days prior to randomization 
with the second sample obtained within 5 days before randomization. The same laboratory  and
sample ty pe should be used for these assessments. Subjects must not have CMV tissue invasive 
disease (s ymptomatic CMV infection), must not have a CMV infection that is known to be 
genot ypically resistant to anti- CMV drugs, and must meet the remaining spec ified eligibility  
criteria. Subjects treated with ganciclovir, valganciclovir, foscarnet, or letermovir for the current 
CMV infection should not be treated with these anti- CMV agents for longer than 72 hours prior 
to enrolling in the stud y.
All eligible su bjects will be stratified based on last prebaseline whole blood or plasma 
CMV DNA concentration (high viral load with CMV DNA ≥27300 IU/mL in whole blood or 
≥9100 IU/mL in plasma, low viral load with CMV DNA ≥2730 IU/mL to <27300 IU/mL  in 
whole blood or 
≥910IU/mL  to <9100 IU/mL in plasma, and in subjects with high- risk infection, 
very low viral load with CMV DNA <2730 IU/mL in whole blood or <910 IU/mL  in plasma) as 
determined b y the local or central specialt y laboratory qPCR; and acute GVHD status (presen ce 
or absence at baseline). Subjects in each stratum will then be randomized in a 1:1 allocation ratio 
to receive double -blind maribavir (400 mgBID) or valganciclovir (900 mgBID, 450 mgBID, or 
450mgQD, based on subject's CrCl at eligibility ) for 8 weeks. Valganciclovir dose may  be 
adjusted during the study for renal function impairment or neutropenia.
An independent Data Monitoring Committee (DMC) will be established to assess the data at 
specified periodic intervals for safet y and to ensure the validi ty and scientific merit of the trial. 
For non-commercial use only
Take da CONFIDENTIAL Page 51
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Detailed plans for the DMC’s purpose and responsibilities will be described in the DMC charter 
and the statistical anal ysis plan.
As shown in the study  schematic in Figure 1(Study  Design Flow Chart) below, the study  will 
have 3 phases: (1) Up to a 2 -week screening phase; (2) 8- week double -blind study  treatment 
phase; and (3) 12-week follow -up phase.
Figure 1. Study Design Flow Chart
Visit 1
Wks -2 to -1Screenin g
PhaseDouble-blind
Phase
Follow-up
Phase
Visits 11-18
Wks 9-20
Every 2 Weeks
(last 8 wks)Weekly
(first 4 weeks)Visit 2
Wk 0SHP620  400mg B ID OR
ValG CV 900mg B IDa
BL/
RandVisits 3-10
Wks 1-8
Double-blind
Study Drug Adm inistration
Visit
2Ab
BID=twice daily; BL=baseline; Rand=randomized; Wks=weeks
aUnless dose adjustment is required for moderate renal impairment.
bVisit 2A is required only for subjects receiving tacrolimus, cyclosporine, everolimus, or sirolimus at baseline.
Subjects will be required to visit the site up to 18 times for up to a 22-week period. During the 
COVID -19 public health emergency , remote visits may  be conducted by  phone (eg, collection of 
AEs and monitoring), video conferencing (Telehealth or Telemedicine, ph ysician), or site staff 
visiting the participant’s residence. Local visits and telemedicine must comply  with national and 
local laws and regulations. The ty pe of alternative visit must b e recorded on the eCRF.
For home healthcare visits, collection of clinical laboratory  samples (blood specimen collection 
or other diagnostic tests) may  be performed by  a qualified and authorized Principal Investigator’s 
(PI) designee who can visit the tria l participant’s residence.
Screening Phase
As presented in Schedule of Assessment 1, Table 1, approximately  612 subjects will be screened 
to establish eligibility  for study  participation. All screening procedures will be completed within 
14days prior to initiation of study  treatment , with the exception of the following:
1.Screening clinical laboratory  tests (hematology, chemistry , and pregnancy ) must be 
performed within 3 days prior to initiation of study  treatment.
For non-commercial use only
Take da CONFIDENTIAL Page 52
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
2. Subjects must have a documented CMV infection with a screening value o f CMV DNA 
≥1365 IU/mL to ≤273000 IU/mL  in whole blood or ≥455 IU/mL  to ≤91000 IU/mL  in 
plasma in 2 consecutive assessments, separated by at least 1 day, as determined by  local or 
central specialty  laboratory  qPCR or comparable quantitative CMV DNA results. The first 
sample must be obtained within 14 days prior to study  enrollment (ie, start of study  
treatment) at Visit 2/Day 0. The second sample must be obtained within 5 days prior to the 
study  enrollment.
3.Historical results for human immunodeficiency  virus (HIV) tests performed within 
3months prior to the study  treatment initiation will be acceptable for screening. If no HIV 
test result within 3 months is available, the subject must have testing done locally during 
the screening period and have negative re sults available prior to randomization.
Study  Treatment Phase
Approximately  550 subjects with an as ymptomatic CMV infection who meet eligibility  
requirements during the screening phase, including the presence of quantifiable (local or central 
specialty  laboratory ) whole blood or plasma CMV DNA levels as specified ( ≥1365 IU/mL  in 
whole blood or ≥455 IU/mL  in plasma), will be stratified based on their CMV viral load and 
GVHD status, and then randomized 1:1 at Visit 2/Day 0 to receive either double -blind 
maribavir/placebo or valganciclovir/placebo (collectivel y, the study treatment) for 8 weeks.
Historical laboratory  results for tests within the time period specified in the Schedule of 
Assessment 1 (Table 1) may  be used for eligibility  assessment (HIV test results within 3 months, 
relevant hematology , and chemistry  results). The Screening and Visit 2/Day 0 visits can occur on 
the same day , if laboratory  resul ts are available for the determination of eligibility. Local 
laboratory  results may  be used for stratification and randomization if central laboratory  results 
are not available at Visit 2/Day 0.
All Visit 2/Day 0 procedures, including blood collection for CMV DNA quantification, 
hematology and chemistry  analy sis in the central laboratory , must be completed and documented 
prior to randomization and study treatment administration and all clinical laboratory  results 
required for eligibility  verification must be available prior to randomization, including 2 separate 
CMV DNA assessments. Central laboratory results of CMV DNA quantification and genot yping, 
hematology and chemistry  from samples taken at Visit 2/Day 0 will not be available for use for 
screening the subjects. Initiation of study  treatment (ie, first dose) will only  occur after 
completion of all required Visit 2/Day 0 procedures, confirmation of eligibility , and completion 
of randomization. This will be done under the supervision of investigator site p ersonnel. Blood 
sample for central laboratory  CMV DNA quantification and genot yping will be obtained at 
Visit 2/Day 0. 
For non-commercial use only
Take da CONFIDENTIAL Page 53
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Ifbaseline central laboratory CMV DNA quantification results do not meet thespecified 
screening value of ≥455 IU/mL , the subject will r emain in the study , but will be excluded from 
the Per Protocol population for efficacy  anal ysis.
All subjects will perform study -specific evaluations weekl y during the 8- week study  treatment 
phase. Refer to Schedule of Assessment 1 (Table 1) for a complete list of the evaluations 
performed in the stud y treatment phase.
Subjects randomized to receive maribavir will take the 400 mgBID dose for the 8 weeks of the 
study  treatment phase. Maribavir 200 mg strengths will be utilized for the daily  dosing. Subjects 
randomized to valganciclovir will take the 900 mgBID for the duration of 8 weeks of the stud y 
treatment phase (unless dose adjustment is requi red for moderate renal impairment) and will 
utilize 450 mg strength tablets.
Depending on the time of the first dose of stud y treatment on Visit 2/Day 0, a second dose 
should be administered on Visit 2/Day 0 provided that doses can be separated by  a minimu m of 
8hours; otherwise, onl y 1dose should be administered on Visit 2/Day 0. Study  treatment will 
then be administered (preferabl y) every  12 hours (q12h). When q12h dosing is not feasible, the 
doses should be separated by  a minimum of 8 hours.
To protect the study  blind, subjects will be required to take 2 tablets of their assigned study  
treatment and 2 tablets of the placebo q12h in a double -dummy  format as shown in Table 5in 
Section 6.2.3.
Subjects randomized to receive valganciclovir will follow the 900 mgBID dosing regimen for 
the 8 weeks of the study  treatment phase, with the exceptions of permitted lower starting dose 
based on renal function, or dose adjustments based on renal function and/or neutropenia ( Table 6
and Table 7
,respectivel y; see Section 6.2.3). The clinical laboratory  test results (see 
Section 7.2.3.4
) for a minimum of complete blood count with differential and serum creatinine 
will be verified before providing the revised valganciclovir dose.
In exceptional situations, eg, neutropenia or other adverse events, stud y treatment may be 
interrupted at investigator's discretion for a maximum of 7 consecutive day s,and this 
interruption will not result in permanent study  treatment discontinuation. Up to 2 study  treatment 
interruptions for a total of up 7 days will be allowed. A third study  treatment interruption will 
lead to permanent study  treatment discontinuation ; the subjects will complete the end of 
treatment procedures described for Visit 10/Study Week 8 in the Schedule of Assessment 1 
(Table 1)
, and will fo llow a modified schedule of assessments through the remaining weekl y 
visits scheduled for the study  treatment phase and the regular schedule of assessments through 
the 12- week follow -up phase as described in Section 4.5.
 
For non-commercial use only
Take da CONFIDENTIAL Page 54
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Various clinical scenarios ofneutropenia, as shown in Table 7, will be prog rammed in the 
interactive response technology  (IRT) and appropriate options will be selected by  the investigator. 
Interruptions and discontinuation of study  treatment will be conducted in a blinded manner; 
therefore, it is possible that treatment with eith er valganciclovir or maribavir will be interrupted or 
discontinued for neutropenia presence. The investigator may  also select to interrupt study  treatment, 
for other adverse events, regardless of the treatment assignment (maribavir or valganciclovir). If 
study drug is interrupted for any  reason and subsequently  resumed, the end of the study  drug 
administration period would remain fixed at a maximum of 8 weeks after the date of the start of 
treatment.
If the subject is unable to travel to the site for the treatment visits, these visits may  be on exceptional 
basis performed remotely  (ie,at subjects’ home) by  a qualified and authorized PI’s designee, and 
only if permitted by local laws and regulations. Clinical laboratory  samples will be collected, and all 
other follow -up assessments will be completed. Adverse events and SAE collection may  be 
completed by  telephone follow -up call on the day  of the scheduled visit. It is recommended that the 
end of study  visit be completed at the site if the subject is able to travel.
All subjects who complete the study  treatment phase through Visit 10/Week 8 will enter the 12 -week 
follow -up phase. See Section 4.5for details regarding discontinuation and/or withdrawal from the 
study  treatment/study .
Follow -up Phase
Study -specific evaluations including central specialty laboratory  CMV testing and safet y assessments 
will occur weekly for the first 4 weeks, then every  2weeks for the final 8 weeks of the 12 -Week 
Follow -up Phase. See Schedule of Assessment 2 (Table 2) for a complete list of evaluations. See 
Section 4.5for details regarding discontinuation and withdrawal.
If the subject is unable to travel to the site for the follow -up visits, these visits may  be on exceptional 
basis performed remotely  (ie,at subjects’ home) by  a qualified and authorized PI’s designee, and 
only if permitted by local laws and regulations. Clinical laboratory  sample s will be collected, and all 
other follow -up assessments will be completed. Adverse events and SAE collection may  be 
completed by  telephone follow -up call on the day  of the scheduled visit. It is recommended that the 
end of study  visit be completed at the site if the subject is able to travel.
3.2Duration and Study Completion Definition
The subject’s maximum duration of participation is expected to be approximately  22weeks 
(screening: up to 2 weeks; double -blind study  treatment phase: 8 weeks; follow -up phase : 12weeks). 
For non-commercial use only
Take da CONFIDENTIAL Page 55
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Follow -up visits will occur weekly  for the first 4 weeks (Weeks 9-12), followed by  visits every  
2weeks for the last 8 weeks (Weeks 12-20) of this 12 -week follow -up phase.
The study  will be completed in approximately  48months. The Study  Compl etion Date is defined 
as the date the final subject, across all sites, completes their final protocol- defined assessment. 
This includes the follow- up visit or contact, whichever is later. The Study  Completion Date is 
used to ascertain timing for study  resu lts posting and reporting.
3.3Sites and Regions
This is a multicenter study. Approximately  105 sites in North America, Europe, and Asia Pacific 
will participate.
3.4 Changes to Study Procedures Due to COVID
-19 Pandemic
The following information provides guidance regarding changes to stud y procedures that may  be 
implemented for study  participants or study  sites affected b y a pandemic (eg, coronavirus disease 
[COVI D-19]) that require phy sical distancing that may  result in subjects missing their visits. 
This guidance takes references from the FDA Guidance on Conduct of Clinical Trials of Medical 
Products during COVID -19 Public Health Emergency  –Guidance for Industry, Investigators, 
and Institutional Review Boards, March 2020, updated 27 January 2021; the EMA Guidance on 
the Management of Clinical Trials During the COVID-
19 (Coronavirus) Pandemic, Version 4 
(04February 2021); and the EMA Points to consider on implications of Coronavirus disease 
(COVID -19) on methodological aspects of ongoing clinical trials, dated 26 June 2020.
Because a pandemic (eg, COVID -19) may  peak in different regions at different times and 
restrictions implemented by  local laws and recommendations may  vary , any  decision on 
procedural changes should be made on a case -by-case basis b y the principa l investigator in 
consultation with the study  team and the medical team as needed, while maintaining patient 
safet y and confidentiality as the priority.
Procedural changes due to COVID -19 may  include the following (refer to DTP guidance 
document for furthe r details):
Allow study  sites to follow COVID- 19 screening requirements per local regulations.
Informed Consent Procedure: If necessary  and permitted by  local laws and regulations, 
informed consent from a potential or current trial participant may  be obtai ned via 
electronic informed consent (eIC) capabilities, or an electronic face -to-face consent 
interview when these individuals are unable to travel to the site (see Section 4). The site
must contact the sponsor for approval of the alternative method for obtaining informed 
consent prior to implementation.
For non-commercial use only
Take da CONFIDENTIAL Page 56
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Study  Visit 1 (Screening) and Study  Visit 2 (Randomization) m ust be done with the subject 
present at the investigative site. Study  Visits 2A through 10 may  be conducted at the clinic or 
by optional home healthcare visits to extend flexibility  to subjects during the COVID -19 
public health emergency , although it is pr eferable to conduct Study  Visit 10 (End of 
Treatment) and Study  Visit 18 (End of Study ) with the subject present at the investigative 
site. The data collected from home healthcare visits may be handled differently in the final 
data anal ysis, with this docu mented in the statistical analy sis plan. 
More flexibility  by allowing some assessments and, where allowed per local laws and 
regulations, remote source document verification to be conducted remotely  (see 
Study  Schedule ). 
‘Remote visits’ via virtual communications (eg, TeleHealth application) may  be performed as 
a safety  check on subject well -being, concomitant medication use, etc.
For home healthcare visits, collection of clinical laboratory  samples (blood specimen 
collection or other diagnostic tests) may  be performed by  a qualified and authorized P I’s 
designee who can visit the trial participant’s residence.
ECG procedures: For home healthcare visits, ECGs may  be performed by  a qualified health 
care professional who is certified/authorized by  the PI  to perform such tests routinely .
Missed clinic visits or subject withdrawals due to COVID -19 must be recorded on the eCRF 
(see Section 4.5, Discontinuation and/or Withdrawal of Subjects).
Subjects who discontinued from screening due to COVID -19-related factors but were 
otherwise qualified to participate in the trial may  be rescreened at any  time if the Takeda 
medical monitor agrees (see Section 7.1.1 , Screening Period).
Allow transfer of study participants to investigational sites away  from risk zones or closer to 
their home to sites already participating in the trial or new ones.
Deviations from the protocol -specified procedures (eg, not collecting a protocol -specified 
specimen, such as post -dose bloodwork) will be recorded as related to COVID -19.
Alternative study  drug deliveries may  include dispensing additional study  drug at clinic visits 
or direct -to-patient (DTP) delivery  of the study  drug from the investigational site to subjects 
in compliance with national laws or temporary  national emergency  measures (s ee 
Section 6.4, Drug Accountability ). When utilizing DTP, the investigator remains responsible 
for ensuring the safety  of subjects and the dispens ation of the investigational product.
In accordance with local laws and regulations, relevant health authorities are to be notified of 
participants who contract COVID -19 during the study .
For non-commercial use only
Take da CONFIDENTIAL Page 57
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
4.STUDY POPULATION
Approximately  550 subjects, ≥16years of age, who a re HSCT recipients with asy mptomatic 
CMV infections will be enrolled.
Each subject must participate in the informed consent process and provide written informed 
consent/assent before any procedures specified in the protocol are performed. 
4.1Inclusion Criter ia
The subject will not be considered eligible for the study  without meeting all of the criteria below.
Subjects must:
1.Be able to provide written, personall y signed, and dated informed consent to participate in 
the study  before completing an y stud y-related procedures. As applicable, a parent/both 
parents or legally  authorized representative (LAR) must provide signature of informed 
consent and there must be documentation of assent by  the subject before completing any  
study -related procedures. During the COVI D-19 public health emergency , informed 
consent from a potential or current trial participant may , if permitted by  local laws and 
regulations, be obtained via electronic informed consent (eIC) capabilities or an electronic 
face-to-face consent interview when these individuals are unable to travel to the site (FDA 
COVID -19 Guidance, 27 Jan2021, Q11).
2.Be ≥16years of age at the time of consent.
3. Be a recipient of hematopoietic stem cell transplant.
4.Have a documented asymptomatic CMV infection, with a screening value of CMV DNA 
≥1365 IU/mL to ≤273000 IU/mL  in whole blood or ≥455 IU/mL  to ≤91000 IU/mL  in 
plasma in 2 consecutive assessments, separated by at least 1 day, as determined by  local or 
central specialty  laboratory  quantitative poly merase chain reaction ( qPCR) or comparable 
quantitative CMV DNA results. Both samples should be taken within 14 days prior to 
randomization with second sample obtained within 5 days prior to randomization. Same 
laboratory  and same sample ty pe (whole blood or plasma) should be us ed for these 
assessments. Asy mptomatic CMV infection is defined as an infection that does not present 
with tissue invasive CMV disease, as assessed b y the investigator.
Subjects with CMV DNA <910 and ≥455 IU/mL in plasma or <2730 and ≥1365 IU/mL in 
whole blood will also need to meet at least 1 of the following criteria for high -risk CMV 
infection to be eligible:
Human leukocy te antigen (HLA) -related (sibling) donor with at least 1 mismatch at 
1of the following 3 HLA -gene loci: HLA -A, -B or - DR,
For non-commercial use only
Take da CONFIDENTIAL Page 58
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Haploidentical donor,
Unrelated donor with at least 1 mismatch at 1 of the following 4 HLA -gene loci: 
HLA -A, -B, -C and -DRB1,
Use of umbilical cord blood as stem cell source,
Use of ex vivo T- cell-depleted grafts,
Grade 2 or greater GVHD, requiring the u se of s ystemic corticosteroids (defined as 
the use of ≥1 mg/kg/day  of prednisone or equivalent dose of another corticosteroid).
5. Have the current CMV infection as the first episode of CMV viremia after HSCT, either 
primary  or reactivation, which in the investigator’s opinion requires treatment.
6.Per investigator’s judgment, be eligible for treatment with valganciclovir.
7. Have all of the following results as part of screening laboratory assessments (results from 
either the central laboratory  or a local labo ratory  can be used for qualification):
a.Absolute neutrophil count ≥1000/mm3[1.0 x 109/L]
b. Platelet count ≥25,000/mm3[25 x 109/L]
c.Hemoglobin ≥8 g/dL
d.Estimated creatinine clearance ≥30mL/min.
8. Have a negative serum beta human chorionic gonadotropin (β- hCG) pregnancy  test at 
screening, if a female of childbearing potential. Urine pregnancy  tests may  be done per 
institutional requirements; however, they  are not sufficient for eligibility  determination. 
Sexually  active females of childbearing potential must agr ee to compl y with any applicable 
contraceptive requirements of the protocol. If male, must agree to use an acceptable 
method of birth control, as defined in the protocol, during the stud y treatment 
administration period and for 90 days afterward the last dose of stud y treatment .
9. Be able to swallow tablets.
10.Have life expectancy  of ≥8weeks.
11.Weigh ≥40 kg.
12.Be willing and have an understanding and abilit y to fully compl y with study procedures 
and restrictions defined in the protocol.
For non-commercial use only
Take da CONFIDENTIAL Page 59
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
4.2 Exclusion Criteria
Subjects must not:
1.Have CMV tissue invasive disease as assessed b y the investigator at the time of screening 
and randomization at Visit 2/Day 0.
2.Have a CMV infection that is known to be genotypically resistant to ganciclovir, 
valganciclovir, foscarnet, or cidofovir based on documented evidence.
3. Be presenting with recurrent CMV infection (defined as a new detection of CMV infection 
in a subject who had at least one previousl y documented episode of CMV infection 
post-transplant, and who has had at least 2 weeks of undetectable CMV DNA between the 
episodes during active surveillance, based on same local laboratory  and same sample ty pe). 
The subject must also have been off an y anti-CMV treatment between the current and prior 
infection. Otherwise, the current infection m ay be considered continuation of the prior 
infection.
4. Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions 
other than CMV when study  treatment is initiated (example: herpes simplex virus [HSV] 
co-infection requiring us e of an y of these agents after the randomization) or would need a 
co-administration with maribavir for CMV infection.
5.Be receiving leflunomide, letermovir, or artesunate when stud y treatment is initiated. 
Note: Subjects who may  be receiving leflunomide mus t discontinue the use at least 14 days 
prior to randomization at Visit 2/Day 0 and the first dose of study  treatment. Subjects 
receiving letermovir must discontinue use 3 days prior to first dose of study  treatment. 
Subjects receiving artesunate must discontinue the use prior to the first dose of study  
treatment.
6.Be on treatment with anti
-CMV agents (ganciclovir, valganciclovir, foscarnet, or 
letermovir) for the current CMV infection for longer than 72 hours.
7.Have known h ypersensitivity  to the active substa nce or to an excipient of the study  
treatments.
8. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours 
prior to the first dose of study  treatment that would preclude administration of oral 
medication.
9.Require mechanical ventilation or vasopressors for hemody namic support at the time of 
randomization.
For non-commercial use only
Take da CONFIDENTIAL Page 60
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
10.Be female and pregnant or nursing.
11.Have previously  completed, discontinued, or have been withdrawn from this study .
12.Have received an y investigational agent with known anti -CMV activity  within 30 days 
before initiation of stud y treatment or CMV vaccine at an y time.
13.Have received an y unapproved agent or device within 30 days before initiation of study  
treatment.
14.Have an y clinicall y significant medical or surgical condition that, in the investigator’s 
opinion, could interfere with interpretation of study  results, contraindicate the 
administration of the assigned stud y treatment, or compromise the safety or well -being of 
the subject.
15.Have previously  received maribavir.
16.Have serum a spartate aminotransferase (AST) >5 times upper limit of normal (ULN) at 
screening, or serum alanine aminotransferase (ALT) >5 times ULN at screening, or total 
bilirubin ≥3.0 x UL N at screening (except for documented Gilbert’s s yndrome), as 
analyzed by loca l or central laboratory .
17.Have known (previousl y documented) positive results for human immunodeficiency  virus 
(HIV). Subjects must have a confirmed negative HIV test result within 3 months of study  
entry  or, if unavailable, be tested by  a local laboratory  during the screening period.
18.Have active malignancy  with the exception of nonmelanoma skin cancer, as determined by  
the investigator. Subjects who experience relapse or progression of their underly ing 
malignancy  (for which HSCT was performed), as determine d by the investigator, are not to 
be enrolled.
19.Be undergoing treatment for acute or chronic hepatitis C.
4.3 Restrictions 
There will be no special restrictions for subjects participating in this study . Subjects are to 
maintain their normal diets, medications (except those listed in Section 5.2.2 ), and activities of 
daily  life as determined by  the investigator.
4.4Reproductive Potential
4.4.1 Female Contraception
There is no clinical experience with maribavir in pregnant subjects.
For non-commercial use only
Take da CONFIDENTIAL Page 61
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
There are no data from the use of valganciclovir in pregnant subjects. Its active metabolite, 
ganciclovir, readil y diffuses across the human placenta. Based on its pharmacological 
mechan ism of action and reproductive toxicity  observed in animal studies with ganciclovir, 
valganciclovir should be considered a potential teratogen and carcinogen in humans (refer to the 
Valcy te Prescribing Information and Valcy te Summary  of Product Characteris tics as documented 
in the Study  Pharmacy  Manual ).
All female subjects of child -bearing potential will be tested and should have negative 
serum -human chorionic gonadotropin pregnancy test results prior to randomization. They  must 
agree to abstain from sex ual activity that could result in pregnancy  or agree to use an acceptable 
method of contraception. Females of child-bearing potential must be advised to use acceptable 
contraceptives throughout the study  period and for 90 days after the last dose of study  treatment. 
If hormonal contraceptives are used they  should be administered according to the package insert 
and in conjunction with another acceptable method of contraception. Females of child -bearing 
potential who are not currently  sexually  active must agr ee to use acceptable contraception, as 
defined below, if they  become sexually  active during the period ofthe study  and 90 days 
following the last dose of study  treatment. Sexually  active females of child -bearing potential 
should be using an acceptable for m of contraception, as defined below.
Methods of contraception that can achieve a failure rate of less than 1% per y ear when used 
consistently  and correctly  are considered highly effective birth control methods for females of 
child- bearing potential are presented below:
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, transdermal) or progestogen -only hormonal 
contraception associated with inhibition of ovulation (oral, injectable, implantable [low user 
dependency ]) stabilized for at least 30 days prior to the screening visit (Visit 1), plus 
condoms.
Note: Since hormonal contraception may  be susceptible to inter action with the study  
treatment(s) in the stud y, which may  reduce the efficacy  of the contraception method, this 
method must be supplemented with a barrier method (preferabl y male condom).
Intrauterine devices (IUD, all ty pes) or intrauterine hormone relea sing s ystems (IUS) plus 
condoms. Note: contraception methods that in the context of the clinical trial facilitation 
group (CTFG) guidance are considered to have lower user dependency .
Bilateral tubal occlusion.
For non-commercial use only
Take da CONFIDENTIAL Page 62
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Vasectomized male partner is a highly  effecti ve birth control method provided that partner is 
the sole sexual partner of the female trial participant who is of childbearing potential and that 
the vasectomized partner has received medical assessment of the surgical success.
Sexual abstinence defined as refraining from heterosexual intercourse during the entire 
period of risk associated with the study treatments. Note: the reliability  of sexual abstinence 
needs to be evaluated in relation to the duration of the clinical trial and the preferred and 
usual lifesty le of the subject.
Female subjects 16 years of age and older, who are amenorrheic for reasons other than 
menopause (12 consecutive months of spontaneous amenorrhea in patients with previous normal 
menstruation), including subjects who did not y et have the menarche, would be allowed to 
participate provided they agree to abstinence or an acceptable form of contraception, as defined 
below.
Female subjects who are postmenopausal (12 consecutive months of spontaneous amenorrhea) or 
surgically  sterile (ha ving undergone 1 of the following surgical acts: h ysterectomy , bilateral 
tubal ligation, bilateral oophorectomy or bilateral salpingectomy) and are at least 6 weeks 
poststerilization do not need a pregnancy  test performed prior to randomization and do not have 
to agree to the use of acceptable methods of contraception.
4.4.2 Male Contraception
Per Clinical Trial Facilitation Group requirements (CTFG), male subjects will be required to use 
a condom in conjunction with a highl y effective method of birth control for their female partners 
of childbearing age. Both male participants and their female partners must use this form of birth 
control from the time prior to first dosing until 90 days after the last dose of study  treatment 
(ie,maribavir or valganciclovir). For male subjects, sexual intercourse with pregnant partners 
should also be avoided during the course of the study  unless condoms are used from the time 
prior to the first dose until 90 days after the last dose of study  treatment. Male subjects must not 
donat e sperm until 90 days after the last dose of study  treatment.
4.5Discontinuation and/or Withdrawal of Subjects
Subjects Who Withdraw from the Study
A subject may  withdraw (eg, withdraw consent) from the study  at an y time for an y reason 
without prejudice to their future medical care by  the phy sician or at the institution. The 
investigator or the sponsor may withdraw the subject at an y time (eg, in the interest of the 
subject’s safet y).
For non-commercial use only
Take da CONFIDENTIAL Page 63
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The investigator is encouraged to discuss withdrawal of a subject from stu dy treatment with the 
sponsor’s medical monitor when possible. Subjects who withdraw consent during the stud y 
treatment phase will be asked to undergo all end of treatment evaluations and procedures listed 
for Visit 10/Week 8, if they  agree; no further fol low-up will be performed.
Subjects who withdraw from the study  during the follow -up phase will undergo all end of stud y 
evaluations and procedures listed for Visit 18/Week 20 (Follow -up Week 12) as soon as possible 
and whenever possible, if they  agree, pri or to initiation of any  nonstudy  anti-CMV treatment (as 
deemed b y the investigator); no further follow -up will be performed.
Subjects Who Discontinue from Screening
Subjects who discontinue from screening due to COVID -19-related factors but are otherwise 
qualified to participate in the trial may  be rescreened at any  time if the Takeda medical monitor 
agrees.
Subjects Who Discontinue Study  Treatment
Subjects who permanently discontinue stud y treatment, but do not withdraw consent, will 
complete the end of tr eatment procedures described for Visit 10/Study  Week 8 in the Schedule of 
Assessment 1 (Table 1); these subjects will follow a modified schedule of ass essments through 
the remaining weekly  visits scheduled for the study  treatment phase and the regular schedule of 
assessments through the 12- week follow -up phase. The end of treatment sample for 
immunosuppressant drug concentration level will be collected a t the next visit scheduled 1 week 
after the treatment discontinuation. Subjects who discontinue study  treatment earl y will not be 
asked to complete the following procedures after the end of treatment visit for subsequent visits 
in the treatment phase: the use of the diary  for study  treatment compliance, dispense or use of 
any study  treatment, and PK sample collection. After completing the 8 -week duration specified 
for the study treatment phase, subjects will enter the 12 -week follow -up phase. After the 
perm anent stud y treatment discontinuation and until the end of the study, subjects might be 
administered other anti- CMV treatment as deemed necessary  by the investigator.
Subjects who discontinue will not be replaced.
4.5.1 Reasons for Discontinuation and/or Withdra wal
The reason for stud y treatment discontinuation and/or withdrawal must be determined b y the 
investigator and recorded in the subject’s medical record and on the case report form (CRF). If a 
subject discontinues treatment or is withdrawn from the study  for more than 1 reason, each 
reason should be documented in the source document and the most clinically relevant reason 
should be entered in the CRF.
For non-commercial use only
Take da CONFIDENTIAL Page 64
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Reasons for discontinuation include but are not limited to:
Withdrawal of consent (by subject or b y a paren t or both parents/legal guardian for 
pediatric subjects). If a subject chooses to withdraw from study participation due to 
personal concerns related to the COVID -19 pandemic (other than a COVID -19-related 
AE), this should be specified as the reason for sub ject withdrawal in the eCRF.
Adverse event (must specify  on the CRF)
CMV central nervous sy stem (CNS) infection (Note: Maribavir is unlikely  to penetrate the 
blood -brain barrier in humans based on animal data. If a subject in the study develops 
CMV CNS infection [eg, meningo -encephalitis], then the subject will discontinue study  
treatment in order to be treated for this condition.)
Protocol deviation (eg, lack of compliance, use of experimental drug)
Pregnancy
Sponsor decision (must specify  on the CRF)
Death
Lost to follow -up
Lack of efficacy
Other (must specify  on the CRF, including unavoidable circumstances such as the 
COVID -19 pandemic)
The end of stud y treatment and the end of stud y date for each subject (ie, the date of completion 
of the study  or pre mature withdrawal from the study ) will be recorded in the CRF.
4.5.2 Subjects “Lost to Follow-up” Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations and return any unused investigational product.
For non-commercial use only
Take da CONFIDENTIAL Page 65
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
5.PRIOR AND CONCOMITAN T MEDICATIONS, THERA PIES, AND PROCEDURES
5.1 Prior Medications, Therapies, and Procedures
Prior treatment information must be recorded on the appropriate C RF page, and will include the 
following presented in Table 3.
Table 3. Prior Medications, Therapies, and Procedures 
Time Period
(prior to Visit 2/Day 0)Category Prior Medications, Therapies, and Procedures
Medications/procedures 
administered/performed 
for transplant related 
reason from their start 
or date of transplant 
(whichever is first )to 
the first dose of study 
treatment on 
Visit 2/Day 0Preparative/conditioning 
regimenaIncluding but not limited to:
Pretransplant irradiation
Various agents including:
oChemotherapy agents
oLymphocyte depleting and nondepleting 
therapies, including monoclonal, polyclonal, 
and anti- thymocyte globulin preparations
Anti-CMV prophylaxis 
and treatmentbIncluding, but not limited to:
Ganciclovir
Valganciclovir
Foscarnet
Cidofovir
Cytomegalovirus immune globulin
Intravenous immunoglobulin (IVIG)
Leflunomide
Artesunate
Letermovir
Cytomegalovirus specific T -cell transfer 
(considered investigational)
GVHD prophylaxis, 
treatment, adjuvant 
therapies, and other 
related therapiesIncluding, but not limited to:
Cyclosporin
Methotrexate
Tacrolimus
Sirolimus
T-cell depleting therapies, including 
antithymocyte globulin, alemtuzumab
Mycophenylate mofetil
Steroids
Photopheresis
Transplant maintenance 
therapyIncluding, but not limited to
Systemic steroids
Cyclosporine, tacrolimus, sirolimus, everolimus, 
mycophenylate mofetil
For non-commercial use only
Take da CONFIDENTIAL Page 66
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 3. Prior Medications, Therapies, and Procedures 
Time Period
(prior to Visit 2/Day 0)Category Prior Medications, Therapies, and Procedures
All medications within 
3months prior to the 
first dose of study 
treatment on 
Visit 2/Week 0/Day 0Hematopoietic growth 
factors
Treatment for the 
underlying disease
Blood or blood product 
transfusions
Anti-Infective agentsProphylaxis and/or treatment of viral, bacterial 
and fungal infections
Within 30 days or 
5half-lives
(whichever is longer)All OtherAll other prescription medications
All herbal supplements
All other over -the-counter (OTC) medications
Any therapeutic or 
diagnostic intervention/
procedure performed 
within 30 days prior to 
the first dose of study 
treatment on 
Visit 2/Week 0/Day 0Including, but not limited to:
Biopsies (along with the results)
X-rays, CT scans (along with results)
Dialysis
Total parenteral nutrition
CMV=cytomegalovirus; CT=computerized tomography; GVHD=graft -versus -host -disease; IVIg=intravenous 
immunoglobulin; OTC=over-the -counter medications
aSubjects for whom transplant was performed >3 months from the time of screening, limited (no dose data) information for 
preparative/conditioning regimen will be collected.
bNOTE: as only subjects with first CMV infection after HSCT will be enrolled, prior anti -CMV medications may include 
anti-CMV prophylaxis; subjects should not have been on treatment with anti - CMV agents (ganciclovir, valganciclovir, 
foscarnet, or letermovir) for the curr ent CMV infection for longer than 72 hours prior to enrollment.
5.2Concomitant Medications, Therapies, and Procedures
Concomitant treatment refers to all treatment taken between the dates of the first dose of 
investigational product and the end of the follow -up period, inclusive. A concomitant procedure 
is any  therapeutic and diagnostic intervention (eg, surgery , biops y) or diagnostic assessment 
(eg,bacterial cultures, imaging such as X- ray, computerized tomograph y [CT] scans) performed 
between the dat es of the first dose of the stud y treatment and the end of the follow -up phase, 
inclusive.
For non-commercial use only
Take da CONFIDENTIAL Page 67
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
5.2.1 Permitted Treatment
All concomitant treatment information must be recorded on the appropriate CRF page.
Additional treatment strategies may  complement the use of the study  treatments (eg, reducing or 
modify ing the immunosuppressant drug use, or use of hemopoietic growth factors as needed for 
neutropenia).
Of note, changes in the net state of immunosuppression can influence response to treatment of 
CMV infection, there fore, whenever possible, investigators should maintain a stable regimen of 
immunosuppressant drugs during the study drug administration period, particularly through 
Study  Visit 10/Week 8. Note that the sample for the assessment of immunosuppressant agent 
concentration is included in the schedule of assessments as maribavir was found to impact the 
metabolism of some immunosuppressive agents. Any changes in immunosuppression regimens 
due to the concomitant administration with maribavir or other reasons must b e recorded in the 
CRF.
Maribavir is specificall y intended to treat human CMV infections. Maribavir is not active in vitro 
against most non -CMV herpesvirus infections, including herpes simplex virus (HSV ty pe1 and 
type 2) and varicella zoster virus (VZV). At baseline, investigators will assess subjects to 
determine whether prophylaxis for these viruses is appropriate according to institutional 
guidelines or standard practices; the need for continued proph ylaxis or initiation of prophy laxis 
will be assessed. If considered appropriate, permitted medications to use for this purpose include 
systemic acy clovir, valacy clovir, or famciclovir. Choice of medication, dose, and duration of 
such therap y is at the discretion of the investigator based on a given subject’s clinical condition 
(eg,net state of immunosuppression, risk factors, and other medications). These medications 
(acyclovir, valacy clovir, or famciclovir) also can be used to treat any  HSV or VZV infection that 
may occur during the study . Antifungal and antibacterial medications will be allowed as deemed 
appropriate b y the investigator for proph ylaxis or treatment.
Although potent inhibitors of CYP 3A4 (such as ketoconazole) could increase blood levels of 
maribavir, they  are likel y to be associated with minimal increased risk given the safet y profile of 
maribavir demonstrated at up to 1200 mg BID in Phase 2 studies.
The following concomitant medications should be taken with caution:
Maribavir has the potential to inhibit P -gp and therefore, may  increase t he concentration of drugs 
that are substrates of P -gp.For drugs with narrow therapeutic window, the increase in drug 
concentration may  lead to toxicity . A drug interaction study  showed that maribavir (400 mg 
BID) increased blood concentrations of tacrolim us (a substrate of CYP3A4 and P -gp) with C max
and AUC increased b y 38% and 51%, respectively. 
For non-commercial use only
Take da CONFIDENTIAL Page 68
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Therefore, monitoring tacrolimus blood concentration and tacrolimus -associated adverse events, 
and the appropriate dose adjustment of tacrolimus is recommended wh en maribavir and 
tacrolimus are used concomitantly . Conversel y, after a period of coadministration, 
discontinuation of maribavir could lead to reduced blood levels of tacrolimus and potentially  
reduced therapeutic effect. Similarly , for drugs that are substrates of P -gp and have narrow 
therapeutic window, such as other immunosuppressants including cyclosporine, sirolimus, and 
everolimus, careful monitoring is recommended both after initiation of maribavir (when substrate 
levels may  increase) and after discontinuation of maribavir (when substrate levels may  decrease).
Maribavir is an inhibitor of BCRP based on in vitro data, therefore has the potential to increase 
the drug concentration of rosuvastatin which is a sensitive BCRP substrate. When initiating 
maribavir dosing in patients who are on a stable dose of rosuvastatin, patients should be closely  
monitored for the signs of my opath y and rhabdomy olysis.
5.2.2 Prohibited Treatment
Maribavir is contraindicated with valganciclovir/ganciclovir as it may  antagonize gan ciclovir’s 
antiviral effects due to maribavir’s inhibitory  effect on HCMV UL97 encoded kinase which is 
required for activation/phosphory lation of ganciclovir.
Table 4details the washout period for common prior treatments that are excluded medications 
for this study .
Table 4. Common Excluded Treatments and Associated Washout Period
Minim um Number of Days Before First Dose
Treatm ent Prior to the first dose of 
study treatm ent3 7 14 30
Ganciclovir, valganciclovira, foscarnet, artesunate X
Letermovir X
Cidofovir, leflunomide X
Any investigational anti -CMV agent X
Any unapproved agent or device X
CMV vaccine Any time before or during study
CMV=cytomegalovirus
aValganciclovir will be provided by the Sponsor for this study; commercially available/prescribed valganciclovir is not 
allowed through the study and must be discontinued prior to the first dose of the study treatment.
Use of any  investigational anti -CMV agents, or unapproved agents or devices during the study  is not 
permitted. Infusion of T cells specific for CMV or regulatory  Tcells (Tregs), which is considered an 
experimental treatment, is not allowed.
For non-commercial use only
Take da CONFIDENTIAL Page 69
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Besides the medications indicated in Table 4, concomitant use of any  of the following medications is 
prohibited while the subject is receiving the study  treatment (maribavir/placebo or 
valganciclovir/placebo).
Strong CYP 3A inducers: avasimibe, carbamazepine, pheny toin, rifampin, rifabutin, St. John’s 
wort ( Hypericum perforatum )
Herbal medications known to have potential toxicities or drug interactions, eg, Ginkgo biloba or 
Piper methysticum (kava)
Except for ganciclovir/valganciclovir, maribavir does not antagonize the effects of other antiviral 
(anti-CMV) agents.
Potent inducers of CYP 3A4 and/or P -gp (such as rifampin, rifabutin, or p henobarbital) could reduce 
blood levels of maribavir , potentially  reducing its antiviral activity . Use of alternate agents with less 
enzyme induction potential should be considered during administration of maribavir .
In vivo drug interaction studies with V alcyte have not been performed. Since valganciclovir is 
extensively  and rapidly metabolized to ganciclovir ; drug interactions associated with ganciclovir 
will be expected for valganciclovir (refer to the Valcy te Summary  of Product Characteristics as 
docume nted in the Study  Pharmacy  Manual).
Administration of any  of the prohibited treatments (except coadministration of foscarnet or 
cidofovir for indications other than CMV infection) will require discontinuation of study  
treatment.
5.2.3 Treatments Taken During the Follow -up Phase
All permitted (Section 5.2.1) and prohibited medications (Section 5.2.2) specified for the study  
treatment phase are applicable to the follow -
up phase; however, in case of no viremia clearance, 
onset of tissue invasive CMV disease, a CMV recurrence, appropriate medications req uired for 
CMV treatment may  be administered in the follow -up phase as deemed necessary  by the 
investigator. The secondary  proph ylaxis for subjects with viral clearance is not recommended in 
the follow-up phase. All medications will be recorded on the CRF.
For non-commercial use only
Take da CONFIDENTIAL Page 70
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
6.IDENTITY OF INVESTIG ATIONAL PRODUCTS
6.1Identity of Investigational Product
The test product is maribavir, which will be provided by  the sponsor in 200 mg strength tablet 
form. Additional information is provided in the current maribavir investigator’s brochure.
The reference/comparator product is valganciclovir which will be provided by  the sponsor in 
450mg strength tablet form. Refer to the local approved product information for additional 
details.
Matching placebo will be provided for both maribavir and valganciclovir.
6.2 Administration of Investigational Product(s)
6.2.1 Interactive Response Technology for Investigational Product 
Management
An IRT will be employ ed in this study  to manage the tracking and confirmation of shipment, 
supply , inventory , ordering, expiration, randomization, site -assignments, and dose modifications 
of the study  treatment. The I RT provider will provide a user manual and training to each site, 
with detailed instruction on the use of the IRT and unblinding procedures when situation aris es.
6.2.2 Allocation of Subjects to Treatment
This is a double -blind, double -dummy , active -controlled study . The actual treatment given to 
individual subjects is determined b y a randomization schedule.
Subject numbers are assigned to all subjects as they consent to take part in the study . Within each 
site (numbered uniquel y within a protocol), the subject number is assigned to subjects according 
to the sequence of presentation for study  participation.
The randomization number represents a unique number corresponding to investigational product 
allocated to the subject, once eligibility  has been determined.
All eligible subjects will first be stratified based on 2 factors:
1.By last prebaseline whole blood or plasma CMV DNA concentration categorized in 
to 3CMV DNA co ncentration level groups based on local or central specialty  
laboratory  qPCR results:
High viral load with CMV DNA ≥27300 IU/mL to ≤273000 IU/mL in whole 
blood or 
≥9100 IU/mL  to ≤91000 IU/mL in plasma
For non-commercial use only
Take da CONFIDENTIAL Page 71
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Low viral load with CMV DNA ≥2730 IU/mL to <27300 IU/mL in whole blood 
or ≥910 IU/mL  to <9100 IU/mL in plasma
Very  low viral load and high risk with CMV DNA≥1365 IU/mL  to 
<2730 IU/mL in whole blood OR ≥455 IU/mL to <910 IU/mL in plasma and 
high-risk infection
2.By presence or absence of acute GVHD
Following stra tification, subjects will be randomized in a 1:1 allocation ratio to receive either 
double -blind maribavir or valganciclovir for 8 weeks.
The actual treatment given to individual subjects is determined b y a randomization schedule 
automatically  assigned by  the IRT. The randomization number represents a unique number 
corresponding to study treatment allocated to the subject, once eligibility has been determined. 
Once a randomization number/unique identifier has been assigned, that number must not be used 
again if, for example, a subject is withdrawn from the study . If a randomization number/unique 
identifier is allocated incorrectl y, the clinical research associate (CRA)/study monitor must be 
notified as soon as the error is discovered.
Investigational product packaging identification numbers, separate from randomization 
numbers/unique identifiers, may  also be assigned to subjects for specific treatment assignment as 
dictated b y the study. In these cases, the same investigational product packing identification 
number may  not be assigned to more than 1 subject.
6.2.3 Dosing
Initiation of stud y treatment, (ie, the first dose administration), will occur at Visit 2/Week 0 on 
Day 0 after completion of all required assessments for that visit. The first dose should be 
admini stered under supervision of investigator site personnel.
Depending on the time of the first maribavir/placebo or valganciclovir/placebo dose on 
Visit 2/Day 0, a second dose should be administered on Visit 2/Day 0 provided that doses can be 
separated b y a m inimum of 8 hours; otherwise, only  1 dose should be administered on 
Visit 2/Day 0. The second dose will then be administered (preferabl y) every 12 hours (q12h). 
When q12h dosing is not feasible, the doses should be separated b y a minimum of 8 hours.
Mariba vir 200 mg strength tablets will be utilized for the dail y dosing. Subjects will take the 
maribavir 400 mg BID dose for the 8 weeks of the study  treatment phase. There are no dose 
modifications for maribavir.
For non-commercial use only
Take da CONFIDENTIAL Page 72
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Daily  dosage for valganciclovir (450 mg QD to 900 mg BID as adjusted for renal function, 
based on chemistry  labs at screening) will utilize 450 mg strength tablets. Subjects will take 
valganciclovir for the 8 weeks of the stud y treatment phase. To protect the study blind, subjects 
will be required to t ake 2 tablets of their assigned study  treatment and 2 tablets of the placebo 
q12h in a double- dummy format as shown in Table 5.
Table 5. Study Treatment Dosing – Standard Regimen
Regim en AM PM
maribavir
400 mg BIDmaribavir active 400 mg (2 tablets) 400 mg (2 tablets)
valganciclovir placebo placebo (2 tablets) placebo (2 tablets)
valganciclovir
900 mg BIDvalganciclovir active 900 mg (2 tablets) 900 mg (2 tablets)
maribavir placebo placebo (2 tablets) placebo (2 tablets)
BID=twice daily
Valganciclovir tablets should be administered with food, and should not be broken or crushed 
(refer to the Valcy te Prescribing Information and Valcy te Summary  of Product Characteristics as 
documented in the Study  Pharmacy  Manual). In order to maintain the blind, maribavir will also 
be administered with food and will not be broken or crushed for administration. Therefore, all 
subje cts eligible for this study  must be able to swallow tablets. Based on the evaluation of the 
effect of food on the PK of 200 mg tablet formulation of maribavir in Phase 1 Study 1263-104, 
only a modest effect on C maxand no effect on AUC was observed; therefore, no clinicall y 
important food effect is expected with tablet formulation.
Subjects with estimated CrCl of ≥30 mL /min will be enrolled; adjustment of the valganciclovir 
dose for renal function will be allowed at entry  and during the stud y, as deemed necessary b y the 
investigator and consistent with the suggested doses in the valganciclovir label (shown in 
Table 6). The decision to modify  the dose will be at investigator's discretion and it will be done 
in a manner, through IRT, so that the treatment assignment remains blinded. Placebo tablets will 
be assigned in a blinded manner to make up for adjusted dose an d decrease in valganciclovir 
tablets.
For non-commercial use only
Take da CONFIDENTIAL Page 73
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 6. Valganciclovir Dosing –Adjustment for Renal Function
Valganciclovir 450 mg Tablets
CrCla(mL/min) Dose
≥60 900mg (2 tablets) BID
40 –59 450mg (1 tablet) BID
25 –39 450mg (1tablet) QD
10 –24 450mg every 2 days
BID=twice daily; CrCl=creatinine clearance; QD=once daily
aAn estimated creatinine clearance in adults is calculated from serum creatinine by the following formulas:
For males, eCrCl [mL/min] = (140 –age [years]) × (body weight [kg]) / (72) × (serum creatinine [mg/dL])
For females, eCrCl [mL/min] = 0.85 × (male value)
Valganciclovir administration is not recommended below CrCl of 10 mL/min.
Patients on valganciclovir are at risk for bone marrow suppressio n and development of 
neutropenia. In the Phase 2 study  (SHP620-203) of maribavir, measured degrees of neutropenia 
were 18% versus 5% (ANC<1000/mm3) and 5% versus 2% (ANC<500/mm3) through Week 12 
study  for the valganciclovir and overall maribavir groups, re spectively . Based on discussions 
with regulatory  authorities, dose of valganciclovir has been chosen as 900 mg BID for 8 weeks 
of study  treatment period duration, given ANC ≥1000/mm3and CrCl ≥60mL/min. Since 
neutropenia is an identified risk with valganc iclovir intake, and specificall y with the induction 
dose maintained through the treatment duration, subjects will be assessed for neutropenia 
development and valganciclovir dose may  be adjusted based on ANC level. It is recommended 
that ANC level and creatinine clearance is verified and taken into consideration before the study  
drug is dispensed at each study  visit. Therefore, complete blood count with differential count and 
serum creatinine anal ysis will be performed within 2 day s of each visit by  the loca l laboratory  to 
confirm ANC level and creatinine clearance (see Section 7.2.3.4 ). Table 7shows predefined 
criteria for valganciclovir dose adjustment based on ANC level and CMV DNA clearance which 
may be used, as deemed necessary  by the investigator and in a manner that the treatment 
assignment remains blinded, to manage treatment of subjects who experience neutropenia.
Valganciclovir should not be administered if the ANC is <500/mm3(per the product label), the 
platelet count is <25,000/μL , or the hemoglobin is <8 g/dL. Consistent with the produ ct label and 
peer reviewed published literature; two different ANC levels have been selected to guide 
valganciclovir dose adjustment. Three studies identify ing risk factors for neutropenia reported 
ANC level <1000/mm3(Venton et al., 2014 ; Tomonari et al., 2008 ) or <1500/mm3
(Salzberger et al., 1997 ). Salzberger et al. ( 1997 ) concluded that ANC level of <1000/mm3is 
predictive of both progression of neutropenia and mortality  and postulated that ganciclovir 
should be disconti nued when the ANC reached 1000/mm3rather than at an ANC level of 
750/mm3(the threshold ANC level specified in the study). 
For non-commercial use only
Take da CONFIDENTIAL Page 74
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Inaddition, inthisstudy , aclear trend was observed between the degree of neutropenia and the 
rate of bacterial infection; for the fungal infection the increased trend was only  present when 
ANC was <200/μL. Other studies (Goodrich et al., 1993 ; Boeckh et al., 1996 ) reviewed in 
Salzberger et al. ( 1997 ) showed that neutropenia with an ANC of <750/μL occurs in 30% of 
ganciclovir recipients and has been assoc iated with increased rates of bacterial sepsis and 
invasive fungal infection in marrow transplant recipients.
Subjects who do not achieve CMV viremia clearance may  need to continue treatment to resolve 
viremia, even though ANC level is between 500 -1000/mm3, at the discretion of the investigator 
and with the support of hematopoietic growth factors, if needed. However, considering the 
presence of neutropenia, the dose of valganciclovir may  be adjusted to 450 mg BID. For subjects 
who achieve CMV viremia cleara nce and have ANC level between 500 -1000/mm3, benefit/risk 
assessment for continued treatment may  need to be considered b y the investigator, and the option 
of either valganciclovir dose adjustment or dose interruption may  be chosen. I n each of the 
clinical scenarios hematopoietic growth factors may  be used as deemed necessary  by the 
investigator to prevent/manage neutropenia in addition to other strategies such as modification of 
other treatments that may be contributing to neutropenia development (eg, my cophenolate 
mofetil, Bactrim).
Table 7. Valganciclovir Dose Adjustment Based on ANC Level and CMV DNA 
Clearance
ANC >1000/mm3
[1.0 × 109/L]
ANC based on local 
or central laboratory 
resultsANC 500/mm3[0.5 ×109/L] 
to 1000/mm3[1.0 ×109/L]
ANC based on local or 
central laboratory resultsANC<500/mm3[0.5 × 109/L]
ANC based on local or 
central laboratory results
CMV DNA ≤LLOQ 
(based on local or 
central specialty 
laboratory, most 
recent result prior to 
dose assessment 
should be considered).Continue 
valganciclovir 900 mg 
BID.
Hem atopoietic growth 
factors may be used at 
investigator’s 
discretion.May adjust valganciclovir 
dose to 450 mg BID or 
interrupt the dose and 
resume at 450 mg BID or 
900mg BID (dose choice at 
investigator’s discretion) 
once ANC >1000/mm3
[1.0×109/L].
Hem atopoietic growth 
factors may be used at 
investigator’s discretion.May interrupt valganciclovir 
dose and resume at 450 mg 
BID or 900 mg BID (dose 
choice at investigator’s 
discretion) once ANC 
>1000/mm3[1.0×109/L].
Perm anent valganciclovir 
discontinuation and alternative 
anti-CMV treatment may be 
considered at investigator’s 
discretion.
Hem atopoietic growth factors 
should be strongly considered.
For non-commercial use only
Take da CONFIDENTIAL Page 75
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table 7. Valganciclovir Dose Adjustment Based on ANC Level and CMV DNA 
Clearance
ANC >1000/mm3
[1.0 × 109/L]
ANC based on local 
or central laboratory 
resultsANC 500/mm3[0.5 ×109/L] 
to 1000/mm3[1.0 ×109/L]
ANC based on local or 
central laboratory resultsANC<500/mm3[0.5 × 109/L]
ANC based on local or 
central laboratory results
CMV DNA ≥LLOQ 
(based on local or 
central specialty 
laboratory, most 
recent result prior to 
dose assessment 
should be considered).Continue 
valganciclovir 900 mg 
BID.
Hem atopoietic growth 
factors may be used at 
investigator’ 
discretion.May adjust valganciclovir 
dose to 450 mg BID.
Hem atopoietic growth 
factors m ay be used at 
investigator’s discretion.May interrupt valganciclovir 
dose and resume at 450 mg 
BID or 900 mg BID (dose 
choice at investigator’s 
discretion) once ANC 
>1000/mm3[1.0×109/L].
Perm anent valganciclovir 
discontinuation and alternative 
anti-CMV treatment may be 
considered at investigator’s 
discretion.
Hem atopoietic growth factors 
should be strongly considered.
ANC=absolute neutrophil count; BID=twice daily; CMV=cytomegalovirus; DNA=deoxyribonucleic acid; 
LLOQ=lower limit ofquantitation; QD=once daily
Drug kit dispensing for dose adjustments will be managed b y the IRT s ystem in order to 
maintain the blind. Subjects that require a dose adjustment for renal function or ANC level, 
regardless of study  treatment, will be assigned a new study  drug kit.
Various clinical scenarios of neutropenia, as shown in Table 7, will be programmed in the IRT 
and appropriate options will be selected b y the investigator. Interruptions and discontinuation of 
study  treatment will be conducted in a blinded manner; therefore, it is possible that treatment 
with either valganciclovir or maribavir will be interrupted or discontinued for neutropenia 
presence. The inv estigator may  also select to interrupt study  treatment, for other adverse events, 
regardless of the treatment assignment (maribavir or valganciclovir). The interruption for a 
maximum of 7 consecutive day s will not result in permanent study  treatment discontinuation. 
Upto 2study  treatment interruptions for a total of up to 7 days will be allowed. If study  drug is 
interrupted for an y reason and subsequent ly resumed, the end of the stud y drug administration 
period would remain fixed at a maximum of 8 weeks after the date of the start of treatment. 
Athird study  treatment interruption will lead to permanent stud y treatment discontinuation ; the 
subjects will complete the end of treatment procedures described for Visit 10/Study  Week 8 in 
the Schedule of Assessment 1 (Table 1
), and will follow a modified sche dule of assessments 
through the remaining weekl y visits scheduled for the study treatment phase and the regular 
schedule of assessments through the 12 -week follow -up phase as described in Section 4.5.
For non-commercial use only
Take da CONFIDENTIAL Page 76
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
If valganciclovir dose adjustment is required for both renal function and neutropenia, the lowest 
dose/dose selection as specified in Table 7will occur through the IRT.
6.2.4 Blinding Procedures
This is a randomized, double -blind, double -dummy , active -controlled study. Qualified subjects 
will be randomized in a 1:1 allocation ratio to receive maribavir or valganciclovir using a 
centralized procedure. An I RT will be used to randomize subjects and provide the treatment 
assignment to the blinded pharmacist or a blinded designated study  staff member.
To accomplish the blind, exact matching placebo tablets wi ll be provided for both maribavir and 
valganciclovir, ie, each subject will receive maribavir and placebo (identical to valganciclovir) 
tablets if randomized to maribavir treatment, or valganciclovir and placebo (identical to 
maribavir) if randomized to va lganciclovir treatment To protect the stud y blind, subjects will be 
required to take at a maximum, 2 tablets of their assigned stud y treatment and 2 tablets of the 
placebo q12h in a double -dummy  format as shown in Table 5.
In order to protect the study  blind during the study conduct, it is imperative that the investigator, 
subjects and their families, or an y member of the study  team, either at the study  site or that of the 
Sponsor remain blinded to the subject treatment assignments until the data base lock (after the 
last subject has completed the study ). The investigator and the sponsor will also be blinded to the 
PK data. Every  effort will be made to ma intain the blind except in those emergency
 situations 
when the identification of the investigational product is required for further treatment of the 
subject.
Unblinding the Treatment Assignment
There will be a provision for unblinding to ensure adequate t reatment of the subject in the case of 
an emergency  (details will be provided in the study  manual). The Sponsor medical monitor 
should oversee this process. An unblinded medical monitor independent from the study  will be 
identified by  the sponsor for any  situations that may need unblinding during the study .
In order to maintain the overall quality of the clinical conduct of the trial and integrit y of the 
study  data, the treatment assignment must not be broken during the study  except in emergency  
situations where the identification of the investigational product is required for further treatment 
decisions for the subject. The investigators are encouraged to contact the designated blinded 
study  medical monitor whenever possible to discuss the circumstances and the potential need for 
unblinding. If this is not possible, in the event of emergency  unblinding, the investigator must 
notify  the designated blinded study  medical monitor and the sponsor, as soon as possible after 
breaking the blind, taking care not to r eveal the subject's randomization code (see emergency  
contact information in Section 8.2.2). 
For non-commercial use only
Take da CONFIDENTIAL Page 77
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The date and reason for unblinding will be recorded in subject's source documents. An unblinded 
medical monitor will be contacted if needed for any  matters where treatment assignment will 
need to be revealed.
The investigators will be provided by  the Sponsor with a clear procedure on how to access the 
central randomization system for code -breaking for each subject, disclosing the details of the 
allocated treatment (details provided in the study  manual). The code will be broken onl y in case 
of emergency  where the further treatment of the subject is dependent on the trial medication 
he/she received. In the event that the treatment assignment is broken, the date, the signature of 
the person who broke the code, and the reason for breaking the code are recorded on the IRT and 
the source documents. Any  code break tha t occurs must be reported to the contract research 
organization (CRO)/sponsor.
Since the PK samples for only  those subjects who are taking maribavir will be anal yzed while 
the study  is ongoing, the bioanaly sis will be conducted by  unblinded staff from the bioanaly sis 
laboratory /CRO to allow for the identification of the PK samples from the subjects randomized 
to the maribavir treatment arm. If needed, an interim PK analy sis of maribavir PK data obtained 
from the subjects may  be performed b y an independent unblinded team/CRO outside of the 
blinded study  team, who will also receive the reports of the drug concentrations for the interim 
population PK analy sis.
 
 
 
 
 
 
 
 
 
The DMC may  be unblinded as described in the DMC charter.
6.3Labeling, Packaging, Storage, and Handling
6.3.1 Packaging and Labelin g
Maribavir, valganciclovir, and matching placebos will be packaged and labeled such that the 
products will be indistinguishable from their respective match placebos b y the investigator, study 
site, and subjects (refer to the pharmacy manual for further in formation).
For non-commercial use only
Take da CONFIDENTIAL Page 78
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Study  drug kits will be affixed with a label containing minimally  the protocol number, study  
drug kit number, dosage form, storage conditions, the statements ‘For clinical trial use onl y’, 
and/or ‘CAUTION: New Drug –Limited by  Federal (US) Law to Investigational Use’, and other 
information that may  be required by  the local laws.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor. Additional labels may not be added without the spo nsor’s prior full 
agreement.
6.3.2 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. L imited responsibility  for storage may  be delegated to the 
pharmacy  or member of the study  team, but this delegation must be documented. I nvestigational 
products are distributed by the pharmacy  or nominated member of the study team. The 
pharmacist/nominated team member will enter the unique subject identifier on the investigational 
product bottle/carton labels as they  are distributed.
Investigational products must be stored in accordance with labeled storage conditions which state 
“Do not store above 25°C. Do not freeze.” Temperature monitoring is required at the storage 
location to ensure that the investigational product is maintained within an established 
temperature range. The investigator is responsible for ensuring that the temperature is monitored 
throughout the duration of the study  and that records are maintained; the temperature sho uld be 
monitored continuously  by using either an in -house sy stem, a mechanical recording device such 
as a calibrated chart recorder, or b y manual means, such that both minimum and maximum 
thermometric values over a specific time period can be recorded and retrieved as required. Such 
a device (ie, certified min/max thermometer) would require manual resetting upon each 
recording. The sponsor must be notified immediately  upon discovery  of any  excursion from the 
established range. Temperature excursions will re quire site investigation as to cause and 
remediation. The sponsor will determine the ultimate impact of excursions on the investigational 
product and will provide supportive documentation as necessary. Under no circumstances should 
the product be dispensed to subjects until the impact has been determined and the product is 
deemed appropriate for use by  the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the int egrity  of the product(s); (eg, fumigation of a 
storage room).
For non-commercial use only
Take da CONFIDENTIAL Page 79
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
6.4 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational products to carry  out 
this protocol for the agreed number of subjects. The investigator or desig nee will acknowledge 
receipt of the investigational product, documenting shipment content and condition. Accurate 
records of all investigational product dispensed, used, returned, and/or destroy ed must be 
maintained as detailed further in this section. An IRT will be used to manage subject 
randomization and the investigational product.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pha rmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by the investigator in the applicable study  
delegation of authorit y form) will dispense the investigational product only to subjects included 
in this study  following the procedures set out in the study  protocol. Each subject will be given 
only the investig ational product carry ing his/her treatment assignment. All 
administered/dispensed medication will be documented on the CRFs and/or other investigational 
product records and may  include additional information as required per applicable regulations. 
The inve stigator is responsible for ensuring the retrieval of all study supplies from subjects. 
Compliance will be collected in the subject's diary. The disposition of the unused supply  of the 
dispensed investigational product will be documented in the accountabil ity log.
During the COVID -19 public health emergency , alternative study  drug delivery  to trial 
participants may  be necessary  to avoid unnecessary  subject visits to sites while providing needed 
study  drug. Additional study  drug may  be dispensed during a sch eduled study  visit or study  drug 
may be shipped directly  from investigational sites to participants’ residences by  a contracted 
logistics provider or distributor (direct -to-patient [DTP] shipment) in compliance with national 
laws or temporary  national emer gency  measures and Takeda processes. When utilizing DTP, the 
investigator remains responsible for ensuring the safet y of subjects and the dispensation of the 
investigational product.
No investigational product stock or returned inventory  from a Takeda -spon sored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor. If such transfer is authorized by  the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records provided the blind of the study  is not compromised.
For non-commercial use only
Take da CONFIDENTIAL Page 80
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
With the written agreement of the sponsor, at the end of the study , or as instructed b y the 
sponsor, all unused investigational product stock, subject- returned investigational product, and 
empty /used investigational product packaging will be returned to a sponsor specified 
designation. Should local, state or national laws prohib it the return of unused stock, subject 
returned investigational product, or empt y/used investigational product packaging to the sponsor 
designated locations, it may  be destroy ed at the site or local facility  once the sponsor has 
reviewed and approved the s
ite's standard operating procedure. In this case, Certificates of 
Destruction (CoD) identify ing what was destro yed, when and how, must be obtained with copies 
provided to the sponsor. Destruction of investigational products must be in accordance with 
local , state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be accounted for and all discrepancies i nvestigated and documented to the sponsor’s 
satisfaction.
6.5 Subject Compliance
For drug administration at the site, hospital staff or study  personnel will administer all doses of 
study  drug. Missed/incorrect doses will be recorded in the subject’s diary  and CRF, as 
appropriate.
During the COVID -19 public health emergency , study  drug may  be administered by  a healthcare 
professional as part of home nursing or home healthcare. If a subject participates in home 
healthcare in the treatment phase, they  will receive study  drug through DTP and the site will 
follow -up with the subject. When utilizing DTP, the investigator remains responsible for 
ensuring the safety  of subjects and the dispensation of the investigational product.
For drug administration as outpatients, a study  diary  for tracking adherence to study  drug dosing 
and an adequate suppl y of study drug will be dispensed for home use. Subjects must be 
instructed to bring their unused study  drug, empty /used study  treatment packaging, and the study  
diary  to every  visit. Drug reconciliation must be assessed for all dispensed investigational 
product. Unused investigational product will not be redispensed. Instructions will be provided in 
the pharmacy  manual.
For non-commercial use only
Take da CONFIDENTIAL Page 81
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
7.STUDY PROCEDURES
7.1Study Schedule
See Table 1for study  procedures for the double -blind study  treatment phase and Table 2for 
study procedures for the follow -up phase.
7.1.1 Screening Period 
Screening Visit (Visit 1/ Day -14 to Day 0/Week -2 to Week 0)
As specified in Table 1, the scre ening procedures will include:
Informed consent
Inclusion/Exclusion criteria (See Section 4.1and Section 4.2)
Height and bod y weight (Section 7.2.3.1)
Vital signs (Section 7.2.3.2 )
Medical history , including transplant history  (eg, underly ing disease that led to the HSCT, 
transplant ty pe, other details related to tran splant) and CMV history , HIV status
Prior medication, therapies, and procedures, including an y prior anti -CMV medication used 
to treat the current CMV infection (Section 5.1
)
Hematology /Chemistry  (Section 7.2.3.4). Tests required for eligibility  must be performed 
and results verified within 3 days prior to randomization.
Pregnancy  test (serum) for all females of childbearing potential (Section 7.2.3.4). This must 
be performed and results verified within 3 days prior to randomization.
HIV status: Historical results for human immunodeficiency  virus (HIV) tests performed 
within 3 months prior to randomization will be acceptable for screening. If no HIV test result 
within 3 months is available , the subject must have testing done locall y during the screening 
period and have the results available prior to randomization (Exclusion Criterion 8).
Cytomegalovirus disease assessment (Section 7.2.2.3 )
Interactive response technology  (IRT; Section 6.2.1 ) to manage screening and site enrollment
Invasive bacterial and fungal infections/transplant relevant infection assessment (see 
Section 8.1.4
)
Graft -versus- host-disease assessme nt
For non-commercial use only
Take da CONFIDENTIAL Page 82
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Cytomegalovirus DNA test (quantitation): Documentation of CMV infection in whole blood 
or plasma with a screening value of ≥1365 IU/mL to ≤273000 IU/mL in whole blood or 
≥455 IU/mL to ≤91000 IU/mL  in plasma in 2 consecutive samples separated by  at least 1day 
as determined b y local or central specialty laboratory qPCR or comparable quantitative CMV 
DNA results with the first sample available within 14 days prior to randomization at 
Visit 2/Week 0/Day 0. The second sample must be taken within 5 days prior to 
randomization. The 2 CMV DNA results must be 
≥455 IU/mL  in plasma or ≥1365 IU/mL  in 
whole blood. High -risk CMV infection is defined as meeting an y of the following criteria:
Human leukocy te antigen (HLA) -related (sibling) donor with at least 1 mismatch at 
1of the following 3 HLA -gene loci: HLA -A, -B or - DR;
Haploidentical donor;
Unrelated donor with at least 1 mismatch at 1 of the following 4 HLA gene loci: 
HLA -A, -B, -C, -DRB1;
Use of umbilical cord blood as stem cell source;
Use of ex vivo T- cell-depleted grafts;
Grade 2 or greater GVHD requiring the use of s ystemic corticosteroids (defined as 
the use of ≥1 mg/kg/day  of prednisone or equivalent dose of another corticosteroid).
Results from the same laboratory  are to be used to assess subject eligibili ty criteria. The 
laboratory  used for DNA quantification could be either local specialty laboratory  or central 
specialty  laboratory .
Informed consent must be obtained before an y study -specific procedures are performed. All 
screening procedures will be compl eted within 14 days prior to randomization, with the 
exception of the following:
Clinical laboratory  tests (hematology , chemistry , and pregnancy ), must be performed and 
verified within 3 day s prior to study  treatment initiation. At screening, either centra l or local 
laboratory  results for hematology /chemistry /pregnancy  testing can be used for qualification.
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been randomized or administered study  
treatment. Screen failures due to low platelet count, hemoglobin, and low neutrophil counts or 
liver or renal parameters can be rescreened once within the 14- day screening period at the 
investigator’s discretion when other inclusion criteria are fulfilled. Other screen failures may  be 
rescreened in the future (with new informed consent and screening period) if their clinical course 
results in a change that deems them eligible for the study . 
For non-commercial use only
Take da CONFIDENTIAL Page 83
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
In addition, subjects who discontinued from screening due to COVID -19-related factors but were 
otherwise qualified to participate in the trial may  be rescreened at an y time if the Takeda medical 
monitor agrees.
The screening visit (Visit 1) and Visit 2/Week 0/Day 0 visits can occur in the same day .
7.1.2 Study Drug Administration Period
Visit 2/Week 0 (Baseline; Day 0) to Visit 10/Week 8 (End of Treatment)
Permissible assessment windows during the 8 -week study  treatment phase are: Study  
Day 4
± 1day, Study  Week 1 + 2 days, Study  Weeks 2 to 4 ± 2days; Study  Weeks 5 to 
8 ±
3days.
As specified in Table 1thefollowing assessments will be performed during the study  treatment 
phase:
Randomization on Visit 2/Week 0 (Day 0; baseline)
Physical examination (including weight) at Visit 2/Week 0, Visit 6/Week 4, and 
Visit 10/Week 8 (Section 7.2.3.1)
Review of medical history and prior medication at Visit 2/Week 0 (Section 5.1)
Weight at Visit 4/Week 2 and Visit 8/Week 6 (Section 7.2.3.1)
Vital signs at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, and 
Visit 10/Week 8 (Section 7.2.3.2
)
12-lead ECG at Visit 2/Week 0, Visit 10/Week 8 (Section 7.2.3.3)
Hematology /Chemistry  assessment by  the central laboratory at all visits through the study  
treatment phase; potassium and magnesium at Visit 2A (Section 7.2.3.4). In addition, blood 
samples for complete blood count with differential count and serum creatinine should be 
drawn for the anal ysis by the local laboratory  within 2 days prior to study  
treatment 
dispensation for an y postbaseline visits so that the test results are available for review prior to 
each stud y treatment dispensation. Additional analysis b y local laboratory may be conducted 
at the investigator's discretion.
Urinaly sis at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, and 
Visit 10/Week 8 (Section 7.2.3.4)
Pregnancy  test at Visit 2/Week 0, Visit 6/Week 4, Vi sit10/Week 8 (Section 7.2.3.4)
For non-commercial use only
Take da CONFIDENTIAL Page 84
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Hepatitis B virus (HBV) and hepatitis C virus (HCV) test at Visit 2/Week 0 (Historical 
results available within 3 months prior to study  treatment initiation will be accepted. A test 
will be performed at Visit 2/Week 0 if the historical results are not available.)
Cytomegalovirus DNA test: CMV DNA quantification in the plasma samples obtained at all 
visits (including bas eline) of study  treatment phase will be conducted at central specialt y 
laboratory . CMV genot yping b y the central specialty  laboratory  to assess for mutations in the 
UL97, UL27, and UL54 genes will be conducted only  on the following samples: at baseline; 
 
 
 
Tissue invasive CMV disease assessment (see Appendix 4) at all visits through the stud y 
treatment phase
 
Immunosuppressant drug concentration measured at Visit 2/Week 0, Visit 2A/Day 4, 
Visit 3/Week 1, and Visit 10/Week 8 (see Section 7.2.3.4)
Pharmacokinetic sample collection for adult subjects ≥18years of age will be as follows: 
atVisit 3/Day 7/Week 1 (premorning dose and between 2 -4hours postmorning dose), 
Visit6/Week 4 (only  premorning dose), and Visit 10/Week 8 (premorning dose and between 
2-4hours postmorning dose). Pharmacokinetic sample collection for adolescent subjects 
≥16to <18 y ears of age will be as follows: intensive PK sampling at Visit 3/Week 1
(premorning dose and 1, 2, 3, 4, 6, 8 [all ±5 min], and 12 hours [±15 min] postmorning dose); 
at Visit 6/Week 4 (one premorning dose PK sample); at Visit 10/Week 8 (one premorning 
dose and one between 2 -4hours postmorning dose PK samples).
Interactive re sponse technology  at all visits through the study  treatment phase; except for the 
end-
of-treatment visit (Visit 10/Week 8), IRT will be used for stud y treatment dispensing at 
all other visits through the study  treatment phase.
Study  drug dispensed at every visit except Visit 10/Week 8; study  drug administration 
through 8 weeks of stud y treatment phase (Study Week
0 through Stud y Week 7)
 
 
 
For non-commercial use only
Take da CONFIDENTIAL Page 85
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Assessment of underl ying disease that led to HSCT will be per formed at all visits through 
study  treatment phase
Invasive bacterial and fungal infections/transplant relevant infection assessed at all visits 
throughout the stud y treatment phase
Hepatic function grading according to the Child- Pugh classification (see Appendix 2and 
Section 7.2.2.8) at baseline, Visit 2/Week 0
Graft -versus- host-disease assessment at all visits through the study  treatment phase
Comorbidity  status evaluation at baseline, Visit 2/Week 0, Visit 6/Week 4, and 
Visit 10/Week 8
 
 
Concomitant medications, therapies, and procedures through the study  treatment phase
Adverse event/SAE monitoring throughout the study  treatment phase
For subjects who permanently  discontinue study  treatment early  but do not withdraw consent, 
refer to Section 4.5regarding modified schedule of assessments.
7.1.3 Follow -up Period
Visit 11/Week 9/Follow- up Week 1 to Visit 18/Week 20/Follow- up Week 12 (End of Study )
The follow -up period for thi s protocol is 84 days or 12 weeks (post -treatment Visits 11 to 18). 
The permissible assessment windows for the visits are: Study  Weeks 9
-12 (Follow -up 
Weeks 1-4) ±2 days; Study  Weeks 14-20 (Follow -up Weeks 6-12) ±3 days.
As specified in
 Table 2study  evaluations include:
Physical examination (including weight) at Visit 18/Week 20
Vital signs at Visit 18/Week 20
12-Lead ECG at Visit 18/Week 20
Hematology /Chemistry  assessment by  the central laboratory  at Visit 12/Week 10, 
Visit 14/Week 12, Visit 16/Week 16, Visit 18/Week 20
For non-commercial use only
Take da CONFIDENTIAL Page 86
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Urinaly sis at Visit 18/Week 20
Immunosuppressant drug concentration level at Visit 11/Week 9, if treatment continued until 
Week 8 (drug concentration level to be measured 1 week after the end of the study treatment)
Assessment of underl ying disease that led to HSCT will be performed at all visits during the 
follow -up phase
Invasive bacterial and fungal infectio n assessment at all visits during the follow -up phase
Cytomegalovirus DNA test: Cy tomegalovirus DNA quantification in the plasma samples 
taken at each visit of study follow -up phase will be conducted at central specialty  laboratory . 
Cytomegalovirus genot yping will be conducted only  on the samples:  
 
 
Tissue invasive CMV disease assessment (see Appendix 4) at all visits during the foll ow-up 
phase
Graft -versus- host-disease assessment at all visits through the follow -up phase 
(Section 7.2.2.5; Appendix 8, and Appendix 9)
Comorbidity  status evaluation at Visit 14/Week 12, Visit 16/Week 16, and Visit 18/Week 20
 
Monitoring of nonserious AEs not deemed related to
the investigational product up to 
30days after the last dose of study  medication (all AEs deemed related to the investigational 
product are collected until Visit 18/Week 20)
SAE monitoring through the follow -up phase
Concomitant medications, therapies, a nd procedures collected throughout the follow -up 
phase
All SAEs not resolved at the time of end of stud y visit (Visit 18/Week 20 or Follow -up Week 12) 
will be followed to closure or stabilization (see Section 8.1). If a subject is withdrawn from the 
study , all Follow -up Week 12/end of study  procedures must be performed as soon as possible 
after discontinuation.
For non-commercial use only
Take da CONFIDENTIAL Page 87
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
7.1.4 Additional Care of Subjects after the Stu dy
No aftercare is planned for this study .
7.2Study Evaluations and Procedures
All study  evaluations and procedures are specified in Schedule of Assessment 1, Table 1, and 
Schedule of Assessment 2, Table 2 .
7.2.1 Demographic and Other Baseline Characteristics
Age and/or year of birth, sex, race, and ethnicity  will be recorded for all subjects.
7.2.2 Efficacy
7.2.2.1 CMV DNA Quantitation
Blood samples will be assessed at a central specialty  laboratory  for the quantification of CMV 
DNA in plasma using the COBAS®AmpliPrep/COBAS®TaqMan®CMV Test. Central specialt y 
laboratory  plasma CMV DNA results will be reported to the investigator site as available. 
Additional CMV DNA testing at local specialty laboratories may  be performed and collected at 
more frequent intervals or using additional assay  methods at the discretion of the investigator.
Confirmed CMV viremia clearance will be defined as plasma CMV DNA concentration below 
the lower limit of quantification (<LLOQ; ie, <137 IU/mL ]), when assessed by  COBAS®
AmpliPrep/COBAS®TaqMan®CMV Test at a central specialt y laboratory, in 2 consecutive 
postbaseline samples, separated b y at least 5 days.
Confirmed Recurrence or the confirmed CMV viremia recurrence will be defined as plasma 
CMV DNA concentration ≥LLOQ when assessed by  COBAS®AmpliPrep/COBAS®TaqMan®
CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable 
(<LLOQ) for at least 5 days in 2 consecutive samples.
7.2.2.2
CMV Genotyping and Phenotyping
Subjects with known resistance to anti- CMV agents, as dete rmined b y the local specialt y 
laboratory  (testing will be done as directed by  the investigator) at the site, will be excluded from 
the study . At Visit 2/Day 0 plasma samples will be obtained and tested b y the central specialt y 
laboratory  to identify  mutati ons in the viral UL 97 and UL54 genes known to confer resistance to 
anti-CMV agents. In addition, UL 27 gene will be tested. Given the urgency  to treat subjects, it is 
not possible to wait for this central specialty  laboratory  assessment prior to a subject’s
randomization. Potential for mutation conferring resistance at baseline will be limited, given that 
for the current infection, any  anti
-CMV treatment will not be administered for longer than 
72hours. 
For non-commercial use only
Take da CONFIDENTIAL Page 88
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Ininstances when amutation conferring resistance toanti-CMV agents willbe reported in the 
baseline sample anal yzed by  the central specialt y laboratory these subjects will be excluded from 
the Per Protocol Set for analy sis.
 
 
 
 Rebound is 
defined as increase in viral DNA load without prior clearance of viremia. The entire UL97, 
UL54, and UL27 CMV genes will be sequenced in every  sample that meets the criteria for 
genot yping, including the baseline samples.
 
 
 
The list of CMV mutations known to confer resistance to valganciclovir, and other commercially 
available anti- CMV agents (ganciclovir, foscarnet, and cidofovir) is presented in Appendix 3.
7.2.2.3
 
 
 
 
 
 
 
 
 
 
 
 
 
For non-commercial use only
Take da CONFIDENTIAL Page 89
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
7.2.2.4
 
 
 
 
 
 
 
 
7.2.2.5 Underlyi ng Disease Assessment
Hematopoietic stem cell transplant offers potentially  life-saving treatment for advanced 
malignancies and other diseases of hematologic, immunologic or metabolic origin. Underl ying 
disease that led to HSCT, including relapse/progressi
on, will be assessed at all visits throughout 
the study  as indicated in Table 1andTable 2. Dates of relapse or progression of the underl ying 
disease/malignancy  during the study  will be documented. All available methods of detection, 
such as hematological, cy togenetic, molecular, cytological/histolo gical, organs or sites involved 
etc., will be provided as appropriate for the underly ing condition.
7.2.2.6 Graft -versus- host-disease Assessments
Graft -versus- host-disease is a well -recognized complication of transplantation, and all blood 
stem cell sources can le ad to this complication. Graft- versus
-host-disease occurs when the donor 
cells (the “graft”) recognize the patient being transplanted (the “host”) as being foreign, 
(ie,when donor T lymphocy tes respond to mismatched protein antigens expressed in host 
Tcells). It presents in an acute and chronic form.
The most influential protein mismatches are human leukocy te antigens (HLAs) and the incidence 
of acute GVHD is directly related to the degree of mismatch between HLA proteins expressed by  
the HCT donor and re cipient ( Loiseau et al., 2007 ). Even in patients that receive HLA -matched 
(HLA- A/B/C/DRB1) grafts, however, GVHD arises in approx imately  40% of patients due to 
differences in minor histocompatibility  antigens, and requires sy stemic therapy . Acute GVHD 
that ty picall y occurs in first 100 days after transplant includes: ery thema, maculopapular rash, 
nausea, vomiting, anorexia, profuse diarrhea, ileus or cholestatic liver disease. A recent National 
Institute of Health classification also includes late -onset acute GVHD (after day  100) and an 
overlap s yndrome with features of both acute and chronic GVHD ( Cho et al., 2009).
Chronic GVHD t ypicall y occurs later (>100 days after transplant) and is manifested on skin, 
appendages, mouth, ey es, lungs, genitalia, esophagus and connect ive tissues. 
For non-commercial use only
Take da CONFIDENTIAL Page 90
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Chronic GVHD diagnosis is supported by  histologic evidence of GVHD from any  affected site. 
The diagnosis might be difficult as negative histological findings do not exclude the existence of 
chronic GVHD, and similarity  to other conditions that often occur in HSCT patients (such as 
mycophenolate mofetil [MMF] toxicity  or the presence of GI tissue invasive CMV disease).
Investigators are expected to consider recommendations for diagnosis provided in guidance in 
Appendix 8and Appendix 9(Jagasia et al., 2015 ; Shulman et al., 2015). Detailed information on 
GVHD at screening, baseline or during the study  will be collected in separate CRF forms.
Assessment of absence or presence of acute GVHD will be done at baseline, and if present, 
grading will be performed according to published guidelines provided in Appendix 7
(Harris et al., 2016 ); acute o
r chronic GVHD present at baseline will also be followed throughout 
the study  treatment phase, at every  study  visit, utilizing the same diagnosis until resolution 
(during the duration of the study ) as indicated in Table 1andTable 2.
7.2.2.7 Comorbidity Status
Transplant patients often have multiple other comorbidities, resulting from their 
immunosuppressed status (co- infections, graft -versus -host-disease, transplant malfunctioning 
due to rejection), toxicities from therapies for maintenance of the transplant or reactivation of the 
baseline disease for which they  had been transplanted (malignancy  for example), and other 
concomitant diseases resulting in very
 diverse population that might be enrolled into the study . 
The comorbidity  assessment will be conducted to allow for the comparison of the population 
enrolled into two treatment arms and to account for the subjects’ health status when assessing 
overall and individual subject response. Comorbidity  assessment will be performed at time 
points indicated in Table 1and Table 2. The difference between treatment arms in terms of 
baseline comorbidities might be controlled for in the anal yses, if determined to be substantial.
Comorbidity  assessment will utilize Karnofsky  Performance Status (KPS) scale for subjects 
(Peus et al., 2013 ;Schag et al., 1984 ). Karnofsk y Performance Status is a valuable tool for 
measurement of and comparison between the fu nctional statuses of individual patients.). Refer to 
Appendix 5for the KPS performance status scale forms.
7.2.2.8 Medical History
A medical history  will be ta ken during the screening period and updated on 
Visit 2/Day 0/Week 0 as specified in Table 1
. All medical history  findings that have been 
present/active within the 2 years prior to enrollment at Visit 2/Day 0 will be recorded regardless 
of clinical relevance or presence at stud y start. Medical history finding that have not been 
present/active wit hin the 2 years prior to enrollment will be recorded if deemed clinically  
relevant b y the investigator to the conduct of the study. 
For non-commercial use only
Take da CONFIDENTIAL Page 91
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Medical history related tothetransplant (including the disease/diseases leading to transplant) and 
CMV infection will be r ecorded without a time limit. The medical history  should include any  
history  of allergic reactions to drugs. Refer to Section 5.1for prior medicat ion history .
Specific information regarding the subject’s transplant history  that will be collected, including 
but not limited to, disease/condition that led to the transplant, the number of past transplants 
prior to the current transplant; the details of transplant, such as cell source and transplant ty pe; 
the human leukocy te antigen (HLA) matching level; the date and the history  of the current 
transplant including complications; transplant related infections; preparatory regimen for 
transplant; history  ofrelevant viral serology ; history  of anti -viral proph ylaxis; and status of the 
transplant at baseline.
Specific information regarding the subject’s CMV infection will be collected in separate CRFs. 
The collected information will include, but will not be li mited to: CMV serology  of donor and 
recipient and date of onset of the current CMV infection.
Subjects will be classified into 1 of the following categories with respect to hepatic function, 
based on baseline clinical and laboratory  assessments (see Appendix 2). This information will 
primarily  be utilized in the interpretation of the PK data for which the samples will be collected 
at the specified visits in the study :
No chronic liver disease
Chronic liver disease -Child -Pugh Class A
Chronic liver disease -Child -Pugh Class B
Chronic liver disease -Child -Pugh Class C
7.2.2.9 Subject Survival
Subject survival (yes/no) will be determined at all visits during the study . The date and cause of 
death will be recorded in the CRF.
7.2.3 Safety
7.2.3.1 Physical Examination (Including Weight)
Abnormalities identified at the screening visit (Visit 1) will be documented in the 
subject’s source documents and on the medical history  CRF. Ch
anges after the screening visit 
(Visit 1) will be captured as AEs on the AE CRF page, as deemed clinically relevant b y the 
investigator.
For non-commercial use only
Take da CONFIDENTIAL Page 92
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The investigator or designee will perform phy sical examinations at time points specified in 
Table 1and Table 2. Physical examinations will be performed in accordance with standard 
practices at the investigational site. Body  weight and height will be measured at time points 
specified in the schedule of assessments.
7.2.3.2 Vital Signs
Vital signs (bod y temperature, arterial blood pressure, and pulse) will be collected in a standard 
manner at the time points specified in Table 1and Table 2. An y changes from baseline 
(Visit 2/Day 0/Week 0) which are deemed clinically  significant in the opinion of the inves tigator 
are to be recorded as an AE.
7.2.3.3 Electrocardiogram
A 12 -lead ECG will be performed at Visit 2/Day 0, Visit 10/Week 8 (end of treatment visit), 
Visit 18/Week 20 (end of study  visit), and at an y additional time during the study , if clinicall y 
indicated. ECG data will include heart rate, RR duration, PR duration, QT duration, QRS 
duration. The corrected QT interval (QTc) will be calculated using the Fridericia’s formula. The 
investigator will be responsible for providing the interpretation for all ECGs in terms of clinical 
significance to the subject.
7.2.3.4 Clinical Laboratory Evaluations
Clinical laboratory  tests (hematology , chemistry , urinaly sis, HBV, HCV, pregnancy ) will be 
performed b y a central laboratory  at the time points, including baseline, specified in Table 1and 
Table 2.
 During screening, clin ical laboratory  tests (hematology , chemistry parameters required 
for eligibility  verification, pregnancy) must be performed and results verified within 3 days prior 
to randomization; either central or local laboratory  results can be used for qualification. This also 
applies to CMV DNA quantification results. If no result of HIV testing within 3 months prior to 
screening is available, an HIV test will be performed at a local laboratory  during the screening 
period for eligibility  assessment. I f local laborato ry results are used for the assessment of 
eligibility , the reference ranges must be provided. Local laboratory  results will be recorded in the 
CRF.
Historical results available within 3 months prior to study  treatment initiation will be accepted 
for HBV an d HCV at Visit 2/Week 0; however, a test will be performed if historical results are 
not available.
At baseline (Visit 2/Week 0) blood samples will be taken for CMV DNA quantification and 
genot yping, hematology  and chemistry  and tested in the central specialty  laboratories. At 
assigned visits, blood samples and urine for clinical safety  laboratory  testing should be collected 
prior to the administration of study  drug. 
For non-commercial use only
Take da CONFIDENTIAL Page 93
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Allclinical laboratory assay swillbeperformed according to the central laboratory ’s standard 
procedures. In addition, blood samples for complete blood count with differential and serum 
creatinine should be drawn and anal yzed by the local laboratory  within 2 day s prior to study  
treatment dispensation so that results are available and revie wed prior to each study  treatment 
dispensation during the treatment phase.
Reference ranges will be supplied by  the central laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of- range pathological changes. The investigator 
should assess out -
of-range clinical laboratory  values for clinical significance, indicating if the 
value(s) is/are not clinically  significant or clinically  significant. Clinicall y significant finding 
should be reported as an AE unless signs of already  reported conditions exist. Abnormal clinical 
laboratory  values that are unexpected or not explained by  the subject’s clinical condition may , at 
the discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, 
explained, or resolved.
The following clinical laboratory  assessments will be performed:
Chemistry
Serum sodium, potassium, chloride, bicarbonate/carbon dioxide, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, uric acid, total protei n, albumin, creatine 
phosphokinase, total bilirubin, direct bilirubin, ALT, AST, gamma glutam yltransferase (GGT), 
alkaline phosphatase (ALP), cholesterol (total and HDL /LDL ratio), and trigl ycerides. The 
samples for chemistry  are preferred to be taken unde r fasting conditions, although this is not 
mandatory . The information whether samples were taken under fasting conditions will be 
collected.
A local laboratory  will be used to assess potassium and magnesium levels at Visit 2A 
(Day 4±1day for subjects rece iving tacrolimus, cy closporine, everolimus, or sirolimus at 
baseline, and at 4±1 days after initiating any  of these agents for subjects starting the 
immunosuppressive therapy  after baseline and during the study  treatment period).
Hematology
White blood cell (WBC) and differential counts (including ANC), hemoglobin, hematocrit, red 
blood cell (RBC) count, reticulocy tes, platelet count.
Urinalysis
pH, specific gravity , protein, glucose, ketones, hemoglobin, and microscopic evaluation (RBC, 
WBC, cry stals, c asts, bacteria), protein/creatinine ratio. Leukocy te esterase for the macroscopic 
evaluation.
For non-commercial use only
Take da CONFIDENTIAL Page 94
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Virology
Hepatitis (hepatitis B surface antigen and/or viral DNA, hepatitis C antibody  and/or viral 
RNA) at baseline onl y, if applicable. Historical results within 3 months of randomization are 
acceptable. If historical results are unavailable, blood will be drawn at Visit 2/Week 0 for 
hepatitis B surface antigen and hepatitis C antibody  testing at the central lab. Central 
laboratory  results do not need to be available prior to randomization.
Human immunodeficiency virus (HIV) test. Historical results within 3 months prior to the 
study  treatment initiation will be acceptable for screening. If no result of HIV testing within 
the prior 3 months is available, the subje ct must have resting done locally  during the 
screening period, and must have the results available prior to randomization.
Other
International normalized ratio (INR) and prothrombin time at baseline only
Immunoglobulins IgG and immunoglobulins total (a tot al of IgG + IgA + IgM) with no reference 
ranges associated with the immunoglobulins total value
Local Laboratory Test to Monitor Immunosuppressant Drug Concentration Levels
For subjects who are receiving tacrolimus, cy closporine, sirolimus, or everolimus, testing of the 
blood concentration levels of these drugs will be performed at each site’s local laboratory , using each 
site’s standard assay  and standard therapeutic drug monitoring practice (eg, time of sample collection 
relative to dosing). The testing w ill be performed at the time points outlined below, provided the 
subject is still receiving tacrolimus, cy closporine, or everolimus on these study day s.
If the subject is receiving tacrolimus, cy closporine, sirolimus or everolimus on 
Study Visit 2/Day 0/We ek0, obtain a tacrolimus, cyclosporine, sirolimus or everolimus blood level:
At Visit 2/Day 0/Week 0 prior to initiation of study  treatment
At Visit 2A/Day 4±1day
At the Visit 3/Day 7 (±2 day)/Week 1 study  visit
At Visit 10/Week 8 (±2 days) or on end of treatment visit (if earlier than Week 8)
At the Week 1 post -treatment follow -up visit (ie, 1 week [±2 days] after discontinuation of study  
treatment)
For non-commercial use only
Take da CONFIDENTIAL Page 95
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
If the subject is not receiving tacrolimus, cy closporine, sirolimus or everolimus on Study  Day 0, but 
starts any  of these drugs after Day 0 while still receiving study  treatment, obtain a tacrolimus, 
cyclosporine, sirolimus or everolimus blood level:
At 4±1 days after initiating treatment with tacrolimus, cy closporine, everolimus, or sirolimus
At the next sche duled study visit after first starting the tacrolimus, cy closporine, sirolimus, or 
everolimus, while still receiving study  treatment
At Visit 10/Week 8 (+2days) or on end of treatment (if earlier than Week 8)
At the Week 1 post -treatment follow -up visit ( ie, 1 week [±2 days] after discontinuation of study  
treatment)
Pregnancy Test 
A serum β -hCG pregnancy  test will be performed on all females of child -bearing potential at the 
screening visit (Visit 1), baseline (Visit 2/Week 0), Visit 6/Week 4, and at the end of stud y 
treatment visit (Visit 10/Week 8), or if pregnancy is suspected, or on withdrawal of the subject 
from the study . Local laboratory  test results can be used for the assessment of pregnancy  on 
Day 0/Week 0.
7.2.3.5 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way  to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
All AEs are collected from the time informed consent is signed through 30 days after the last 
dose of study  medication. All AEs deemed related to the investigational product and all SAEs are 
collected through the end of the study  (Visit 18/Week 20 [Follow -up Week 12]).
7.2.4 Others 
7.2.4.1 Clinical Pharmacology Assessments 
Pharmacokinetic samples will be obtained for all subjects as in the Schedule of Assessments 
(Table 1), but anal yzed for only  those subjects who are taking maribavir. Bioanaly sis of 
PKsamples will be conducted while the stud y is ongoing. The anal ysis will be conducted b y 
unblinded staff from the bioanaly sis laboratory /CRO to allow for the identification of the 
PKsamples from the subjects randomized to the maribavir treatment arm.
For subjects ≥18 years of age ( Table 8), 1 or 2 PK samples will be collected on each of the study  
days specified in Table 1.The premorning dose PK sample will be obtained at all 3 PK visits. 
The postmorning dose PK samples at Visit 3/Week 1 and at Visit 10/Week 8 will be obtained 
any time betwee n 2 to 4 hours after the morning dose. 
For non-commercial use only
Take da CONFIDENTIAL Page 96
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Any episode ofvomiting occurring within 2to 4hours after the morning dose at Visit3/Week 1 
and Visit 10/Week 8 must be documented. Subjects will record the date and time of the previous 
maribavir dose taken before a PK visit in their electronic diary . The instructions will be provided 
in the study  manual.
Table 8. Subjects ≥18Years Sparse PK Schedule
Week 1, Day 7 (±1d) Week 4, Day 28 (±2d) Week 8, Day 56 (±2d)
Study Treatment Period
Prem orning dose
2-4 hours postmorning doseOne premorning dose Prem orning dose
2-4 hours postmorning dose
For subjects ≥16 to <18 years of age ( Table 9), an intensive PK sampling will be performed at 
Visit 3/Week 1. Subjects will be asked to complete the 12 -hour postmorning dose PK sample 
prior to taking their evening dose. Sparse PK sampling similar to adults ( ≥18 y ears) will be 
performed at Week 4 and Week 8.
Table 9. Subjects ≥16 to <18 Years Including Intensive PK (Week 1) Schedule
Week 1, Day 7 (±1d)
(Intensive PK)Week 4, Day 28 (±2d) Week 8, Day 56 (±2d)
Study Treatment Period
Prem orning dose, 1, 2, 3, 4, 6, 8 (all 
±5min), and 12 hours (±15 min) 
postmorning doseOne premorning dose Prem orning dose and
2-4 hours postmorning dose
The following will be recorded in the study  diary  and/or CRF:
Date and time of the last dose of blinded study  treatment before the predose PK sample was 
taken
Date and time that the predose PK sample was taken
Date and time of the last dose of blinded study  treatment before the postdose PK sample was 
taken
Date and time that the 2 –4hour postdose PK sample was taken
Date and time of vomiting within 2 -4 hours after the morning dose and before the 
postmorning dose PK sample collection
For non-commercial use only
Take da CONFIDENTIAL Page 97
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
If a subject has study  treatment dose interrupted for 2 consecutive day s prior to the morning dose 
on a PK visit, no PK sample will be collected. If a subject has completed the premorning dose 
PK sample collection, but has missed the morning dose of blinded study  treatment on the day  of 
the PK visit, then no postdose PK sample will be collected.
Unscheduled PK Sample Collection
For purposes of special PK sampling, GIGVHD is defined as an y of the following 
(Boeckh et al., 2003 ):
Biopsy -proven GVHD of the GI tract plus diarrhea (>300 mL/day)
Biopsy  proven GVHD of the GI tra ct and nausea
Documented acute GVHD of the liver (stage II, total bilirubin >3 mg/dL or biopsy -proven) 
plus diarrhea (>500 mL/day) with no other explanation or
Biopsy -proven acute GVHD of the skin plus diarrhea (>500 mL/day) with no other 
explanation
If a subject is diagnosed with GI  GVHD during the study  treatment phase and therapy  with study  
drug remained permissible, study drug will be continued and blood samples for the determination 
of study  treatment in plasma concentrations will be collected. Th is unscheduled PK sampling 
will occur at the next visit after the first occurrence of a GI GVHD diagnosis, and will follow the 
schedule of sampling and recording of information as described in Table 1(Schedule of 
Assessments).
7.2.4.2
 
 
 
 
 
 
For non-commercial use only
Take da CONFIDENTIAL Page 98
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
 
 
 
 
 
 
 
 
7.2.4.3
 
 
 
 
 
 
 
 
For non-commercial use only
Take da CONFIDENTIAL Page 99
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
7.2.5 Volume of Blood to Be Drawn from Each Subject
The volume of blood drawn from each subject per visit is shown in Table 10.
Table 10. Volume of Blood Drawn Per Study Visit
Study Visit Blood Volum e per Visit (mL)
Screening 29
Visit 2Aa11
Visit 2 51
Visit 3 42
Visit 4, Visit 5, Visit 7, Visit 8, Visit 9 31
Visit 6 37
Visit 10 60
Visit 11 20
Visit 12, Visit 14, Visit 16 23
Visit 13, Visit 15, Visit 17 15
Visit 18 43
Additional PK PK Blood Volum e per Blood Draw (m L)
See Section 7.2.4.1 4
PK=pharmacokinetic
aTo be drawn only from subjects receiving immunosuppressive agents tacrolimus, cyclosporine, everolimus, or sirolimus at 
baseline (on Day 4 ±1 day), or from subjects who initiate treatment with any of these agents after baseline (4 ±1 day after 
starting the immunosuppressant).
Note: See Schedule of Assessment 1 (Table 1) and Schedule of Assessment 2 (Table 2).
During this study, it is expected that approximately 551mL of blood will be drawn from all 
subjects, regardless of sex. Subjects between the ages of 16 to 18 years will have an additional 
24mL of blood drawn for intensive PK visits.
Note: The amount of blood to be drawn for each assessment at an y visit is an estimate. The 
amount of blood to be drawn may  vary  according to the instructions provided by  the 
manufacturer or laboratory  for an individual assessment. When more than 1 blood assessment is 
to be done at the time point/period, if they  require the same type of tube, the assessments may  be 
combined.
For non-commercial use only
Take da CONFIDENTIAL Page 100
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is an y untoward medical occurrence in a clinical investigation subject admi nistered a 
pharmaceutical product and that does not necessarily  have a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product 
(ICHGuidance E2A 1995).
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.3 . This includes events occurring during the screening phase of 
thestudy , regardless of whether or not investigational product is ad ministered. Where possible, 
adiagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, 
then each s ymptom should be listed individually . All AEs should be captured on the 
appropriate AE pages in the CRF and in source documents. In addition to untoward AEs, 
unexpected benefits outside the investigational product indication should also be captured on the 
AE CRF.
All SAEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all vari ables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severit y of AEs must be recorded during the course of the event including th e start and stop 
dates. The highest level of severit y will be recorded for an event. Worsening of pretreatment 
events, after initiation of investigational product, must be recorded as new AEs (for example, if a 
subject experiences mild intermittent dy speps ia prior to dosing of investigational product, but the 
dyspepsia becomes severe and more frequent after first dose of investigational product has been 
administered, a new AE of severe d yspepsia [with the appropriate date of onset] is recorded on 
the appropriate CRF).
For non-commercial use only
Take da CONFIDENTIAL Page 101
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The medical assessment of severit y is determined by using the following definitions:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to t he research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
Besides the above mentioned standard categories of severit y grading for a few selected events of 
special interest (see Section 8.1.4 ), the severity  (intensity ) of AEs will also be assessed according 
to the National Can cer Institute Common Terminology  Criteria for Adverse Events (CTCAE) 
Version 4.0.
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related.” Otherwise, i f there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related.” The causality  assessment mu st be 
documented in the source document.
The following additional guidance may  be helpful:
Related: The temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected 
response pattern to that product, and the event cannot be explained by  the 
subject’s medical condition, other therapies, or accident.
Not Related: The event can be readil y explained by  other factors such as the subject’s 
underly ing medical condition, concomitant t herapy, or accident and no plausible 
temporal or biologic relationship exists between the investigational product and 
the event.
For non-commercial use only
Take da CONFIDENTIAL Page 102
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the stud y on the CRF. Outcomes are 
as follows:
Fatal
Not recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae 
Recovering/Resolving
Unknown
8.1.4 Adverse Events of Special Interest
In addition, the following adverse events of special interest will be closel y monitored and 
reported throu ghout the study  regardless of seriousness or of relationship to study  treatment. 
Medical assessment of severity will be determined using standard grading category  (mild, 
moderate, and severe), and by  using other specific severit y grading for each adverse e vent of 
special interest (AESI) as mentioned below:
Adverse Events of Special I nterest (severit y grading based on CTCAE Version 4.0)
1.Tissue invasive CMV disease. Any new development or onset of tissue invasive CMV 
disease in the as ymptomatic subjects (at b aseline) will be monitored throughout the study . 
At each visit the investigator will provide the evaluation of the tissue invasive CMV 
disease, which will be collected on the CRF. The investigator will have the final discretion 
in determining whether or not the CMV DNA test results and other clinical data represent a 
new tissue invasive CMV disease for a given subject. When these events are entered into 
the CRF, they  should be recorded using the terminology  shown in Appendix 4(eg,‘CMV 
pneumonitis’, ‘CMV colitis’, etc.). For details on how the disease under study  will be 
reported see Section 8.1.5 .
2.Relapse or progression of the underl ying disease (disease for which transplant was 
performed).
3.Taste disturbance (d ysgeusia): If a subject reports an AE of taste disturbance, the 
investigato r will record the subject’s description of the taste disturbance (when available) 
as part of the event verbatim in the CRF.
For non-commercial use only
Take da CONFIDENTIAL Page 103
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
4.Events of nausea, vomiting, and diarrhea will be recorded. These adverse events are 
common for both maribavir and valganciclovir.
5.Adverse event of neutropenia will be recorded based on laboratory  results (central or local) 
considered clinically  significant by  the investigator. In addition, to the adverse events of 
neutropenia reported b y the investigator, incidence of neutropenia defin ed as 
ANC <500/mm3[0.5x109/L] or ANC <1,000/mm3[1.0x 109/L]) based on central 
laboratory  data will be analy zed.
Adverse Events of Special I nterest (grading based on standard severity categorization to mild, 
moderate, and severe)
1.Immunosuppressant drug concentration level increased: Immunosuppressant drug levels 
will be monitored as specified Section 7.2.3.4 . High to toxic levels will be recorded as AEs.
2.Invasive fungal (aspergillus, candida, Pneumocystis jiroveci , etc.) or bacterial infections 
(Staphylococcus aureus, Streptococcus pneumonia , enterococcus, pseudomonas, etc.). 
Baseline conditions will be captured as part of medical history , while ne w events will be 
captured as AEs. The additional information such as diagnostic method used for the 
pathogen and the source of the sample used for the diagnosis will be collected. 
Additionally , the presence of viral infections frequently  occurring in trans plant population 
will also be collected (see Appendix 10).
3.Graft -versus- host-disease: GVHD will be diagnosed based on the investigator’s judgment 
(see Section 7.2.2.5). Severity  of Acute GVHD (Grading I -IV) will be assessed using 
grading scale provided in Appendix 7(Harris et al., 2016 )and for chronic GVHD using 
severit y grading into mild, moderate and severe according to the scoring provided in 
Appendix 8,as in the consensus project b y Jagasia et al. ( 2015) .Harris et al. (2016)
provides the confidence levels of the diagnosis (refer to Table 2 in
 Harris et al., 2016 ). For 
the purpose of this study
, the disease considered 'confirmed' or 'probable' should be 
reported as GVHD. Acute or chronic GVHD present at baseline will also be fo llowed 
utilizing the same diagnosis and severit y assessments at every stud y visit until resolution 
(during the duration of the study ) or the end of the study . The baseline presence of the 
acute or chronic GVHD will be reported on the Transplant History  page.
8.1.5 Disease Under Study
Subjects will be enrolled in study  after fulfilling the criteria for CMV viremia ( ≥1365 IU/mL to 
≤273000 IU/mL in whole blood or ≥455 IU/mL to ≤91000 IU/mL in plasma) and their viral load 
will be monitored throughout the study . Virem ia clearance, persistence, or recurrence will be 
analyzed as the part of efficacy assessment based on central laboratory  result.
For non-commercial use only
Take da CONFIDENTIAL Page 104
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
It is anticipated that some subjects, although as ymptomatic at baseline, may have a new onset of 
tissue invasive CMV disease du ring the 8 week of study  treatment or in the 12 -week follow -up 
phase. Since new tissue invasive CMV disease constitutes a medically  important event, 
independent of hospitalization or prolongation of hospitalization required for this event, it will 
qualify  to be reported as an SAE. Cy tomegalovirus disease involving specific organ is to be 
reported, for example CMV disease involving liver will be reported as CMV hepatitis.
The investigator has the final discretion in determining whether or not CMV test result s and 
other clinical data represent a new CMV event for a given subject.
If a CMV event crosses into different categories over time, the category  of greatest severit y 
should be recorded.
The terminology  used for reporting should be:
Asymptomatic CMV infection
Tissue invasive CMV disease, specify  organ for example CMV pneumonitis, CMV colitis
Table 11presents the criteria for reporting tissue invasive CMV disease as an AE or as an SAE 
during its clinical course during the stud y.
Table 11. Criteria for Reporting Tissue Invasive CMV Disease as an AE or as an SAE
Course during the study (based 
on the investigator’s assessment)Reportable as AE Reportable as SAE
New onset of/
change in tissue 
invasive CMV 
diseaseNew onset No Yes
Improving No No
Worsening No Yes, but same event with 
upgraded severity
Asympto matic 
CMV infection 
at baselineImproving No No
Worsening CMV viremia (or CMV 
viremia recurrence or rebound after 
clearance)Determined by the 
investigator based on the 
assessment of clinical 
significance; either local or 
central laboratory results to 
be used at investigator’s 
discretion.Yes, if fulfilling 
seriousne ss criteria.
If the only reason for 
hospital admission or 
prolongation of 
hospitalization is the need 
for IV treatment in the 
hospital setting, then this 
will not qualify as an SAE.
Worsening to tissue invasive 
CMV diseaseNo Yes
AE=adverse event; CMV=cytomegalovirus; IV=intravenous; SAE=serious adverse event
For non-commercial use only
Take da CONFIDENTIAL Page 105
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
8.1.6 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory , vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during treatment with the investigational product, a shift 
of a parameter is observed from a normal value to an abnormal value, or a further worsening of 
an alread y abnormal value. When evaluating such changes, the extent of deviation from the 
reference ra nge, the duration until return to the reference range, either while continuing treatment 
or after the end of treatment with the investigational product, and the range of variation of the 
respective parameter within its reference range, must be taken into c onsideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory , vital sign, or 
ECG values which were not present at the pretreatment value observed closest to the start of 
study  treatment, further investigations should be perfo rmed until the values return to within the 
reference range or until a plausible explanation (eg, concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whe ther a change in a clinical laboratory , vital sign, or ECG parameter is clinicall y 
significant and therefore represents an AE.
8.1.7 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated i n Section 7.1.3 .
Any report of pregnancy  for any  female study  participant must be reported within 24 hours to the 
Takeda Global Pharmacovigilance a nd Risk Management Department using the Investigational 
and Marketed Products Pregnancy Report Form. The pregnant female study participant must be 
withdrawn from the study.
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
30calendar day s after the initial notification and approximately  30 calendar day s and 1 year 
postpartum. An ethics committee (EC) and Institutional Review Board (IRB) approved informed 
consent form must be signed by  a pregnant partner of a study  participant prior to obtaining 
pregnancy  outcome information from the nonstudy  participant.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Clinical Study  Serious Adverse Event and 
Nonserious AEs Required by  the Protocol Form. Note: An elective abortion is not considered an 
SAE.
For non-commercial use only
Take da CONFIDENTIAL Page 106
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
In addition to the above, if the invest igator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Clinical Study  Serious Adverse Event and Nonserious 
AEs Required b y the Protocol Form as well as the Investigational and Marketed Products 
Pregnancy  Report Form. The test date of the first positive serum/urine -hCG test or ultrasound 
result will determine the pregnancy  onset date.
8.1.8 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported t o the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour report ing requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –Persistent or sporadic inte ntional intake of investigational product when used for a 
nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a manner that 
may be detrimental to the individual and/or society
Misuse –Intentional use of investigational product ot her than as directed or indicated at an y 
dose (Note: this includes a situation where the investigational product is not used as directed 
at the dose prescribed b y the protocol)
Overdose – Intentional or unintentional intake of a dose of maribavir exceeding a 
prespecified total daily  dose.
The highest dose of maribavir studied in Phase 2 treatment studies (SHP620 -202 and 
SHP620 -203) was 1200 mg BID. There was no significant difference in safety  across all 
3doses (400 mg BID, 800 mg BID, and 1200 mg BID) studied. Assuming a normal or onl y 
mildly  impaired renal function and serum creatinine levels, a maximum dose of 900 mg 
valganciclovir should be administered at a time (refer to the Valcy te Prescribing Information 
and Valcy te Summary  of Product Characteristic s as documented in the Study  Pharmacy  
Manual). Valganciclovir dose may  be adjusted based on renal function and ANC level (see 
Section 6.2.3).
Medic ation Error –An error made in prescribing, dispensing, administration, and/or use of 
an investigational product. For studies, medication errors are reportable to the sponsor only  
as defined below.
For non-commercial use only
Take da CONFIDENTIAL Page 107
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Cases of subjects missing doses of the investigational pro duct are not considered reportable as 
medication errors. Medication errors should be collected/reported for all products under 
investigation. The administration and/or use of the unassigned treatment is/are alway s reportable 
as a medication error. The admi nistration and/or use of an expired investigational product should 
be considered as a reportable medication error.
All investigational product provided to pediatric subjects should be supervised by  the 
parent(s)/legally  authorized representative/caregiver.
8.2Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study  is the maribavir investigator's brochure, which 
the sponsor has provided under separate cover to all investigators.
The reference for safet y information for the comparator/reference product, valganciclovir, in this 
study  is the summary  of product characteristics (SmPC), which the sponsor has provided under 
separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE r eports must be reported by  the investigator to the Takeda Global 
Pharmacovigilance and Risk Management Department within 24 hours of the first awareness of 
the event (but with no information that would unblind the study  treatment assignment). 
Note: The 24- hour reporting requirement for SAEs does not apply to reports of abuse, misuse, 
overdose, or medication errors (see Section 8.1.8 ) unless they  resu lt in an SAE.
The investigator must complete, sign, and date the Clinical Study  Serious Adverse Event and 
Nonserious AEs Required by  the Protocol Form and verify  the accuracy  of the information 
recorded on the form with the corresponding source documents ( Note: Source documents are not
to be sent unless requested) and fax or e -mail the form to the Takeda Global Pharmacovigilance 
and Risk Management Department.
In the event of an SAE, the investigator must:
1.Fax or e -mail the clinical trial serious adverse event form within 24 hours to the 
Takeda Global Drug Safety Department. Applicable fax numbers and e -mail address 
can be found on the form (sent under separate cover) and are provided below:
Global
Fax: +1-484-595-8155 
Email: DrugSafet y@shire.com
For non-commercial use only
Take da CONFIDENTIAL Page 108
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
8.2.3 Serious Adverse Event Definition
An SAE is any  untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose:
Results in death
Is life -threatening.
Note: The term “life -threatening” in the definition of “ serious” refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event which 
hypothetically  might have caused death if it was more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization.
Note: Hospitalizations, which are the result of elective or previously  scheduled surgery  for 
pre-existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospitalization for an elective or previousl y scheduled surgery  that meet(s) serious criteria 
must be reported as SAE(s).
Results in pe rsistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event.
Note: I mportant medical events that may  not result in death, be life -threatening, or require 
hospitalization may  be considered an SAE when, based upon appropriate medical judgment, 
they may  jeopardize the subject and may  require medical or surgical intervention to prevent 
1of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring inte nsive treatment in an emergency  room or at home; blood 
dyscrasias or convulsions that do not result in inpatient hospitalization; or the development of 
drug dependency  or drug abuse.
For this protocol, the following events will not be collected as SAE(s):
Pre-existing conditions that have not worsened during study  participation:
Preplanned (planned prior to the initiation of the study ) hospitalizations
Preplanned treatments or surgeries
For non-commercial use only
Take da CONFIDENTIAL Page 109
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of rel ationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.3 and must be reported 
to the Takeda Global Drug Safety  Department within 24 hours of the first awareness of the 
event.
In addition, any SAE(s) considered “related” to the investigational product and discovered by  the 
investigator at an y interval after the st udy has completed must be reported to the Takeda Global 
Drug Safet y Department within 24 hours of the first awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious cr iteria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
date the event is considered chronic. In the case of hospitalizations, the hospital admission and 
discharge dates are considered the o nset and resolution dates, respectivel y.
In addition, any  signs or sy mptoms experienced by  the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing a t the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigat ional product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, 
and Site Reporting
The sponsor and/or the clinical CRO is responsible for notify ing the relevant regulatory  
authorities US central IRBs/European Union (EU) central ECs of related, unexpected SAEs.
For non-commercial use only
Take da CONFIDENTIAL Page 110
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The study  population is HSCT recipients with CMV infections. The following SAEs are 
common in this study  populati on and are anticipated to occur, hence these SAEs (including fatal 
outcome) will not be considered unexpected and will not be individually  reported to the 
regulatory  agencies, IRBs, Ethics Committees, and investigators, provided there is no increased 
frequ ency  of these events ( Maribavir Phase 2 [Studies 1263- 202 and 1263- 203] data will be used 
as reference) :
Any CMV infection, including CMV reactivation/recurrence,  
Any other viral, bacterial, or fungal infection
Acute and chr onic GVHD
Reactivation/progression of the malignancy  or other disease, which is an underlying disease, 
that led to the transplant
This includes fatal outcomes of the aforementioned SAEs.
However, these are AESI and will be closel y monitored and recorded on the CRF. See 
Section 8.1.4 for more information on AESI.
In addition, if the event is serious (fulfilling seriousness criteria) it will be reporte d on SAE 
report form per Section 8.2.2 . An independent DMC will be established per Section 9.5.
In addition, sponsor or the sponsor's delegate is responsible for notify ing active sites of all 
related, unexpected SAEs occurring during all interventional studies across the maribavir 
program.
The i nvestigator is responsible for notify ing the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
For non-commercial use only
Take da CONFIDENTIAL Page 111
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
9.DATA MANAGEMENT AND STATISTICAL METHODS
9.1Data Collection
The investigators’ authorized site personnel must enter the information required by  the protocol 
on the CRF. A study  monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy. Discrepancies 
between sourc e data and data entered on the CRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Once a subject is randomized, it is expected that site 
personnel will complete the CRF entry  within approximately  3 business days of the subject’s 
visit.
9.2Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, an d values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all cor rections are documented in an auditable manner.
9.3Data Handling Considerations
Data that may  potentiall y unblind the treatment assignment (ie, valganciclovir dose adjustment 
for CrCl/neutropenia, investigational product serum concentrations, CMV DNA plasma or blood
concentrations, treatment allocation, and investigational product preparation/accountability  data) 
will be handled with special care during the data cleaning and review process. These data will be 
handled in such a way  that, prior to unblinding, an y data that may  unblind study  team personnel 
will be presented as blinded information or otherwise will not be made available. If applicable, 
unblinded data may  be made available to quality  assurance representatives for the purposes of 
conducting independe nt drug audits.
9.4Statistical Analysis Process
The study  will be anal yzed by  the sponsor or its agent. All statistical anal yses will be performed 
using SASVersion 9.1 2 or higher (SAS Institute, Cary , NC 27513).
For non-commercial use only
Take da CONFIDENTIAL Page 112
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, in vestigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused and spurious data will be addressed 
and plan for subgroup analy sis.
 
 
 The SAP will be finalized prior to 
unblinding to preserve the integrity  of the statist ical anal ysis and study  conclusions. Maribavir 
PK concentrations will be anal yzed by a population PK analysis approach. A separate SAP will 
be prepared for this anal ysis and a separate report will present the pharmacokinetic anal ysis 
results in addition to the primary  clinical study  report.
9.5Data Monitoring Committee
An independent DMC will be established to act in an expert, advisory  capacity  for periodic 
assessment of the data to monitor participant safety and to ensure the validity  and scientific merit 
ofthe study .
Further details regarding the DMC can be found in the DMC charter, which will be available 
prior to the administration of study  treatment.
9.6Sample Size Calculation and Power Considerations
The primary  testing is to establish that maribavir is not inferior to valganciclovir in treatment of 
CMV infection in HSCT recipients. For ethical reasons it would not be possible to conduct a 
study  of maribavir versus placebo since different treatment strategies are already  used and well 
established in clinical practice to treat CMV infection. Valganciclovir has been selected as the 
active control because of its documented effectiveness for the treatment of CMV infection, 
including in patients after hematopoietic stem cell transplantation. While clinical tria ls of 
ganciclovir and valganciclovir versus placebo have been conducted for CMV prophy laxis, no 
placebo- controlled studies have been done to date for the treatment of CMV infection or disease. 
Therefore, the effect size of valganciclovir against placebo is not available, and treatment effect 
estimate had to be derived indirectly . Literature reports viremia clearance rate for valganciclovir 
at 70% to 100%. In the VICTOR stud y, a randomized controlled study to compare valganciclovir 
with ganciclovir for the t reatment of CMV disease in SOT subjects ( Asberg et al., 2007), the 
Week 7 viremia clearance rate was reported at 67% and the derived lower limit of the 95% CI 
was 60% for valganciclovir treatment group (n=164). 
For non-commercial use only
Take da CONFIDENTIAL Page 113
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
In Phase 2 treatment SHP620 -203 study , 75% of HSCT subjects (n=61 across 3 dose groups) in 
the maribavir group and 48% in valganciclovir group (n=21) had confirmed CMV viremia 
clearance within 6 weeks. Based on these available data, the proportion of subjects who achieve 
viremia clearance after 8 weeks of treatment in the current stud y is assumed at 60% for the 
valganciclovir treatment group.
A 7% noninferiorit y (NI) margin is chosen for the current stud y based on the following 
considerations. First, a 7% of margin preserves at least 85% of the effect size assumed for the 
valganciclovir treatment gro up. Secondl y, a 7% margin is less than half of 15%, a common 
NImargin used in antiviral trials and is considered very  conservative. Two NI studies on 
comparing valganciclovir with ganciclovir in CMV treatment were identified after a thorough 
literature re search. One study  was reported by  Chawla et al. ( 2012 ), and the other is VICTOR 
study  (Asberg et al., 2007); both used a NI margin of 15%. Discussions with clinical experts 
confirmed that a 7% NI margin is considered a conservative choice and in clinical practice, a 
lower response rate might even be considered gi ven the favorable safet y profile of the test drug 
and where toxicities of available treatments such as valganciclovir limit their use.
Although based on the SHP620- 203 study  result 75% of HSCT subjects in the maribavir group 
and 48% in valganciclovir group had confirmed CMV viremia clearance within 6 weeks, it is 
expected that maribavir may  be superior to valganciclovir in the treatment setting. Given the 
uncertainties regarding the differences in this study  design from that of SHP620 -203, literature 
report ed treatment effect for valganciclovir, and practical consideration for enrollment of 
sufficient number of patients in this orphan patient population, the primary objective of this 
study  is testing for noninferiorit y with testing for superiority to be cond ucted only  after 
noninferiority  is established.
For sample size calculation, to be conservative, it is assumed that 68% and 60% subjects will 
achieve confirmed CMV viremia clearance for the primary  efficacy  endpoint, in the maribavir 
and valganciclovir gro ups, respectivel y. Using the normal approximation method, a 2 -sided 
95% confidence interval (CI) of the difference in the proportions of subjects with the confirmed 
CMV viremia clearance will be calculated. If the lower limit of the CI  is greater than -7%,the 
noninferiority  will be assumed. The sample size is estimated based on a 2
-group test of 
equivalence in proportions by  using nQuery  Advisor 7.0. Based on the above assumptions, 
494 eligible subjects (247 per treatment group) will result in a >90% power to declare 
noninferiority  of maribavir to valganciclovir for the primary  efficacy  endpoint. Considering 
10%
dropout subjects, not included in the Per Protocol (PP) Set, 550 subjects (275 subjects per 
treatment arm) will be enrolled and randomized .
For non-commercial use only
Take da CONFIDENTIAL Page 114
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
9.7Study P opulation
The Enrolled Set will consist of all subjects who have signed an informed consent and have 
begun some study  procedures.
The Randomized Set will consist of all subjects in the Enrolled Set for whom a 
randomization number has been assigned.
The Modified Randomized Set will consist of all subjects in the Randomized Set who have 
taken at least 1 dose of assigned stud y treatment.
The Safet y Set will consist of all subjects who have taken at least 1 dose of study  treatment.
The PP Set will consist of al l subjects in the Randomized Set who do not have major 
predefined protocol deviations that may  affect the primary  efficacy  assessment.
The PK Set will consist of all subjects in the Safety  Set who had plasma samples drawn and 
tested for maribavir concentra tions.
The adolescent pharmacokinetic set will consist of all subjects of 16 to <18 years of age in 
the safet y set who had plasma samples drawn and tested for maribavir concentrations.
The Modified Randomized Set and PP Sets will be used for efficacy  analyses. The Safet y Set 
will be used for safet y analyses. Pharmacokinetic data will be anal yzed using the 
Pharmacokinetic Set.
9.8Efficacy Analyses
Efficacy  measurements assessed after the initiation of prohibited anti- CMV treatment will be 
excluded from the efficacy  anal ysis for the assigned study  drug. Efficacy  measurements after 
initiation of alternative anti -CMV treatment will be marked in data listings. Summary  descriptive 
statistics will include the number of subjects (N), mean, standard deviation, medi an, minimum 
and maximum (range) values for continuous variables, and incidences and percentages for 
categorical variables. The denominator for the percentages will be based on the number of 
patients in the anal ysis set unless otherwise specified. Time -to-event endpoints will be 
summarized using Kaplan -Meier estimation. Ninety -five percent (95%) confidence intervals for 
the estimated 25%, 50%, and 75% times will be presented.
9.8.1 Primary Efficacy Endpoint
The primary  efficacy  endpoint of this study  is confirmed clearance of plasma CMV DNA 
(CMV viremia clearance) at the end of Study  Week 8.
For non-commercial use only
Take da CONFIDENTIAL Page 115
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Confirmed CMV viremia clearance at the end of Study  Week 8/Study  Visit 10(study  treatment 
phase) is defined as plasma CMV DNA concentrations <LLOQ (ie, <137 IU/mL), when asses sed by  
COBAS®AmpliPrep/COBAS®TaqMan®CMV Test at a central specialty  laboratory , in 
2consecutive postbaseline samples separated by  at least 5 days, at the end of Study Week 8, 
regardless of whether either study -assigned treatment was discontinued before the end of the 
stipulated 8 weeks of therapy . This is further described with examples in Table 12. For clearance of 
CMV viremia to be declared at the end of Study  Week 8 during the treatment period, the subject 
must have received exclusively  study -assigned treatments.
Table 12. Assessments of Virological Responders at Study Week 8
ScenarioCMV DNA Weeks on Study
Week 6 Week 7 Week 8 Week 9aResponse Rationale
1 + / - - - +/-/NA Yes 2consecutive “ -” at Week 7 and Week 8
2 + / - - + +/-/NA No Not2 consecutive “ -” at Week 7 and Week 8
3 + / - + - +/-/NA No Not 2 consecutive “ -” at Week 7 and Week 8
4 + / - - NA - Yes2consecutive “ -” as sho wn by available data 
and both “ -” at Week 7 and Week 9 for 
missing Week 8, otherwise nonresponder
5 - NA - +/-/NA Yes2consecutive “ -” as sho wn by available data 
and both ‘ -‘ at Week 6 and Week 8 for 
missing Week 7, otherwise nonresponder
6 - NA NA - Yes2consecutive “ -” as sho wn by available data 
at Week 6 and Week 9 and both “ -”, otherwise 
nonresponder
CMV=cytomegalovirus; NA=not available for evaluation of study drug effect; reason could be not assessable by lab, or starting 
alternative anti -CMV treatment or withdrawal from study etc.
aWeek 9 data, if available to evaluate effect of study drug, only to be used if Week 8 data are unavailable or missing.
Notes: Scenarios in the table above are provided as examples and may not be all -inclusive of all possibilities.
Only CMV DNA data evaluable for assessment of effect of study drug will be included (ie, prior to the start of alternative an ti-CMV 
treatment if any).
"-" = CMV DNA concentration <LLOQ (<137 IU/mL)
"+" = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Confirmed clearance of plasma CMV DNA (CMV viremia clearance) = 2 consecutive postbaseline assessments of CMV DNA target 
<LLOQ, separated by at least 5 days.
Statistical Methodology  for Primary  Efficacy  Endpoint:
The proportion of subjects with confirmed CMV viremia clearance, at the end of Study Week 8 
and the corresponding 95% CI s will be calculated for each treatment group. The difference in 
proportion of subjects with confirmed CMV viremia clearance, at the en d of Study Week 8, 
between treatment groups (maribavir and valganciclovir) will be obtained using 
Cochran -Mantel -Haenszel (CMH) weighted average across strata with baseline plasma CMV 
DNA concentration levels and presence or absence of acute GVHD as the st ratification factors. 
The baseline plasma CMV DNA concentration will be the last central laboratory  assessment 
before the first dose of study treatment. 
For non-commercial use only
Take da CONFIDENTIAL Page 116
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The 2 -sided 95% CI of the weighted average of difference across strata will be calculated using 
the normal approximation method. If the lower limit of the 95% CI  is greater than -7%, it will be 
concluded that maribavir is as efficacious as valganciclovir. The noninferiority  analy sis will be 
performed on the PP Set as the primary  anal ysis and on the Modifie d Randomized Set as a 
secondary  anal ysis.
Sensitivity  and supportive anal yses of the primary endpoint of confirmed CMV viremia 
clearance at Week 8 will be conducted to evaluate the robustness of the result from the primary  
method. This will be specified in the SAP. Some examples are given below:
The primary  efficacy  endpoint analy sis will be repeated b y using the CMV DNA level used 
for the randomization rather than the CMV DNA levels based on central laboratory  values as 
one of the stratification factors.
Subjects who discontinue study  treatment earl y, with no CMV DNA measurement for 
responder evaluation of study  drug effect at Study  Week 8 (see Table 12), however, they  
meet the criteria of confirmed CMV viremia clearance defined as 2 consecutive postbaseline 
assessments of CMV DNA target <LLOQ, separated by  at least 5 days within Study  Week 8, 
will be included as responders.
Multivariate regression analy sis to evaluate treatment difference after controlling for 
important demographic and baseline clinical characteristics. The list of demographic and 
baseline clinical characteristics to be considered will include but will not be limited to 
CMV viral load, C MV serostatus, immune function status, presence of acute GVHD, high 
dose steroids use at baseline, prior use of CMV prophy laxis.
Subjects with missing data due to alternative anti -CMV treatment or death due to 
CMV infection by  Study  Week 8 will be consider ed treatment failure, hence non -responder. 
Subjects with missing data due to earl y discontinuation from study  with reason other than 
alternative anti -CMV treatment or death due to CMV infection at Study  Week 8 may have 
the response data imputed.
Subject to the multiplicity  adjustment method described in Section 9.8.3, the superiorit y 
hypothesis of the primary  efficacy  endpoint will be tested by  compar ing the lower limit of the 
95% CI  of the difference with 0 in the proportion of subjects with confirmed CMV viremia 
clearance at the end of Study  Week 8 between maribavir and valganciclovir. The superiorit y 
testing will be performed on the Modified Randomi zed Set.
For non-commercial use only
Take da CONFIDENTIAL Page 117
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
9.8.2 Key Secondary Efficacy Endpoint
The key  secondary  efficacy  endpoint is defined as the maintenance of confirmed CMV viremia 
clearance achieved at the end of Study  Week 8 through Week 16. Example criteria for defining 
responders at Study  Week 16 are presented in Table 13.
For clearance of CMV viremia achieved at the end of Study  Week 8, regardless of whether either 
study -assigned treatment was discontinued before the end of the stipulated 8 weeks of therap y, 
and maintenance of such effect through Week 16, the subject must have received exclusively  a 
study -assigned treatment and must also have s ymptom control.
Table 13
. Assessments of Responders for Key Secondary Endpoint
Response (both 
Virological 
Response and 
Symptom atic 
CMV Infection 
Control) at 
Study Week 8CMV DNA Assessment Week
Key 
Secondary 
Endpoint 
ResponderbRationale
9 10 11 12 14 16 18a
Yes +/-+/-+/-+/-+/-+/-+/-
/NANoAny 2 consecutive “+” in FU by 
Week 16
Yes +/-+/-+/-+/-+/- -+/-
/NAYesWeek 16 is “ -” and no 2 consecutive 
“+” during FU
Yes +/-+/-+/-+/-+/- ++/-
/NANoWeek 16 is “+” and Week 18 is “+” 
or NA, criteria of 2 consecutive “+” 
ismet
Yes +/-+/-+/-+/-+/- + - YesWeek 16 is “+”, and 2 consecutive 
“+” criteria is not met based on 
Week 18 data
Yes +/- +/- + - - NA - YesWeek 16 is missing, 2 consecutive 
“+” criteria is not met based on 
Week 14 and 18 data
Yes +/- +/- + - - NA +/NA NoWeek 16 is missing, 2 consecutive 
“+” criteria may be met based on 
available Week 18 data
Yes+/-
/NA+/-
/NA+/-
/NA+/-
/NANA NA+/-
/NANoLack of data to show maintaining 
effect through Week 16
No No
CMV=cytomegalovirus; FU=follow -up; NA=not available for evaluation of study drug effect; reason could be starting alternative 
anti-CMV treatment, withdrawal from study, etc.
aWeek 18 data will be used only if Week 16 data are unavailable or missing.
bMust also meet the criterion of CMV infection symptom control to be a responder.
Notes: Scenarios in the table above are provided as examples and may not be inclusive of all possibilities.
Only CMV viremia data prior to receiving nonstudy CMV treatment or rescue treatment will be included in the assessment.
Statistical Methodology  for Key  Secondary  Efficacy  Endpoint:
The proportion of subjects who achieve response, as defined for the key secondary  efficacy  
endpoint, and the corresponding 95% CIs will be calculated for each treatment group. 
For non-commercial use only
Take da CONFIDENTIAL Page 118
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The difference in proportion between treatment groups (maribavir and valganciclovir) will be 
obtained using CMH weighted average across strata with baseline plasma CMV DNA 
concentration level (based on the last central laboratory assessment before the first dose of stud y 
treatment) and presence or absence of acute GVHD as the stratification factors. The 2 -sided 
95% CI of the weighted average of difference across strata will be calculated using the normal 
approximation method. Sensitivity  anal yses for the key secondary  endpoint will also be 
performed.
Subject to the multiplicity  adjustment method described in Section 9.8.3 , the noninferiorit y 
testing wil l be done b y comparing the lower limit of the 95% CI with the same NI margin as the 
primary  efficacy  endpoint. I f the lower limit of the 95% CI  is greater than -7%, it will be 
concluded that maribavir is as efficacious as valganciclovir in maintaining trea tment effect. The 
noninferiority  anal ysis will be performed on the PP Set as the primary  analy sis and on the 
Modified Randomized Set as a secondary  anal ysis.
Subject to the multiplicity  adjustment method described in Section 9.8.3, the superiorit y in key 
secondary  efficacy  endpoint will be tested by  comparing the lower limit of the 95% CI of the 
difference with 0 in the proportion of subjects who achi eve response as defined for the key  
secondary  efficacy  endpoint between maribavir and valganciclovir. The superiority  testing will 
be performed on the Modified Randomized Set.
9.8.3 Multiplicity Adjustment
The hy pothesis testing of the primary  and key  secondary  efficacy  endpoints will be adjusted for 
multiple comparisons using a gatekeeping testing procedure to control the family -wise Ty pe1 
error rate at 2 -sided α=5% level. The testing will be done in the order of primary  efficacy  
endpoint NI testing (H11) first , the primary  efficacy  endpoint superiorit y testing (H12) and the 
key secondary  efficacy  endpoint NI  testing (H21) second, and lastl y the key secondary efficacy 
endpoint superiority testing (H22).
First, the NI testing of the primary  efficacy  endpoint will be assessed based on the 
2-sided 95% CI of the adjusted difference in proportion of subjects who have CMV 
viremia clearance at the end of Study  Week 8 stratified by  baseline CMV DNA level 
andpresence/absence of acute GVHD at baseline. This analy sis will be conducted 
using PerProtocol Set as the primary  and Modified Randomized Set as secondary . If the 
lower limit of the 95% CI is above the predefined NI margin of -7%, NI is considered 
established.
For non-commercial use only
Take da CONFIDENTIAL Page 119
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
If and onl y after the NI of the primary  efficacy  endpoint is established, the superiority  
hypothesis of the primary  efficacy  endpoint and the NI hy pothesis of the key  secondary  
endpoint will be tested in parallel. Hochberg procedure will be used to control family -wise 
Type1 error rate at 2 -sided α=5% level.
If and onl y if the superiority of the primary efficacy endpoint and NI of key secondary 
efficacy  endpoint are established, the superiorit y hypothesis of the key  secondary  efficacy  
endpoint will be tested.
9.8.4 Subgroup Analyses
The proportion of responders and the corresponding 95% CI will be summarized for primary  and 
key secondary  endpoints by  treatment group for the following subgroups (inclusive, but not 
limited to):
Cytomegalovirus DNA viral load (high, low, very  low/high -risk)
Acute GVHD presence/absence at b aseline
Adolescents ≥16 to <18 years of age (exploratory anal ysis: may  be conducted if sample size 
is adequate)
Enrolling regions (enrolling centers will be grouped by geographic locations to explore 
homogeneity  of treatment effect across regions).
9.8.5 Secondary Efficacy Endpoints
The other secondary  endpoints of this study  are:
The achievement of the confirmed CMV viremia clearance after 8 weeks of receiving 
study -assigned treatment.
The proportion of subjects achieving the confirmed CMV viremia clearance afte r 
receiving 8 weeks of study- assigned treatment, and the corresponding 95% CI s will 
be calculated for each treatment group separatel y. The difference in each respective 
proportion between treatment groups and the associated 95% CI will be calculated 
using the same approach as the primary  efficacy  endpoint, and will be assessed using 
CMH test with acute GVHD and baseline CMV DNA concentration as 2 stratification 
factors.
For non-commercial use only
Take da CONFIDENTIAL Page 120
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The maintenance of the confirmed CMV viremia clearance after completion of 8 weeks of 
receiving study- assigned treatment, through Study  Weeks 12 (4 weeks post -treatment 
period), 16 (8 weeks of post -treatment/follow -up phase), and 20 (12 weeks post -treatment).
The proportion of subjects who maintained the confirmed CMV viremia clearance 
achiev ed after receiving 8 weeks of study -assigned treatment, through 
Study Weeks 12, 16, and 20, and the corresponding 95% CIs will be calculated for 
each treatment group separatel y. The difference in each respective proportion 
between treatment groups and the associated 95% CI  will be calculated using the 
same approach as the primary  efficacy  endpoint, and will be assessed using CMH test 
with acute GVHD and baseline CMV DNA concentration as 2 stratification factors.
The maintenance of the CMV viremia clearance achieved at the end of Study  Week 8 
through Stud y Weeks 12, and 20, regardless of whether either study -assigned treatment was 
discontinued before the end of the stipulated 8 weeks of therap y. For maintenance effect to 
be achieved at a time point, the subje cts must have received exclusively  study -assigned 
treatments up to that time point and also must have sy mptom control.
The proportion of subjects maintaining the CMV viremia clearance from the end of 
Study  Week 8 through Study  Weeks 12 and 20 and the corre sponding 95% CI s will 
be calculated for each treatment group separatel y. The difference in each respective 
proportion between treatment groups and the associated 95% CI will be calculated 
using the same approach as the primary  efficacy  endpoint, and will be assessed using 
CMH test with baseline CMV DNA concentration and presence or absence of acute 
GVHD as 2 stratification factors.
The recurrence of CMV viremia during the first 8 weeks of the stud y, in the follow -up period 
of 12 weeks, and at an y time durin g the 20 weeks of the study , regardless of whether either 
study -assigned treatment was discontinued before the end of the stipulated 8 weeks of 
therap y.
The proportion of subjects with confirmed recurrence of viremia during the first 
8weeks of the stud y, when off treatment in the 12 -week follow -up phase, at any  time 
during the 20 weeks of the study  will be calculated.
The recurrence of confirmed CMV viremia in the 2 study  treatment arms when subjects are 
on treatment and off treatment.
The proportion of su bjects with confirmed recurrence of viremia while on study  
treatment and when off treatment will be calculated.
For non-commercial use only
Take da CONFIDENTIAL Page 121
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The incidence of grade 3 or 4 neutropenia (defined as ANC <1,000/mm3[1.0×109/L]) or 
ANC <500/mm3[0.5×109/L], respectivel y)
The proportions of subjects with neutropenia while receiving study  treatment will be 
calculated for each treatment group.
The time to first neutropenia while receiving stud y treatment will be summarized using the 
Kaplan -Meier method. The anal ysis of the secondary  efficacy  endpoints will be conducted using 
the Modified Randomized Set and PP Set unless otherwise specified. Secondary  efficacy  
endpoints will be summarized by  treatment arm, and, if indicated, anal yzed statistically  at 
α=0.05 (2-sided), without adjustment for multi ple comparisons.
9.8.6 Exploratory Efficacy Endpoints
 
9.9Safety Analyses
The safet y analy ses will include evaluation and procedures to meet the secondary  objective of 
assessing the safety  and tolerability  of the study  treatments .
For non-commercial use only
Take da CONFIDENTIAL Page 122
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Statistical Methodology  for Safety  Endpoints
Safet y evaluation will be made during the periods as illustrated in Figure 1, ie, Screening Phase, 
Treat ment Phase, and Follow -up Phase.
Two observation periods are defined for the purpose of analy ses:
1.The on -treatment observation period starts at the time of study  treatment initiation 
through 7 days after the last dose of study  treatment. For subjects who t ransfer from the 
study  treatment to a nonstudy anti -CMV treatment, the on -treatment observation period 
starts at the time of the study  treatment initiation through 7 days after the last dose of 
study  treatment, or until the nonstudy  anti-CMV treatment init iation, whichever is earlier. 
This will serve as the primary  analy sis of safety .
2.The overall -study  observation period starts at the time of the start of the study  
treatment through the end of the study . 
An AE (classified b y preferred term) that has a star t date on or after the first dose of study  
treatment, or that has a start date before the date of first dose of stud y treatment but increases in 
severit y after the first dose of study treatment, will be considered a treatment -emergent AE 
(TEAE).
The overal l study  AEs are those occurring during the overall- study  observation period.
Safety  endpoints will be summarized descriptively  for the on -treatment period, and overall study  
period, as appropriate. Baseline assessments will be the last assessment before th e first dose of 
study  treatment. The Safety  Set population will be used to anal yze the safety  data.
The safet y endpoints for this study  are as follows:
TEAEs and treatment- emergent SAEs, overall study  AEs and overall study  SAEs
Clinical laboratory  evaluati ons (including incidence of neutropenia defined as ANC 
<500/mm3[0.5× 109/L] or ANC <1,000/mm3[1.0× 109/L] at any  time during the stud y [on 
treatment and overall study  period], time to neutropenia development), and study  treatment 
dose adjustment due to AEs
Safety  assessments will also include vital sign measurements, phy sical examination, and 
ECG.
For non-commercial use only
Take da CONFIDENTIAL Page 123
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The number of events, incidence, and percentage of TEAEs and overall -study  AEs will be 
display ed for each treatment group by  preferred terms using the Medical Dictionary  for 
Regulatory  Activities (MedDRA®). Summaries in terms of severit y and relationship to study  
medication will also be provided.
Treatment -emergent SAEs will be summarized separatel y in a similar fashion. Summaries of 
AEs causing discontinuation of study  medication, withdrawals, AEs leading to death, SAEs and 
AESI s will be provided.
Adverse events of special interest as defined in Section 8.1.4 , will be anal yzed according to 
primary  system organ classes (SOCs) and preferred terms (PTs). Standardized MedDRA queries 
(SMQs) may  be used, as applicable. Summary  tables with SOCs and PTs will be generated 
presenting the number and percentage of subjects by  AE, severit y, seriousness, and relationship 
to study  medication. Invasive bacterial and fungal infections , if an y, will be noted.
Usage of concomitant medications will be summarized descr iptively  for each of the treatment 
groups for the on- treatment period and overall study  period. Additionally , summary of 
hematopoietic growth factors, blood, and blood products transfusions will be provided.
Change from Baseline in vital signs and clinical laboratory  test s will be summarized for each 
treatment group with descriptive statistics at each assessment visit. Additional shift tables may be 
produced for selected laboratory  parameters using severit y grades based on National Cancer 
Institute (NCI) c ommon terminology  criteria for adverse events (CTCAE v4.0) or using 
normal/above normal/below normal range. Anal yses of shifts in NCI  CTC toxicity  grades from 
baseline to maximum grade postbaseline for the on -treatment period and the overall -study  period 
will be provided. Potentially  clinicall y important findings will also be summarized.
Treatment -emergent grade 3 or 4 neutropenia (defined respectivel y as ANC <1,000/mm3
[1.0× 109/L]) or ANC <500/mm3[0.5× 109/L]) will be summarized as shifts in laboratory
results from lower grade to maximum grade of either 3 or 4 postbaseline for the on- treatment 
period and the overall -study  period. Time to neutropenia development will be evaluated.
Study  treatment dose adjustment, specificall y valganciclovir dose adjustme nt and interruptions 
for neutropenia or renal function impairment or other AE, and maribavir dose interruptions for 
any AE, will be summarized.
Abnormal ph ysical examination findings will be listed.
Summary  of ECG findings will be provided b y treatment groups.
For non-commercial use only
Take da CONFIDENTIAL Page 124
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
An independent DMC will be established to assess the data for safet y and to ensure the validity  
and scientific merit of the trial. Detailed plans for the DMC’s purpose and responsibilities will be 
described in the DMC charter and the SAP.
9.10 Other Analys es
9.10.1
 
 
9.10.2
 
9.10.3 Pharmacokinetic and Pharmacokinetic/pharmacodynamic Analyses
The PK Population will be used to anal yze the PK endpoints. Since this is a double -blind study , 
PK samples will be obtained for all subjects as in the Schedule of Assessments ( Table 1), but 
analyzed for onl y those subjects who are taking maribavir.
Pharmacokinetic endpoints for this study  are as follows:
Secondary endpoint:
For all subjects:
Maribavir C min(predose maribavir concentration)
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:
AUC (0-tau): area under the concentration -time curve over the 12 -hour dosing interval at steady  
state
Cmax: maximum concentration
Tmax: time when maximum concentration is observed
CL/F: apparent oral clearance
Vz/F: apparent volume of distribution
For non-commercial use only
Take da CONFIDENTIAL Page 125
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
 
Blood samples will be analy zed for plasma maribavir concentration levels. Maribavir concentrations
will be summarized by  visit and planned sampling time. A scatter plot of all reportable maribavir 
concentration vs actual sampling time will be generated. A listing of subjects with maribavir 
concentration below the quantitation limit will be provided alo ng with the Week 8 efficacy  response. 
In a separate analy sis and report, ma ribavir concentrations will be analy zed by population PK 
analysis approach using nonlinear mixed effect model approach using NONMEM Version 7 or 
above. Post hoc maribavir PK parameters such as AUC, C max, and C minwill be generated and 
summarized by  identif ied covariates;  
 This 
analysis may be conducted by  combining maribavir PK data from other Phase 2 and Phase 3 studies.
If needed, an interim population PK analy sis of maribavir PK data obtained from the study  
subjects will be performed. I nterim population PK anal ysis will be performed by  an independent 
unblinded team or CRO who will have no involvement in the cond uct of the study . Results from 
this analy sis will not be shared with an y members of the study  team until after database lock. 
Rules governing this process are detailed in the sponsor’s (or designee’s) standard operating 
procedures.
For non-commercial use only
Take da CONFIDENTIAL Page 126
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
10.SPONSOR’S AND INVEST IGAT OR’S RESPONSIBILITIES
This study  is conducted in accordance with current applicable regulations, International 
Conference on Harmonisation (ICH), EU Directive 2001/20/EC and its revisions/updates, and 
local ethical and legal requirements.
The name and addr ess of each third- party vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 (1996), 
EUDirective 2001/20/EC, I ntegrated Adde ndum to I CH E6 (R1): Guideline for Good Clinical 
Practice E6 (R2) Current Step 4 version dated 09 November 2016, as well as all applicable 
national and local laws and regulations, and an y updates and/or revisions.
Visits to sites are conducted by  represent atives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national government regul ations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adh eres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity  document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO/investigator as necessary .
For non-commercial use only
Take da CONFIDENTIAL Page 127
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
10.1.4 Submission of Summary of Clinical Study Report to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Reporting of COVID -
19 Cases During the Study
The sponsor will, complying with local laws and regulations, notify  relevant health authorities of 
any participant who contracts COVID- 19 during the study .
10.1.6 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the st udy, or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered c linical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an end -of-study  declaration to the relevant competent authority  as 
required b y Article 10(c) of Directive 2001/20/EC.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, I ntegrated Addendum to I CH E6 (R1): Guideline for Good 
Clinical Practice E6 (R2 ) Current Step 4 version dated 09 November 2016, applicable regulatory  
requirements and guidelines, and any updates or revisions.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
For non-commercial use only
Take da CONFIDENTIAL Page 128
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualifica tion. Curriculum vitae for investigators and sub- investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inf orm them of the subject’s participation in the study  and request any  medical 
history  of the subject (with the subject's consent).
A coordinating principal investigator is appointed to review the final clinical study  report for 
multicenter studies. Agreemen t with the final clinical study  report is documented by  the signed 
and dated signature of the principal investigator (single- site study ) or coordinating principal 
investigator (multicenter study ), in compliance with Directive 2001/83/EC as amended b y 
Direc tive 2003/63/EC and I CH Guidance E3 (1995).
The investigator is responsible for supervising any individual or party  to whom the investigator 
delegates stud y tasks conducted at the trial site. If the investigator/institution retains the services 
of an y part y to perform study  tasks they  should ensure this part y is qualified to perform those 
study  tasks, received study -specific training and should implement procedures to ensure the 
integrit y of the stud y tasks performed and an y data generated.
10.2.2 Protocol Adheren ce and Investigator Agreement
The investigator and an y co-investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria. Investigators ar e required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, applicable CRO, investig ator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
For non-commercial use only
Take da CONFIDENTIAL Page 129
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Case report forms are supplied by  the sponsor/CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to rec ord all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data sent to the sponsor must be endorsed b y the investigator.
The CR A/study  monitor will verify  the contents against the source data per the monitoring plan. 
If the data are unclear or contradictory , queries are sent for corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
The investigator should maintain adequate and accurate source documents and trial records that 
include all pertinent observations on each of the site’s trial subjects. Source data should be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be t raceable, should not obscure the original entry  and should be explained if necessary  
(eg,via an audit trail).
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor; the respe ctive national, 
local, or foreign regulatory  authorities; the I RB/EC; and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regula tory inspectors) will check or will verify  
the CRF entries against the source documents. The consent form includes a statement by  which 
the subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorit ies, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays, etc.). Nonstudy  site personnel will not 
disclose an y personal information or personal medical information. Due to the COVI D-19 public 
health emergency , remote source document verification can be utilized where allowed by  local 
laws and regulations. 
For non-commercial use only
Take da CONFIDENTIAL Page 130
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authoriz ed representative of an y regulatory  agency  (eg, the US Food and 
Drug Administration [FDA], European Medicines Agency  [EMA], United Kingdom Medicines 
and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  representatives of, for example, the US FDA (as well as other 
USnational and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4 Fina ncial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor.
The following information is collected: an y significant payments from the sponsor or 
subsidiaries such as a grant to fund ongoing research, compensation in the form of 
equipment, retainer for ongoing consultation or honoraria; an y proprietary interest in 
investigational product; any  significant equity  interest in the sponsor or subsidiaries as defined in 
21CFR 542(b) (1998).
10.2.4 Compliance to all Local, State, and National Controlled- substance 
Biohazard and Infectious Disease Regulations and Legislation
When using controlled substances, biohazardous material, or substances for infectious diseases, 
the investigator must at all times comply  with all local, state, and national laws pertaining to 
registration and reporting with the appropriate regulatory  body  and control and handling of such 
substances.
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent ,and assent, where 
applicable, from all study subjects prior to an y study -related procedures including screening 
assessments; parents will sign the assent form, as applicable. All consent and assent 
documentation must be in accordance with applicable regulations and GCP. 
For non-commercial use only
Take da CONFIDENTIAL Page 131
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Each subject ortheir parent(s)/subjec t’s legally authorized representative, as applicable, is 
requested to sign and date the subject informed consent form or a certified translation if 
applicable, after the subject has received and read (or been read) the written subject information 
and recei ved an explanation of what the study  involves, including but not limited to: the 
objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully  executed signature pages) must be given to the subject or the 
subject’s legall y authorized representative, as applicable. This document may require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by a parent or both parents/legall y authorized representative/caregiver of the safe, responsible 
storage and administration of investigational product to the study  subject.
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved by  the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation.
The applicant for an EC opinion can be the sponsor or investigator for sites within the EU; for 
multicenter studies, the applicant can be the coordinating principal investigator or sponsor, 
according to national provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investig ator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies wi ll not be released until the sponsor/CRO has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in any  case at least once a 
year; this can be done by  the sponsor or investigator for sites within the EU, or for multicenter 
studies, it can be done b y the coordinating principal investigator, according to national 
provisions. The investigator must also keep the local IRB/EC informed of any  serious and 
significant AEs.
For non-commercial use only
Take da CONFIDENTIAL Page 132
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
10.4 Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with Health Insurance Porta bility  and Accountability  Act (HIPAA) of 1996. 
A site that is not a covered entity  as defined b y HIPAA must provide documentation of this fact 
to the CRO/sponsor.
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
reviews their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market maribavir; national or local regulatory  authorities; and the I RB(s)/EC(s) which gave 
approval for the study  to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiali ty of subjects’ identities.
Subjects are assigned a unique number for identification.
The results of studies containing subjects’ unique identify ing number and relevant medical 
records will be recorded. They  may  be transferred to, and used in, other countr ies which may  not 
afford the same level of protection that applies within the countries where this study  is 
conducted. The purpose of an y such transfer would include: to support regulatory submissions, 
to conduct new data analyses to publish or present the study  results, or to answer questions asked 
by regulatory  or health authorities.
10.5 Study Results/Publication Policy
Takeda will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative.
Additionally , Takeda adheres to external guidelines (eg, Good Publication Practices 2) when 
forming a publication steering committee, which may  be done for large, mul ticenter 
Phase 2-4and certain other studies as determined by  Takeda. The purpose of the publication 
steering committee is to act as a noncommercial body
 that advises or decides on dissemination of 
scientific study  data in accordance with the scope of this policy . 
For non-commercial use only
Take da CONFIDENTIAL Page 133
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
The sponsor and/or its representatives accessing the records and data will take all reasonable 
precautions in accordance with applicable laws, regulations, and guidelines to maintain the 
confidentiality  of subjects’ identities.
All publications relating to Takeda products or projects must undergo appropriate technical and 
intellectual propert y review, with Takeda agreement to publish prior to release of information. 
The review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  the 
publisher and cop yright law, the principal investigator will own (or share with other authors) the 
copy right on his/her publications. To the extent that t he principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to an y public di sclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/sci entific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by the sponsor that is necessary  to 
include in an y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by  Takeda, the institution and principal 
investiga tor shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the stud y is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjuncti on with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with th is section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
For non-commercial use only
Take da CONFIDENTIAL Page 134
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) current standards. Participation as an investigator does not confer any  rights to 
authorship of publications.
For non-commercial use only
Take da CONFIDENTIAL Page 135
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
11.REFERENCES
Ariza -Heredia, E. J., Nesher, L. and Chem aly, R. F. 2014. Cytomegalovirus disease after 
hematopoietic stem cell transplantation. Cancer Letters, 342, 1–8.
Asberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., 
Tuncer, M., Noronha, I. L. and Hartmann, A. 20 07. Oral valganciclovir is noninferior to 
intravenous ganciclovir for the treatment of cy tomegalovirus disease in solid organ transplant 
recipients. 
Am J Transplant, 7, 2106–13.
Avery , R. K., Mart y, F. M., Strasfeld, L., Lee, I., Arrieta, A., Chou, S., Tat arowicz, W. and 
Villano, S. 2010. Oral maribavir for treatment of refractory  or resistant cy tomegalovirus 
infections in transplant recipients. Transpl Infect Dis, 12, 489–96.
Barkam, C., Kamal, H., Dammann, E., Diedrich, H., Buchholz, S., Eder, M., Krauter, J., Ganser, 
A. and Stadler, M. 2012. Improving safet y of preemptive therap y with oral valganciclovir for 
cytomegalovirus infection after allogeneic hematopoietic stem cell t ransplantation. 
Bone Marrow 
Res, 2012, 874601.
Biron, K. K., Harvey , R. J., Chamberlain, S. C., Good, S. S., Smith, A. A., 3rd, Davis, M. G., 
Talarico, C. L., Miller, W. H., Ferris, R., Dornsife, R. E., Stanat, S. C., Drach, J. C., Townsend, 
L. B. and Kosz alka, G. W. 2002. Potent and selective inhibition of human cy tomegalovirus 
replication b y 1263W94, a benzimidazole L- riboside with a unique mode of action. Antimicrob 
Agents Chemother, 46, 2365 –72.
Boeckh, M., Gooley , T. A., My erson, D., Cunningham, T., Sc hoch, G. and Bowden, R. A. 1996. 
Cytomegalovirus pp65 antigenemia -guided earl y treatment with ganciclovir versus ganciclovir at 
engraftment after allogeneic marrow transplantation: a randomized double -blind study . 
Blood,
88, 4063–71.
Boeckh, M. and Ljungma n, P. 2009. How we treat cy tomegalovirus in hematopoietic cell 
transplant recipients. Blood, 113, 5711–9.
Boeckh, M., Murph y, W. J. and Peggs, K. S. 2015. Reprint of: Recent advances in 
cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow 
Transplant, 21, S19
–24.
Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R. and Zaia, J. 2003. 
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known 
challenges, and future strategies. Biol Blood Marrow Transplant, 9, 543–58.
Boeckh, M., Zaia, J. A., Jung, D., Skettino, S., Chauncey , T. R. and Bowden, R. A. 1998. 
Astudy  of the pharmacokinetics, antiviral activity, and tolerability  of oral ganciclovir for CMV 
prophy laxis in marrow transpla ntation. 
Biol Blood Marrow Transplant, 4, 13 –9.
Bueno, J., Ramil, C. and Green, M. 2002. Current management strategies for the prevention and 
treatment of cy tomegalovirus infection in pediatric transplant recipients. Paediatr Drugs, 4, 
279-90.
Busca, A., de Fabritiis, P., Ghisetti, V., Allice, T., Mirabile, M., Gentile, G., L ocatelli, F. and 
Falda, M. 2007. Oral valganciclovir as preemptive therap y for cy tomegalovirus infection post 
allogeneic stem cell transplantation. Transpl Infect Dis, 9, 102–7.
For non-commercial use only
Take da CONFIDENTIAL Page 136
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Campani ni, G., Zavattoni, M., Cristina, E., Gazzolo, D., Stronati, M. and Baldanti, F. 2012. 
Multiple ganciclovir -resistant strains in a newborn with sy mptomatic congenital human 
cytomegalovirus infection. J Clin Virol , 54, 86–8.
Chawla, J. S., Ghobadi, A., Mosle y, J., 3rd, Verkruyse, L., Trinkaus, K., Abboud, C. N., Cashen, 
A. F., Stockerl -Goldstein, K. E., Uy , G. L., Westervelt, P., DiPersio, J. F. and Vij, R. 2012. Oral 
valganciclovir versus ganciclovir as delay ed pre -emptive therapy  for patients after allogene ic 
hematopoietic stem cell transplant: a pilot trial (04
-0274) and review of the literature. Transpl 
Infect Dis, 14, 259–67.
Cherrier, L., Nasar, A., Goodlet, K. J., Nailor, M. D., Tokman, S. and Chou, S. 2018. Emergence 
of letermovir resistance in a lung transplant recipient with ganciclovir -resistant cy tomegalovirus 
infection. 
Am J Transplant , 18, 3060–4.
Cho, B. S., Min, C. K., Eom, K. S., Kim, Y. J., Kim, H. J., L ee, S., Cho, S. G., Kim, D. W., 
Lee, J. W., Min, W. S. and Kim, C. C. 2009. Feasibility  of NIH consensus criteria for chronic 
graft -versus
-host disease. Leukemia, 23, 78–84.
Chou, S. 2020. Drug resistance mutations and associated phenot ypes detected in phase 2 
treatment trials of maribavir for cy tomegalovirus infection. Antiviral Res, accepted/i n press.
Chou, S. and Bowlin, T. L. 2011. C ytomegalovirus UL 97 mutations affecting cy clopropavir and 
ganciclovir susceptibility. Antimicrob Agents Chemother , 55, 382–4.
Chulay , J., Biron, K., Wang, L., Underwood, M., Chamberlain, S., Frick, L., Good, S., D avis, 
M., Harvey , R., Townsend, L ., Drach, J. and Koszalka, G. 1999. Development of novel 
benzimidazole riboside compounds for treatment of cy tomegalovirus disease. 
Adv Exp Med 
Biol, 458, 129–34.
de la Hoz, R. E., Stephens, G. and Sherlock, C. 2002. Diagno sis and treatment approaches of 
CMV infections in adult patients. J Clin Virol, 25 Suppl 2, S1–12.
Drew, W. L., Miner, R. C., Marousek, G. I. and Chou, S. 2006. Maribavir sensitivity  of 
cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscar net. J Clin Virol, 37, 124–7.
Dykewicz, C. A. 2001. Summary  of the Guidelines for Preventing Opportunistic I nfections 
among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis, 33, 139–44.
Emery , V. C., Sabin, C. A., Cope, A. V., Gor, D., Hassan
-Walker, A. F. and Griffiths, P. D. 
2000. Application of viral- load kinetics to identify patients who develop cy tomegalovirus disease 
after transplantation. Lancet, 355, 2032–6.
Fischer, L., Imrich, E ., Sampaio, K. L., Hofmann, J., Jahn, G., Hamprecht, K. and Gohring, K. 
2016. I dentification of resistance -associated HCMV UL97
-and UL54- mutations and a UL97 -
polymporphism with impact on phenot ypic drug -resistance. Antiviral Res, 131, 1 –8.
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., I to, J. I ., Mullen, C. A., Raad, II, 
Rolston, K. V., Young, J. A. and Wingard, J. R. 2011. Clinical practice guideline for the use of 
antimicrobial agents in neutropenic patients with cancer: 20 10 update b y the infectious diseases 
society  of america. 
Clin Infect Dis, 52, e56–93.
For non-commercial use only
Take da CONFIDENTIAL Page 137
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Gilbert, C., Azzi, A., Goyette, N., L in, S. X. and Boivin, G. 2011. Recombinant phenoty ping of 
cytomegalovirus UL54 mutations that emerged during cell passages in the pre sence of either 
ganciclovir or foscarnet. Antimicrob Agents Chemother , 55, 4019–27.
Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G. and Meyers, J. D. 1993. 
Ganciclovir proph ylaxis to prevent cy tomegalovirus disease after allogeneic marro
w transplant. 
Ann Intern Med, 118, 173 –8.
Harada, K., Eizuru, Y., Isashiki, Y., I
hara, S. and Minamishima, Y. 1997. Genetic anal ysis of a 
clinical isolate of human cy tomegalovirus exhibiting resistance against both ganciclovir and 
cidofovir. Arch Virol , 142, 215–25.
Harris, A. C., Young, R., Devine, S., Hogan, W. J., Ay uk, F., Bunworasate, U., 
Chanswangphuwana, C., Efebera, Y. A., Holler, E., L itzow, M., Ordemann, R., Qay ed, M., 
Renteria, A. S., Reshef, R., Wolfl, M., Chen, Y. B., Goldstein, S., Jagasia, M. , Locatelli, F., 
Mielke, S., Porter, D., Schechter, T., Shekhovtsova, Z., Ferrara, J. L . and Levine, J. E. 2016. 
International, Multicenter Standardization of Acute Graft
-versus -Host Disease Clinical Data 
Collection: A Report from the Mount Sinai Acute GVH D International Consortium. Biol Blood 
Marrow Transplant, 22, 4 –10.
Humar, A., Gregson, D., Caliendo, A. M., McGeer, A., Malkan, G., Krajden, M., Corey , P., 
Greig, P., Walmsley , S., Lev y, G. and Mazzulli, T. 1999. Clinical utility  of quantitative 
cytomegal
ovirus viral load determination for predicting cy tomegalovirus disease in liver 
transplant recipients. Transplantation, 68, 1305–11.
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., 
Weisdorf, D., Treister, N. S., Cheng, G. S., Kerr, H., Stratton, P., Duarte, R. F., McDonald, G. 
B., Inamoto, Y., Vigorito, A., Arai, S., Datiles, M. B., Jacobsohn, D., Heller, T., Kitko, C. L ., 
Mitchell, S. A., Martin, P. J., Shulman, H., Wu, R. S., Cutler, C. S., Vogelsang, G. B. , Lee, S. J., 
Pavletic, S. Z. and Flowers, M. E. 2015. National Institutes of Health Consensus Development 
Project on Criteria for Clinical Trials in Chronic Graft -versus
-Host Disease: I . The 2014 
Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant, 21, 389–401.e1.
Kern, E. R., Hartline, C. B., Ry bak, R. J., Drach, J. C., Townsend, L . B., Biron, K. K. and 
Bidanset, D. J. 2004. Activities of benzimidazole D -and L -
ribonucleosides in animal models of 
cytomegalovirus infections. Antimicrob Agents Chemother, 48, 1749–55.
Klumpp, T. R. 1993. Antibody -mediated neutropenia following bone marrow transplantation. 
IntJ Clin Lab Res, 23, 4–7.
Krause, H., Hebart, H., Jahn, G., Muller, C. A. and Einsele, H. 1997. Screening for 
CMV -specific T cell pr oliferation to identify  patients at risk of developing late onset CMV 
disease. 
Bone Marrow Transplant, 19, 1111–6.
Krosky , P., Baek, M. and Coen, D. 2003. The human cy tomegalovirus UL97 protein kinase, an 
antiviral drug target, is required at the stage of nuclear egress. J Virol, 77, 905 –14.
Legendre, C. and Pascual, M. 2008. I
mproving outcomes for solid-organ transplant recipients at 
risk from cy tomegalovirus infection: late -onset disease and indirect consequences. Clin Infect 
Dis, 46, 732–40.
For non-commercial use only
Take da CONFIDENTIAL Page 138
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Ljungman, P., Boeckh, M., Hirsch, H. H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., 
Razonable, R. R., Miller, V. and Griffiths, P. D. 2017. Definitions of Cy tomegalovirus Infection 
and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Di s,64, 87–91.
Ljungman, P., Deliliers, G. L ., Platzbecker, U., Matthes
-Martin, S., Bacigalupo, A., Einsele, H., 
Ullmann, J., Musso, M., Trenschel, R., Ribaud, P., Bornhauser, M., Cesaro, S., Crooks, B., 
Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A. J., Wacker, P. and 
Cordonnier, C. 2001. Cidofovir for cy tomegalovirus infection and disease in allogeneic stem cell 
transplant recipients. The I nfectious Diseases Working Part y of the European Group for Blood 
and Marrow Transplantation. Blood, 97, 388–92.
Loiseau, P., Busson, M., Balere, M. L., Dormoy , A., Bignon, J. D., Gagne, K., Gebuhrer, L., 
Dubois, V., Jollet, I ., Bois, M., Perrier, P., Masson, D., Moine, A., Absi, L., Reviron, D., 
Lepage, V., Tamouza, R., Toubert, A., Marry , E., Chir , Z., Jouet, J. P., Blaise, D., Charron, D. 
and Raffoux, C. 2007. HLA Association with hematopoietic stem cell transplantation outcome: 
the number of mismatches at HLA -A, -B, -C, -DRB1, or -DQB1 is strongl y associated with 
overall survival. Biol Blood Marr
ow Transplant, 13, 965 –74.
Lu, H. and Rosenbaum, S. 2014. Developmental pharmacokinetics in pediatric populations. 
JPediatr Pharmacol Ther, 19, 262–76.
Maffini, E., Giaccone, L. and Festuccia, M. 2016. Treatment of CMV infection after allogeneic 
hemaptopo
ietic stem cells transplantation. Expert Rev Hematol, 9(6), 585 –96.
Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, 
N., Davies, S., Okamoto, S., Seber, A., Socie, G., Szer, J., L
int, M. T., Wingard, J. R. and 
Tichelli, A. 2012. Recommended screening and preventive practices for long -term survivors 
after hematopoietic cell transplantation. Rev Bras Hematol Hemoter, 34, 109 –33.
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P. and Corey , L. 2002. Invasive aspergillosis in 
allogeneic stem cell transplant recipients: changes in epidemiology  and risk factors. 
Blood, 100, 
4358–66.
Peus, D., Newcomb, N. and Hofer, S. 2013. Appraisal of the Karnofsky  Performance Status and 
proposal of a simple algorithmic sy stem for its evaluation. 
BMC Med Inform Decis Mak, 13, 72.
Razonable, R. R. and Emery , V. C. 2004. Management of CMV infection and disease in 
transplant patients. 27 -29 February  2004. Herpes, 11, 77–86.
Reusser, P., Einsele, H., Lee, J., Volin, L
., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., 
Link, H., Ljungman, P. and I nfectious Diseases Working Part y of the European Group for Blood 
and Marrow Transplantation 2002. Randomized multicenter trial o f foscarnet versus ganciclovir 
for preemptive therap y of cy tomegalovirus infection after allogeneic stem cell transplantation. 
Blood, 99, 1159–64.
Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C. and Boeckh, M. 1997. Neutropenia in 
allogeneic marro w transplant recipients receiving ganciclovir for prevention of cy tomegalovirus 
disease: risk factors and outcome. Blood, 90, 2502–8.
Schag, C. C., Heinrich, R. L . and Ganz, P. A. 1984. 
Karnofsk y performance status revisited: 
reliability , validity , and guidelines. J Clin Oncol, 2, 187–93.
For non-commercial use only
Take da CONFIDENTIAL Page 139
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Schwartz, G. J., Feld, L . G. and Langford, D. J. 1984. A simple estimate of glomerular filtration 
rate in full -term infants during the first y ear of life. J Pediatr, 104, 849–54.
Shulman, H. M., Cardona, D. M., Greenson, J
. K., Hingorani, S., Horn, T., Huber, E., Kreft, A., 
Longerich, T., Morton, T., My erson, D., Prieto, V. G., Rosenberg, A., Treister, N., Washington, 
K., Ziemer, M., Pavletic, S. Z., Lee, S. J., Flowers, M. E., Schultz, K. R., Jagasia, M., 
Martin, P.J., Vo gelsang, G. B. and Kleiner, D. E. 2015. NIH Consensus development project on 
criteria for clinical trials in chronic graft -versus- host disease: II. The 2014 Pathology  Working 
Group Report. Biol Blood Marrow Transplant, 21, 589 –603.
Sommadossi, J. P. and Ca rlisle, R. 1987. Toxicity  of 3'
-azido -3'-deox ythymidine and 
9-1,3- dihydroxy - 2- propoxy methy l)guanine for normal human hematopoietic progenitor cells in 
vitro. Antimicrob Agents Chemother, 31, 452–4.
Strasfeld, L., Lee, I., Tatarowicz, W., Villano, S. and Chou, S. 2010. Virologic characterization 
of multidrug -resistant cy tomegalovirus infection in 2 transplant recipients treated with maribavir. 
J Infect Dis, 202, 104–8.
Takahata, M., Hashino, S., Nishi
o, M., Sugita, J., Shigematsu, A., Onozawa, M., Fujimoto, K., 
Endo, T., Kondo, T., Tanaka, J., I mamura, M. and Teshima, T. 2015. Occurrence of adverse 
events caused b y valganciclovir as pre -emptive therap y for cytomegalovirus infection after 
allogeneic ste m cell transplantation is reduced by  low-dose administration. Transpl Infect Dis,
17, 810–5.
Tombly n, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., 
Young, J., Boeckh, M., Center for International Blood and Marrow Resea rch, National Marrow 
Donor Program, European Blood and Marrow Transplant Group, American Society  of Blood and 
Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Disease 
Society  of America, Society  for Healthcare Epidemiology  of America, Association of Medical 
Microbiology  and Infectious Disease Canada and Centers for Disease Control and Prevention 
2009. Guidelines for preventing infectious complications among hematopoietic cell 
transplantation recipients: a global perspective. Biol Blood Marrow Transplant, 15, 1143–238.
Tomonari, A., Takahashi, S., Ooi, J., Tsukada, N., Konuma, T., Kobay ashi, T., Takasugi, K., 
Iseki, T., Tojo, A. and Asano, S. 2008. Preemptive therap y with ganciclovir 5 mg/kg once daily 
for cy tomegalovirus infecti on after unrelated cord blood transplantation. Bone Marrow 
Transplant, 41, 371–6.
Van Leer Buter, C. C., de Voogd, D. W. K., Blokzijl, H., de Joode, A. A. E., Berger, S. P., 
Verschuuren, E. A. M. and Niesters, H. G. M. 2019. Antiviral
-resistant cytomegalov irus 
infections in solid organ transplantation in the Netherlands. J Antimicrob Chemother , 74, 
2370-6.
Venton, G., Crocchiolo, R., Furst, S., Granata, A., Oudin, C., Faucher, C., Coso, D., 
Bouabdallah, R., Berger, P., Vey , N., Ladaique, P., Chabannon, C., le Merlin, M., Blaise, D. and 
El-Cheikh, J. 2014. Risk factors of Ganciclovir- related neutropenia after allogeneic stem cell 
transplantation: a retrospective monocentre stud y on 547 patients. Clin Microbiol Infect, 20, 
160–6.
For non-commercial use only
Take da CONFIDENTIAL Page 140
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Viracor, no date. Viracor Euro fins Clinical Diagnostics IBT laboratories brochure 
[cited 09Nov 2020]. Available from: https://www.viracor -eurofins.com/media/1772/mm-0273-
rev6-1018- cmv -avr-mutations -references -final-approved.pdf.
Williams, S. L ., Hartline, C. B., Kushner, N. L., Harden , E. A., Bidanset, D. J., Drach, J. C., 
Townsend, L. B., Underwood, M. R., Biron, K. K. and Kern, E. R. 2003. In vitro activities of 
benzimidazole D -and L -ribonucleosides against herpesviruses. Antimicrob Agents Chemother,
47, 2186–92.
Winston, D. J., Bad en, L. R., Gabriel, D. A., Emmanouilides, C., Shaw, L . M., L ange, W. R. and 
Ratanatharathorn, V. 2006. Pharmacokinetics of ganciclovir after oral valganciclovir versus 
intravenous ganciclovir in allogeneic stem cell transplant patients with graft -versus -
host disease 
of the gastrointestinal tract. Biol Blood Marrow Transplant, 12, 635–40.
Wolf, D., Courcelle, C., Prichard, M. and Mocarski, E. 2001. Distinct and separate roles for 
herpesvirus -conserved UL97 kinase in cy tomegalovirus DNA s ynthesis and encapsid
ation. Proc 
Natl Acad Sci U S A, 98, 1895–900.
Wong, D. D., van Zu ylen, W. J., Hamilton, S. T., Steingruber, M., Sonntag, E., Marschall, M. 
and Rawlinson, W. D. 2019. Patient
-Derived C ytomegaloviruses with Different Ganciclovir 
Sensitivities from UL 97 Muta tion Retain Their Replication Efficiency  and Some Kinase Activity  
In Vitro. Antimicrob Agents Chemother , 63(9): e02425 –18.
Zaia, J. A., Gallez -Hawkins, G. M., Tegtmeier, B. R., ter Veer, A., Li, X., Niland, J. C. and 
Forman, S. J. 1997. L ate cy tomegaloviru s disease in marrow transplantation is predicted b y virus 
load in plasma. J Infect Dis, 176, 782–5.
For non-commercial use only
Take da CONFIDENTIAL Page 141
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 1PROTOCOL HISTORY
Amendment 8 was made to update the sponsor name and address from Shire ViroPharma, Inc 
(Shire) to Takeda Development Center Americas, Inc (TDC Americas; Takeda) and to clarify  the 
secondary  endpoints. Other minor editorial revisions (including changes for consistency  and 
clarity) are not described in the table below.
Protocol Am endment
Summary of Changes Since Protocol Version 8.0 (Protocol Am endment 7)
Amendment Number
8Amendment Date
02 Jul 2021Global
Description and Rationale for Change Section(s) Affected by Change
Updated the sponsor (name and address) from Shire 
ViroPharma, Inc (Shire) to Takeda Development 
Center Americas, Inc (TDC Americas; Takeda) as 
the legal entity will change 01 July 2021.Document headers; Title/Cover ; Protocol Signature Page; 
Product Quality Complaints; Synopsis; Section 3.4, 
Changes to Study Procedures Due to COVID -19 
Pandemic; Section 4.5, Discontinuation and/or 
Withdraw al of Subjects; Section 6.4 , Drug 
Accountability; Section 7.1.1 , Screening Period; 
Section 8.1.7 , Pregnancy; Sectio n 8.2.2 , Reporting 
Procedures; Section 8.2.4 , Serious Adverse Event 
Collection Time Frame; Section 10.5, Study 
Results/Publication PolicyDocument Date Global/Country/Site Specific
Original Protocol 04Aug 2016 Global
Amendment 1 02Mar 2017 Global
Amendment 2 01Jun2017 Global
Amendment 3 01Sep2017 Global
Amendment 4 05Feb2019 Global
Amendment 5 12Feb2020 Global
Amendment 6 07Dec2020 Global
Amendment 6.1 10 Mar 2021 Country (CHN)
Amendment 7 25 Mar 2021 Global
Amendment 7.1 (CHN) 17 May 2021 Country (CHN)
Amendment 8 02 Jul 2021 Global
Amendment 8.1 (CHN) 02 Jul 2021 Country (CHN)
Amendment 9 15Sept 2021 Global
For non-commercial use only
Take da CONFIDENTIAL Page 142
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Changes Since Protocol Version 8.0 (Protocol Am endment 7)
Amendment Number
8Amendment Date
02 Jul 2021Global
Description and Rationale for Change Section(s) Affected by Change
Clarified the secondary efficacy endpoints on 
maintenance of viremia clearance achieved at 
Week 8 through Week 16 (ke y), 12, and 20 
regardless if either study -assigned treatment was 
discontinued before the end of the stipulated 8 w eeks 
of therapy, the subject must also have symptom 
control.Synopsis ; Section 9.8.2 , Key Secondary Efficacy 
Endpoint; Section 9.8.5 , Secondar y Efficacy Endpoints
Amendment 7 to Protocol SPH620- 302 incorporated agency  concerns.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Protocol Am endment
Summary of Changes Since Protocol Version 7.0 (Protocol Am endment 6)
Amendment Number
7Amendment Date
25Mar2021Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Removed language extending measures to other situations beyond the 
COVID -19 pandemic (“or other future similar unexpected public 
health concerns” as this section applies only to the current COVID -19 
pandemic.Section 3.4, Changes to Study 
Procedures Due to COVID -19 
Pandemic
Updated the guidance on management of clinical trials during the 
COVID -19 pandemic. Clarified that the site must contact the sponsor 
for approval of the alternative method for obtaining informed consent 
prior to implementation.Synopsis ; Table 1, Schedule of 
Assessment 1: Screening Phase and 
Study Treatment Phase; Section 3.4, 
Changes to Study Procedures Due to 
COVID -19 Pandemic; Section 4.1, 
Inclusion Criteria
Clarified the recording of abuse, misuse, overdose, and medication 
errors on the AE CRF.Section 8.1.8, Abuse, Misuse, 
Overdose, and Medication Error
Amendment 6 to Protocol SHP620- 302 incorporated the following major changes: 
The protocol was amended to maintain subject safety , confidentiality , and study  integrit y in 
the context of healthcare delivery  challenges presented by  the COVID -19 pandemic. 
Amendment 6 provided flexibility  to study  participants to opt for home healthcare (HHC) 
solutions as permitted by local regulations. This “hy brid study  design” would offer study  
participants the option of in clinic or HHC for all study  visits in the treatment phase.
For non-commercial use only
Take da CONFIDENTIAL Page 143
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Guidance was provided regarding changes to the study  procedures that could be implemented 
for study  participants or study  sites affected by  the COVID -19 Public Health Emergency . 
The guidance took references from the FDA Guidance on Conduct of Clinical Trials of 
Medical Products during COVID- 19 Public Health Emergency  -Guidance for Industry , 
Investigators, and Institutional Review Boards, March 2020, updated 03 June 202 0, and the 
EMA Guidance on the Management of Clinical Trials During the COVID -19 (Coronavirus) 
Pandemic, Version 3 (28 April 2020).
As the COVID -19 pandemic could peak in different regions at different times and restrictions 
implemented by  local laws and recommendations could vary , any decision on procedural 
changes was to be made on a case -by-case basis by  the principal investigator in consultation 
with the study  team and the medical team as needed, while maintaining patient safet y and 
confidentiality  as the priority
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Protocol Am endment
Summary of Changes Since Protocol Version 6.0 (Protocol Am endment 5)
Amendment Number
6Amendment Date
07Dec2020Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated Sponsor Approval on Protocol Signature Page. Protocol Signature Page
Updated number of completed Phase 1 studies from 15 to 17. Section 1.2.2, Efficacy
Updated number of completed Phase 1 studies from 16 to 17. Section 1.2.3, Safety
Included language regarding home healthcare services/remote visits 
for the treatment phase.Study Schedules; Section 3.1, Study 
Design and Flow  Chart; Section 3.4, 
Changes to Study Procedures Due to 
COVID -19 Pandemic; Section 6.4, 
Drug Accountability
Included language regarding Direct -to-Patient study drug services 
where allowed per local regulations.Section 3.1, Study Design and Flow  
Chart; Section 3.4, Changes to Study 
Procedures Due to COVID -19 
Pandemic; Section 6.4, Drug 
Accountability
Implem entation of remote source document verification where allow ed 
per local laws and regulations.Section 3.4, Changes to Study 
Procedures Due to COVID -19 
Pandemic; Section 10.2.3.2, Recording, 
Access, and Retention of Source Data 
and Study Documents
For non-commercial use only
Take da CONFIDENTIAL Page 144
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Changes Since Protocol Version 6.0 (Protocol Am endment 5)
Amendment Number
6Amendment Date
07Dec2020Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Included language to cover subjects who discontinued due to 
COVID -19.Section 3.4, Changes to Study 
Procedures Due to COVID -19 
Pandemic; Section 4.5, Discontinuation 
and/or Withdraw al of Subjects
Included language to cover subjects who discontinued due to 
COVID -19.Section 3.4, Changes to Study 
Procedures Due to COVID -19 
Pandemic; Section 4.5, Discontin uation 
and/or Withdraw al of Subjects
Included language concerning the notification of relevant health 
authorities about participants who contract COVID -19 during the 
study.Section 3.4, Changes to Study 
Procedures Due to COVID -19 
Pandemic; Section 10.1.5, Reporting of 
COVID -19 Cases During the Study
Maribavir tablet strength corrected to 200 mg, which was previously 
inadvertently stated as 20 mg.Section 3.1,Study Design and Flow  
Chart
Added the possibility of valganciclovir dose adjustments for subject s 
with moderate renal impairment to Figure 1,Study Design Flow  Chart .Section 3.1,Study Design and Flow  
Chart
Replaced cidofovir with letermovir in the list of anti -CMV agents that 
must not be taken for current CMV infection for longer than 72 hours.Section 3.1, Study Design and Flow  
Chart; Section 4.2, Exclusion Criteria; 
Section 5.1, Prior Medications, 
Therapies, and Procedures
Reinserted the clinical laboratory assessment for immunoglobulins 
under the heading labeled “Other”, which was inadvertently removed 
from Protocol Amendment 5.Section 7.2.3.5, Clinical Laboratory 
Evaluations
Changed the assessment of severity (intensity) of adverse events 
according to version 4.0 of the National Cancer Institute Common 
Term inology Criteria for Adverse Events (CTCAE).Section 8.1.1, Severity Categorization; 
Section 8.1.4, Adverse Events of 
Special Interest
Clarified the recording of abuse, misuse, overdose, and medication 
errors on the AE CRF.Section 8.1.8, Abuse, Misuse, 
Overdose, and Medication Error
For subjects w ith CMV DNA ≤910 IU/m L in plasma or ≤2730 IU/mL 
in whole blood with high -risk CMV infection, the requirement was 
removed that the second result must be higher or decrease no more 
than 30% relative to the first result.Section 7.1.1, Screening Per iod
Corrected value for inclusion criteria 4 from ≥730 IU/mL in whole 
blood to ≥2730 IU/mL in whole blood under changes for Protocol 
Amendment 4, which was inadvertently not stated correctly in 
Protocol Amendment 5.Appendix 1, Protocol History
Updated data and sources in Table A-2 and Table A-3 listing CMV 
genetic mutations associated with resistance to anti -CMV drugs.Appendix 3, CMV Genetic Mutations 
Associated with Resistance to Anti 
CMV Drugs
For non-commercial use only
Take da CONFIDENTIAL Page 145
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Amendment 5 to Protocol SHP620 -302 incorporated the following major changes:
Added Modified Randomized Set, consisting of all subjects in Randomized Set who take at 
least 1 dose of assigned study  treatment.
.
Updated comorbidit y status evaluation.
To align with the investigator’s brochure, updated the C maxand AUC values for the increased 
tacrolimus when concomitantly  administered with maribavir (400 mg BID) (33% changed to 
38% and 54% changed to 51%, respectively ) and changed 2D6 substrate to CYP2C19 
substrate.
Updated number of completed for Phase 1 studies in Section 1.2.3 from 15 to 16.
Removed references to an electronic diary  (e-diary ) due to the introduction of paper back -up 
diaries.
Updated the versions of the Valcy te Prescribing Information and Summary  of Product 
Characteristics (SmPC) to specify  the current version as documented in t he Study  Pharmacy  
Manual.
Corrected the unit of measure for hemoglobin from mg/dL  to g/dL.
Clarified that timing of comorbidity  status evaluation is at Visit 6/Week 4 and 
Visit 10/Week 8.
Clarified follow -up to closure of unresolved serious adverse events (SAEs) rather than AEs 
at end of stud y.
Corrected pregnancy  reporting information to indicate that it is the investigator’s 
responsibility  to obtain pregnancy  outcome/infant condition information within 
approximately  30calendar day s and 1 year postpartum. Removed requirement for a cop y of 
the Investigational and Marketed Products Pregnancy  Report Form being sent to the CRO/ 
Shire medical monitor using details specified in the emergency  contact information section of 
protocol.
For non-commercial use only
Take da CONFIDENTIAL Page 146
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Corrected information regardin g reporting of SAEs.
Removed confidence intervals from 3 secondary  efficacy  endpoints as they  are not clinicall y 
meaningful for these analyses.
Removed the L jungman 2002 reference, updated the Ljungman reference from 2016 
(e-publication date) to 2017 (fina l publication date), and added a statement to refer to the 
citation for full details on the definition of CMV disease.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Protocol Am endment
Summary of Changes Since Protocol Am endment 4 (Version 5.0)
Amendment Number
5Amendment Date
12Feb2020Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated Sponsor Approval on Protocol Signature Page. Protocol Signature Page
Updated study period dates to 2017 -2021. Synopsis
Added Modified Randomized Set, consisting of all subjects in 
Randomized Set who take at least 1 dose of assigned study treatment.Synopsis; Section 9.7, Study 
Population; Section 9.8.1, Primary 
Efficacy Endpoint; Section 9.8.2, 
Key Secondary Efficacy Endpoint; 
Section 9.8.3, Multiplicity 
Adjustment; Section 9.8.5, 
Secondary Efficacy Endpoints; 
 
 
 
 
 
  
Updated comorbidity status evaluation. Study Sc hedules, Table 1, Schedule 
of Assessment 1: Screening Phase 
and Study Treatment Phase
To align with the investigator’s brochure, updated the C maxand AUC 
values for the increased tacrolimus when concomitantly administered 
with maribavir (400 mg BID) (33% changed to 38% and 54% changed to 
51%, respectively) and changed 2D6 substrate to CYP2C19 substrate.Section 1.2.1, Pharmacokinetics, 
Metabolism, and Drug -Drug 
Interactions; Section 5.2.1, Permitted 
Treatment
Updated number of completed Phase 1 studies fr om 15 to 16. Section 1.2.3, Safety
For non-commercial use only
Take da CONFIDENTIAL Page 147
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Changes Since Protocol Am endment 4 (Version 5.0)
Amendment Number
5Amendment Date
12Feb2020Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Removed references to an electronic diary (e -diary) due to the 
introduction of paper back -up diaries.Section 6.4, Drug Accountability; 
Section 6.5, Subject Compliance
Updated the versions of the Valcyte Prescribing Information and 
Summary of Product Characteristics (SmPC) to specify the current 
version as documented in the Study Pharmacy Manual.Section 2.2, Rationale for the Study 
Design; Section 4.4.1, Female 
Contrace ption; Section 5.2.2, 
Prohibited Treatment; Section 6.2.3, 
Dosing; Section 8.1.8, Abuse, 
Misuse, Overdose, and Medication 
Error
Corrected the unit of measure for hemoglobin from mg/dL to g/dL. Section 6.2.3, Dosing
Clarified timing of comorbidity status evaluation is at Visit 6/Week 4 and 
Visit 10/Week 8.Section 7.1.2, Study Drug 
Administration Period
Clarified follow -up to closure of unresolved serious adverse events 
(SAEs) rather than AEs at end of study.Section 7.1.3, Follow -up Period; 
Section 8.1, Definition of Adverse 
Events, Period of Observation, 
Recording of Adverse Events
Corrected pregnancy reporting information to indicate that it is the 
investigator’s responsibility to obtain pregnancy outcome/infant condition 
information within approximately  30calendar days and 1 year 
postpartum. Removed requirement for a copy of the Shire Investigational 
and Marketed Products Pregnancy Report Form being sent to the 
CRO/Shire medical monitor using details specified in the emergency 
contact information sect ion of the protocol.Section 8.1.7, Pregnancy
Corrected information regarding reporting of SAEs. Section 8.2.2, Reporting Procedures
Removed confidence intervals from 3 secondary efficacy endpoints as 
they are not clinically meaningful for these analyses.Section 9.8.5, Secondary Efficacy 
Endpoints
Updated Appendix 1, Protocol History to include Protocol Amendment 5 
and added the summary of change information from Protocol 
Amendment 4.Appendix 1, Protocol History
 
 
  
Amendment 4 to Protocol SHP620 -302 incorporated the following major changes:
Expanded eligibility  criteria for viral load and creatinine clearance rate (CrCl).
For non-commercial use only
Take da CONFIDENTIAL Page 148
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Added a third viral -load stratum for subjects with very  low viral load (CMV DNA 
≥1365 IU/mL to < 2730 IU/mL  in whole blood or ≥455 I U/mL to <910 IU/mL  in plasma at 
baseline) and high -risk infection, in addition to the existing low viral-load (CMV DNA 
≥2730 IU/mL to <27300 IU/mL in whole blood or ≥910 IU/mL to <9100 IU/mL  in plasma) 
and high viral -load (CMV DNA ≥27300 IU/mL in whole blood or ≥9100 IU/mL  in plasma ) 
strata.
Added a stud y visit at Study  Day 4 (±1) for subjects taking a narrow therapeutic index 
immunosuppressive agent (ie, tacrolimus, cy closporine, everolimus, sirolimus) at baseline to 
align the protocol with a recent recommendation from the Data Monitoring Committee 
(DMC) for Study  SHP620 -303.
Added a visit 4 day s after starting new therapy with a narrow therapeutic index 
immunosuppressive agent for subjects who begin new therap y during the course of the 
treatment period to align the protocol with a recent recommendation from the DMC for 
Study SHP620 -303.
Updated contact list, including removal of contacts for sites in Latin America.
Updated safet y reporting contacts to a single Shire Global Safet y e-mail and fax contact per 
revised safet y reporting procedures.
Added exclusion for concomitant letermovir and specified required washout period.
Clarified end of period for collecting nonserious AEs as up to 30 day s after the last dose of 
study  medication.
Modified the definition of overall stud y AEs to include events during the overall study period 
through the end of stud y observation, regardless of initiation of alternative anti- CMV 
treatment.
Modified criteria for reporting of CMV as an AE or SA E to harmonize with the reporting 
format used in Study  SHP620 -303.
Updated Table 12 Assessments of Responders for Key  Secondary  Endpoint (confirmed 
CMV viremia clearance at the end of Study Week 8 through Week 16) to ensure assessment 
of responder rates co nsistent with assessment specified in Study SHP620 -303.
Eliminated the Hematopoietic Cell Transplant Comorbidity  Index (HCT -CI) assessment and 
deleted Appendix 5 containing the index.
Clarified language regarding starting dosage regimens, as updated entry  criteria require 
expansion of starting doses.
For non-commercial use only
Take da CONFIDENTIAL Page 149
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Added GVHD assessment criteria forms from publications cited in new Appendix 8 
(formerl y Appendix 9, containing onl y citation references) and added tables for GVHD 
diagnosis criteria to new Appendix 9 (formerl yAppendix 10, containing only  citation 
references).
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Protocol Am endment
Sum mary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
05 Feb 2019Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated Sponsor representative to , MD. Protocol Signature Page
Removed HCT CI from list of abbreviations. Abbreviations
Updated Emergency Contact Information, including removal of hotline 
numbers for Latin America, and removal of specific medical monitor 
contacts.Emergency Contac t Information
Updated product quality complaint reporting contact to a single e -mail 
and phone contact.Product Quality Complaints
Removed Latin America from listed Sites and Regions. Synopsis, Section 3.3 Sites and 
Regions
Modified inclusion criterion 4 for viral load from ≥910 IU/mL in plasma 
or ≥2730 IU/mL in whole blood to ≥455 IU/mL in plasma or 
≥1365 IU/mL in whole blood to include a very low  viral -load stratum for 
high-risk subjects, in addition to the existing high and low  viral load 
strata.Syno psis, Table 1, Section 3.1 Study 
Design and Flow  Chart;
Section 4.1 Inclusion Criteria; 
Section 8.1.5 Disease Under Study; 
Section 9.8.4 Subgroup Analyses
Modified inclusion criterion 7d for CrCl from 60 mL/min to 30 mL/min. Synopsis, Section 4.1 Inclusion 
Criteria
Added letermovir to exclusion criterion 5 and specified w ashout. Synopsis, Section 4.2 Exclusion 
Criteria
Removed details of washout for anti -CMV agents from exclusion 
criterion 6.Synopsis, Section 4.2 Exclusion 
Criteria
Added requir ement for negative result of HIV testing within 3 months 
prior to start of study treatment to exclusion criterion 17.Synopsis, Table 1, Section 3.1 Study 
Design and Flow  Chart; Section 4.2 
Exclusion Criteria; Section 7.2.3.5
Specified that starting dosage of valganciclovir could be adjusted for 
renal function at screening; removed statement of assumption of only 
mild renal impairment.Synopsis; Section 3.1Study Design 
and Flow  Chart
For non-commercial use only
Take da CONFIDENTIAL Page 150
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Sum mary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
05 Feb 2019Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Removed additional table listing valganciclovir dose adjustments for 
subjects with both neutropenia and renal impairment as redundant with 
table describing dose adjustment for renal impairment.Synopsis; Section 6.2.3 Dosing
(previous Table 8)
Modified Study Flow Chart, Schedule, and Procedures to include new 
visit 2A for subjects receiving tacrolimus, cyclosporine, everolimus, or 
sirolimus at baseline, added description of local lab testing of potassium 
and magnesium.Synopsis, Table 1, Section 3.1 Study 
Design and Flow  Chart; 
Section 7.2.3.5 Clinical Laboratory 
Evaluation s
Modified the definition of the overall study period for the summary of 
overall study AEs as including the entire study period through the end of 
study observation, regardless of initiation of alternative anti -CMV 
treatment.Synopsis; Section 9.9
 
Added minimum washout window  of 3 days prior to first dose of study 
medication for letermov ir.Section 5.2.2 Prohibited Treatment, 
Table 4
Updated event reporting procedure to specify a single e -mail and fax 
contact for reporting of SAEs and pregnancies and updated department 
name to Global Drug Safety.Section 8.2.2 Reporting Procedures; 
Section 8.2.4 Serious Adverse Event 
Collection Time Frame
Added a column for additional visit 2A to collect the following 
assessments: Hematology/Chemistry, Immunosuppressant drug 
concentration levels, Adverse events, Study diary, Concomitant meds, 
Therap ies, and Procedures.Table 1; Section 7.1.2 Study Drug 
Administration Period
Added new footnote and text explanation that Visit 2A is required only 
for subjects receiving tacrolimus, cyclosporine, everolimus, or sirolimus, 
and will occur at Day 4±1 day fo r subjects receiving agent at baseline or 
4±1day after initiating for those subjects who start after baseline.Table 1, Footnotes; Section 7.1.2
Study Drug Administration Period
Clarified that local laboratory will assess potassium and magnesium 
levels a t Visit 2A (Day 4±1 day for subjects receiving tacrolimus, 
cyclosporine, everolimus, or sirolimus at baseline, and 4±1 day after 
initiation of treatment for subjects initiating treatment with any of these 
agents after baseline during the treatment period).Table 1; Footnote h; Section 7.2.3.5 
Clinical Laboratory Evaluations
Clarified that nonserious AEs occurring only during the study or w ithin 
30days of last dose of study medication will be collected.Table 2; Section 7.1.3 Follow -up 
Period; Section 7.2.3.6 Adverse 
Event Collection
Updated timeframe for collection of medical history data from 5 years to 
2years.Section 7.2.3.1 Medical History
Specified requirements for prior hepatitis testing within 3 months before 
randomization.Section 7.2.3.5 Clinical Laboratory 
Evaluations
For non-commercial use only
Take da CONFIDENTIAL Page 151
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Sum mary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
05 Feb 2019Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated the blood volume expected to be drawn from each subject to 
include additional volumes for subjects receiving tacrolimus, 
cyclosporine, everolimus, or sirolimus.Section 7.2.5 Volume of Blood to Be 
Drawn from Each Su bject, Table 8
Clarified criteria for reporting CMV infection as an AE or as an SAE. Section 8.1.5 Disease Under Study , 
Table 9
Clarified that the Safety Set will be used for analyses of safety endpoints. Section 9.7 Study Population
  
Clarified that the primary analysis of safety will be based on the 
on-treatment observation period.Section 9.9 Safety Analyses
Redefined treatment -emergent adverse events to include events with start 
dates before initiation of study treatment that increase after the first dose 
of study treatment, as well as events with start dates after the first dose.Section 9.9 Safety Analyses
Specified that clinical laboratory evaluations w ould be assessed for 
on-treatment and overall study periods.Section 9.9 Safety Analyses
Added study treatment dose adjustments due to AEs as a single safety 
endpoint, and remov ed specific endpoints of valganciclovir dose 
adjustment/interruptions and maribavir dose interruptions for AEs.Section 9.9 Safety Analyses
Removed specific examples of adverse events of special interest, and 
referred instead to Section 8.1.4.Section 9.9Safety Analyses
Removed blood product transfusions and invasive bacterial or fungal 
infections as separate safety endpoints, and noted inclusion of invasive 
bacterial and fungal infections w ith discussion of analyses of adverse 
events of special interest .Synopsis, Section 9.9 Safety 
Analyses
Com bined vital sign measurements, physical examination, and ECG as 
safety assessments.Synopsis, Section 9.9 Safety 
Analyses
Removed statement that a shift table summarizing changes from normal 
and vice versa for all laboratory tests, and added a statement that shifts in 
National Cancer Institute Common Toxicity Criteria toxicity grades from 
baseline to maximum grade postbaseline will be analyzed for the 
on-treatment and overall study periods.Section 9.9 Safety An alyses
Added statement that transfusions of hematopoietic growth factors, blood, 
and blood products w ill be summarized.Section 9.9 Safety Analyses
Specified that treatment -emergent shifts to grade 3 or grade 4 neutropenia 
from lower grade to maximum grade w ill each be summarized for the 
on-treatment period and the overall study period, and that time to 
development of neutropenia will be evaluated.Section 9.9 Safety Analyses
For non-commercial use only
Take da CONFIDENTIAL Page 152
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Sum mary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
05 Feb 2019Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added statement that study treatment dose adjustment, specifically 
valganciclovir dose adjustment and interruptions for neutropenia or renal 
function impairment or other AE, and maribavir dose interruptions for 
any AE, will be summarized.Section 9.9 Safety Analyses
Revised assessment of responders for the key secondary endpoint to be 
aligned w ith assessment methods used in Study SHP620 -303.Synopsis ;Table 11
Deleted previous Appendix 5, The Hematopoietic Cell Transplant 
Com orbidity Index; renumbered subsequent appendices 6 to 11 as 
Appendices 5 to 10.(previous) Append ix 5; (new) 
Appendices 5 to 10.
Restored figure attachments for new  Appendix 8, Recommendations for 
Chronic GVHD Diagnosis and Grading; restored tables to Appendix 9, 
Diagnostic Criteria for Chronic GVHD.(new ) Appendix 8, (new ) 
Appendix 9
Amendment 3 to Protocol SHP620 -302 incorporated the following major changes:
Storage conditions of investigational product were revised.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Sep 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added reference to the pharmacy manual Section 6.3.1
Revised storage conditions:
The investigator has overall responsibility for ensuring that 
investigational product is stored in a secure, limited -access 
location. Maribavir and corresponding placebo tablets will be 
stored at room temperature (15°C 30°C 86°F). Valganciclovir 
tablets do not require any special storage conditions and should 
be stored in a similar condition as maribavir tablets to maintain 
the blind. Limited responsibility for storage may be delegated to 
the pharmacy or member of the study team, but this delegation 
must be documented. Investigational products are distributed by 
the pharmacy or nominated member of the study team. The 
pharmacist/nominated team member w ill enter the unique 
subject identifier on the investigational product bottle/carton 
labels as they are distributed.Section 6.3.2
For non-commercial use only
Take da CONFIDENTIAL Page 153
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Sep 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Investigational products must be stored in accordance with 
labeled storage conditions of up to 25°C or 77°F.
Added sentence after final bullet point:
For subjects who permanently discontinue study treatm ent early but 
do not withdraw consent, refer to Section 4.5 regarding modified 
schedule of assessments.Section 7.1.2
Amendment 2 to Protocol SHP620-302 incorporated the following major changes:
Stated “CMV central nervous sy stem (CNS) infection” as one of the reasons for 
discontinuation and/or withdrawal.
Added basic descriptive statistics generall y for all endpoints.
Added sensitivity  analy sis for invest igation of homogeneity  of treatment effect across 
centers/regions.
Added rules for conducting the interim population PK analy sis.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for con sistency  and clarity ) are not described in this table.
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
01 Jun 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Revised definition of the terms:
Resistant to “Documented failure to achieve >1 log10 decrease 
in CMV DNA level in whole blood or plasma after of 2 or more 
weeks of treatment with IV ganciclovir, oral valganciclovir, IV 
foscarnet, or IV cidofovir (or any combination thereof).
Documentation of 1 or more CMV genetic mutations associated 
with resistance to ganciclovir, valganciclovir, foscarnet, and/or 
cidofovir. ”
Symptom atic subjects to: “Transplant recipients with refracto ry 
CMV infections, including CMV infections with confirmed 
resistance to 1 of the anti -CMV agents (ganciclovir, 
valganciclovir, foscarnet, or cidofovir), who have tissue invasive 
CMV disease, as initially determined by the investigator at 
baseline. HSCT re cipients who have tissue- invasive CMV Definitions
For non-commercial use only
Take da CONFIDENTIAL Page 154
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
01 Jun 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
disease as determined by the investigator according to the 
criteria specified by Ljungman et al. 2016. ”
Asymptomatic subjects to “Transplant recipients with 
refractory CMV infections, including CMV infections with 
confirmed resistance to 1 of the anti -CMV agents (ganciclovir, 
valganciclovir, foscarnet, or cidofovir), who do not have tissue 
invasive CMV disease as diagnosed by the investigator at 
baseline . HSCT recipients who do not have tissue -invasive 
CMV disease as de termined by the investigator according to the 
criteria specified by Ljungman et al. 2016.”
Added rationale for dosing of adolescents:
Currently available maribavir pharmacokinetics, PK modeling and 
extrapolation of systemic exposure from adult s, and safety and 
tolerability data in adults support the administration of the 400 mg BID 
dose in adolescents who weigh ≥35 kg and are able to sw allow  tablets. 
Per Lu and Rosenbaum (2014), the expression of CYP3A4 and CYP 
2C19, which are primary enzymes f or maribavir metabolism in the liver, 
occurs during the first weeks of life. The expression of CYP1A2, which is 
also involved with maribavir metabolism, the last enzyme to develop, is 
present by 1 to 3 months of life. By 1 to 2 years of age, all the isoenz yme 
activities are similar to those of adults. Therefore, the bioavailability and 
systemic exposure of maribavir in adolescent subjects (≥16 and <18 years 
of age) is not expected to be different from adults at the same oral dose.Section 2.3
Moved CMV cen tral nervous system (CNS) infection as a reason for 
discontinuation and/or withdrawal from Section 5.2.2 (Prohibited 
Treatment) to Section 4.5.1 (Reasons for Discontinuation and/or 
Withdraw al).Section 4.5.1
Changed pharmacokinetic sample collection for a dolescent subjects from 
≥12 to <18 years of age to ≥16 to <18 years of ageSection 7.1.2
Moved description of summary statistical methods from “Exploratory 
Efficacy Endpoints” to “Efficacy Analyses”:
Summary descriptive statistics w ill include the number of subjects (N), 
mean, standard deviation, median, minimum and maximum (range) 
values for continuous variables, and incidences and percentages for 
categorical variables. The denominator for the percent ages will be based 
on the number of patients with nonmissing information in the randomized
analysis set unless otherwise specified. Time -to-event endpoints will be 
summarized using Kaplan -Meier estimation. Ninety -five percent (95%) 
confidence intervals for the estimated 25%, 50%, and 75% times will be 
presented.Section 9.8, Section 9.8.6
Added another example of a sensitivity analysis of the primary endpoint 
of confirmed CMV viremia clearance at Week 8:
The primary efficacy endpoint analysis will be repea ted by using 
the CMV DNA level used for the randomization rather than the 
CMV DNA levels based on central laboratory values as one of 
the stratification factors.Section 9.8.1
For non-commercial use only
Take da CONFIDENTIAL Page 155
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
01 Jun 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Revised description of subgroup analyses as follows:
The primary and key secondary endpoints will be examined for the 
following subgroups The proportion of responders and the corresponding 
95% CI w ill be summarized for primary and key secondary endpoints by 
treatment group for the following subgroups (inclusive, but not limited
to):
Cytomegalovirus DNA viral load (high, low)
Acute GVHD presence/absence at baseline
Adolescents ≥16 to <18 years of age (exploratory analysis: may 
be conducted if sample size is adequate)
Enrolling regions (enrolling centers will be grouped by 
geographic locations to explore homogeneity of treatment effect 
across regions).Section 9.8.4
Added more information regarding interim analyses:
If needed, an interim population PK analysis of maribavir PK data 
obtained from the study subjects will be pe rformed. by an independent 
unblinded team/CRO. Interim population PK analysis will be performed 
by an independent unblinded team or CRO who will have no involvement 
in the conduct of the study. Results from this analysis will not be shared 
with any members of the study team until after database lock. Rules 
governing this process are detailed in the sponsor’s (or designee’s) 
standard operating procedures.Section 9.10.3
Amendment 1 to Protocol SHP620- 302 incorporated the following major changes:
Modificatio n of primary , key  secondary , and secondary  objectives to include subjects 
who discontinue study  treatment early  and meet the criteria of confirmed CMV viremia 
clearance as responders in the primary  efficacy  analy sis.
Modified Inclusion Criterion 5 to indic ate that the current CMV infection must be the 
first episode of CMV viremia after HSCT, either primary  or reactivation.
Clarified Inclusion Criterion 8 to indicate that urine pregnancy  tests may  be done per 
institutional requirements in addition to serum; however, they are not sufficient for 
eligibility  determination.
Added a new Exclusion Criterion 3 to exclude subjects with recurrent CMV infection.
Amended Exclusion Criterion 6 to indicate that subjects must not be on treatment with 
anti-CMV agents (ganciclovir, valganciclovir, foscarnet or cidofovir) for the current 
CMV infection for longer than 72 hours.
For non-commercial use only
Take da CONFIDENTIAL Page 156
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Note : A subject who is receiving these anti- CMV agents must discontinue their use before the 
first dose of study  treatment. A subject who may  be receiving cidofovir must discontinue this 
antiviral at least 14 day s prior to randomization at Visit 2/Day 0 and the first dose of study  
treatment.
Note : Subjects who were administered these anti- CMV agents for proph ylaxis should have these 
treatments compl eted at least 2 weeks prior to the study  entry  or start of the treatment for current 
infection, whichever comes first, and have undetectable CMV DNA (based on local laboratory ) 
for at least 2 weeks between the completion of the anti- CMV prophy laxis and onset of the 
current infection.
Clarified in Exclusion Criterion 13 that subjects who have received an unapproved agent 
or device within 30 day s before initiation of study  treatment will not be eligible.
Clarified Exclusion Criterion 16 indicating that known (previousl y documented) HIV 
historical results will be accepted and no additional study  testing will be required.
Added an intensive PK sampling schedule for adolescents.
An additional pregnancy  test at 4 weeks (Visit 6/Week 4) to obtain a monthly  testing 
interval.
Addition of highly  effective method of female and male contraception per the 
recommendations related to contraception and pregnancy  testing in clinical trials by  
clinical trial facilitation group (CTFG).
Emphasis on potent inducers of C ytochrome P450 (CYP) 3A4 and/or P -glycoprotein 
(P-gp) and caution for concomitant use of potent inhibitors of CYP 3A4, in alignment 
with the guidance to the investigators provided in the maribavir investigator’s brochure.
Caution and recommendation for careful monit oring of concentration levels of 
concomitant medications that are substrates of CYP2C19 and P -gp both after initiation of 
maribavir (when substrate levels may  increase) and after discontinuation of maribavir
(when substrate levels may  decrease), in alignme nt with the guidance to the investigators 
provided in the maribavir investigator’s brochure.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
For non-commercial use only
Take da CONFIDENTIAL Page 157
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
02 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated signatory to Obiamiwe Umeh, MD, MSc. Protocol Signature Page
Added “FU = follow -up” to the abbreviations list. Abbreviations
Created a list of definitions pertaining to evaluations/analysis for the 
study for easy access and convenience.Definitio ns
Added clarifying text to indicate that initiation of study treatment (ie, first 
dose) w ill only occur after completion of all required Visit 2/Day 0 
procedures, confirmation of eligibility, and completion of randomization.Synopsis , Table 1 (footnote “c”), 
Section 3.1
Modification of primary objective and corresponding endpoint and 
analysis to clarify that subjects who discontinue study treatment early and 
meet the criteria of confirmed CMV viremia clearance at Study Week 8 
will be considered as respo nders in the primary efficacy analysis.Synopsis , Section, 2.4.1, 
Section 9.8.1
Modification of key secondary objective and corresponding endpoints 
and analyses to clarify that subjects who discontinue study treatment 
early and meet the criteria of confir med CMV viremia clearance at Study 
Week 8 w ill be considered as responders in the efficacy analysis.Synopsis , Section, 2.4.2, 
Section 9.8.2
Modification of secondary objectives and corresponding endpoints and 
analyses as follows.
Added the former primary and key secondary objectives as secondary 
objectives:
•“To compare the efficacy of maribavir to valganciclovir in CMV 
viremia clearance after 8 w eeks of treatment of asymptomatic CMV 
infection in HSCT recipients .”
•“To compare the efficacy of maribavir and valganciclovir on 
maintenance of CMV viremia clearance, achieved after completion 
of 8 w eeks of treatment, through Study Weeks 12 (4 w eeks 
post-treatment period), 16 (8 weeks of post -treatment/follow -up 
phase), and 20 (12 w eeks post -treatment).”
Added the secondary objectives:
•“To assess the maintenance of CMV viremia clearance achieved at 
the end of Study Week 8, through Weeks 12 (4 w eeks 
post-treatment) and 20 (12 w eeks post -treatment).”
•“To evaluate the incidence of recurrence of confirmed CMV viremia 
in the 2 study treatment arms during the first 8 weeks of the study, 
during the 12 w eeks of the follow -up study phase, and at any time 
during the study .”
•“To evaluate the incidence of recurrence of confirmed CMV viremia 
in the 2 study treatment arms when subjects are on treatment and off 
treatment.”Synopsis , Section 2.4.3, 
Section 9.8.5
For non-commercial use only
Take da CONFIDENTIAL Page 158
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
02 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Deleted the following objective and the corresponding endpoint since it 
became redundant with the modified primary objective:
•“To assess the two stud y treatment arms for maintenance of CMV 
viremia clearance achieved while on study treatment, irrespective of 
its duration, at 8 weeks of study”
 
 
 
  
Updated the published article Ljungman 2002 w ith Ljungman 2016 
where relevant.Section 1.1, Section 3.1, 
Section 7.2.23
Modified Inclusion Criterion 5 to exclude subjects with recurrent CMV 
infection:
“The current CMV infection must be the first episode of CMV viremia 
after HSCT, either primary or reactivation.”Synopsis , Section 4.1
Clarified Inclusion Criterion 8 to indicate that urine pregnancy tests may 
be done per institutional requirements; however, they are not sufficient 
for eligibility determination.Synopsis , Section 4.1
Added a new Exclusion Criterion 3 to exclude subjects with recurrent 
CMV infection:
“Bepresenting wit h recurrent CMV infection (defined as a new  detection 
of CMV infection) in a subject who had at least one previously 
documented episode of CMV infection post -transplant, and who has had
at least 2 w eeks of undetectable CMV DNA between the episodes (during 
active surveillance, based on same local laboratory and same sample 
type). The subject must also have been off any anti -CMV treatment 
betw een the current and prior infection. Otherwise, the current infection 
may be considered continuation of the prior infection.”Synopsis , Section 4.2
Amended Exclusion Criterion 6 to indicate that subjects must not “be on 
treatment” with anti -CMV agents (ganciclovir, valganciclovir, foscarnet 
or cidofovir) for the current CMV infection for longer than 72 hours.
Note : A subject w ho is receiving these anti -CMV agents must 
discontinue their use before the first dose of study treatment. A subjects 
who may be receiving cidofovir must discontinue this antiviral at least 
14days prior to randomization at Visit 2/Day 0 and the f irst dose of 
study treatment.Synopsis , Section 4.2
For non-commercial use only
Take da CONFIDENTIAL Page 159
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
02 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Note : Subjects who w ere administered these anti -CMV agents for 
prophylaxis should have these treatments completed at least 2 w eeks 
prior to the study entry or start of the treatment for current infection, 
whichever comes first , and have undetectable CMV DNA (based on 
local laboratory) for at least 2 weeks between the completion of the 
anti-CMV prophylaxis and onset of the current infection.”
Clarified in Exclusion Criterion 13 that subjects who have received an 
unapproved agent or device within 30 days before initiation of study 
treatment will not be eligible.Synopsis , Section 4.2, Section 5.2.2 
(Table 4)
Clarified Exclusion Criterion 16 indicating that known historical results 
will be accepted and no additional study testing will be required.
“Have known (previously documented) positive results for human 
immunodeficiency virus (HIV).”Synopsis , Table 1 (footnote “i”), 
Section 3.1, Section 4.2, 
Section 7.1.1, Section 7.2.3.5 
(Virology)
Removed text indicating that PK samples collected from subjects 
receiving valganciclovir w ould be discarded:
“Pharmacokinetic samples collected from subjects receiving 
valganciclovir will be discarded prior to analysis.”Synopsis , Section 7.2.4.1
Clarified that the Random ized Set rather than the FAS will be used for 
efficacy analysis along with the Per -Protocol Set and that the 
Randomized Set w ould be used for the primary analysis and the Per -
Protocol Set w ould be used as the supportive analysis.Synopsis , Section 9.7
Added the definition of adolescent pharmacokinetic set. Synopsis , Section 9.7
Updated Table 11 and Table 12 to include additional scenarios for 
responder determination.Synopsis , Section 9.8.1, 
Section 9.8.2
Updated the primary, key secondary, secondary, and exploratory 
endpoints to align with updates made to the objectives.Synopsis , Section 9.8.1, 
Section 9.8.2, Section 9.8.5, 
Section 9.8.6
Added an additional subgroup analysis for adolescents:
Adolescents ≥16 to <18 years of age (exploratory analysis: may be 
conducted if sample size is adequate)Synopsis , Section 9.8.4
Added PK parameters assessed as secondary endpoints for adolescent 
subjects who provided intensive PK sample at Visit 3/Week 1. The 
secondary PK endpoint for all subjects who received maribavir will be 
maribavir C min(predose maribavir concentration).Synopsis , Section 9.10.3
Per CTFG requirements, added an additional pregnancy test at 4 w eeks 
(Visit 6/ Week 4) so that tests are performed at a regular interval. Table 1, Secti on7.1.2
Added intensive PK sampling schedule for adolescents. Table 1 (footnote “o”), 
Section 7.2.4.1
Added text for the study rationale regarding pediatric subjects. Section 2.2
For non-commercial use only
Take da CONFIDENTIAL Page 160
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
02 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added recommendations related to contraception in clinical trials, per the 
clinical trial facilitation group (CTFG). Elaborated on highly effective 
method of contraception for sexually active females of childbearing 
potential participating in the study. Added that vasectomized male partner 
is a highly effective birth control method provided that partner is the sole 
sexual partner of the female trial participant who is of childbearing 
potential and that the vasectomized partner has received medical 
assessment of the surgical success.Section 4.4.1
Added the following to male contraception per the Clinical Trial 
Facilitation Group requirements (CTFG):
“Male subjects will be required to use a condom in conjunction with a 
highly effective method of birth control for their female partners of 
childbearing age. Both male participant s and their female partners must 
use this form of birth control from the time prior to first dosing until 90 
days after the last dose of study treatment (ie, maribavir or 
valganciclovir). For male subjects, sexual intercourse with pregnant 
partners should also be avoided during the course of the study unless 
condoms are used from the time prior to the first dose until 90 days after 
the last dose of study treatment. Male subjects must not donate sperm 
until 90 days after the last dose of study treatment”.Section 4.4.2
Added caution and recommendation for careful monitoring of 
concentration levels of concomitant medications that are substrates of 
CYP2C19 and P -gp both after initiation of maribavir (when substrate 
levels may increase) and after discontinuatio n of maribavir (when 
substrate levels may decrease), in alignment with the guidance to the 
investigators provided in the maribavir investigator’s brochure.Section 5.2.1
Added caution for concomitant use of potent inhibitors of CYP 3A4 and 
emphasized proh ibition of potent inducers of Cytochrome P450 (CYP) 
3A4 and/or P -glycoprotein (P -gp), in alignment with the guidance to the 
investigators provided in the maribavir investigator’s brochure.Section 5.2.1, Section 5.2.2
Corrected error in cited w eek number for end of study visit. Section 7.1.3
Added additional clinical laboratory evaluations for:
Hem atology: manual differential results for band neutrophils, basophils, 
eosinophils, lymphocytes, monocytes, segmented neutrophils, and total 
neutrophils.
Urinalysis: leukocyte esterase in the microscopic evaluation.
Other: i mmunoglobulins IgG and immunoglobulins total (a total of IgG + 
IgA + IgM) with no reference ranges associated with the 
immunoglobulins total value.Section 7.2.3.5
 
 
For non-commercial use only
Take da CONFIDENTIAL Page 161
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Protocol Am endment
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
02 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added the additional blood draw  volume required for intensive PK 
sampling for adolescents:
“Subjects betw een the ages of 12 to <18 years will have an additional 
24mL of blood drawn for intensive PK visits.”Section 7.2.5, Table 8
Amended Section 8.2.7 to include fatal outcomes:
“The study population is HSCT recipients with CMV infections. The 
following SAEs are common in this study population and are anticipated 
to occur, hence these SAEs (including fatal outcome) will not be 
considered unexpected and will not be individually reported to the 
regulatory agencies, IRBs, Ethics Committees, and investigators, 
provided there is no increased frequency of these events*:
Any CMV infection, including CMV reactivation/recurrence, 
Any other viral, bacterial, or fungal infection
Acute and chronic GVHD”
Reactivation/progression of the malignancy or other disease, 
which is an underlying disease, that led to the transplant
This includes fatal outcomes of the aforementioned SAEs.
*Maribavir Phase 2 (studies 1263 -202 and 1263 -203) data will be used as 
reference.Section 8.2.7
Added reference to updated industry regulation: Integrated Addendum to 
ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2) Current Step 
4 version dated 09 November 2016.Section 10.1.1, Section 10.2.1
Updated the table in Appendix 3 w ith the followi ng pUL97 substitutions: 
D456N, M460L, C480R, P521L, C592F, L595T, N597D/I, G598D/V, 
and C603Y and the following pUL54 substitutions: L862F, D879G, and 
A972V.Section 12 
Applied editorial changes throughout the document for clarity. Synopsis and Sections, as needed
For non-commercial use only
Take da CONFIDENTIAL Page 162
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 2CHILD -PUGH CLASSIFI CATION OF CHRONIC LI VER DISEASE
Table A1 Child -Pugh Classification of Chronic Liver Disease
Score Bilirubin
(mg/dL)Albumin
(gm/dL)INR Hepatic Encephalopathy
(grade)Ascites
(grade)
1 <2 >3.5 <1.7 None None
2 2-3 2.8-3.5 1.7 -2.2Mild
(controlled medically)Mild
(controlled medically)
3 >3 <2.8 >2.2Marked
(poor control)Marked
(poor control)
Child -Pugh Class:
A Score of 5 -6
B Score of 7 -9
C Score >9
For non-commercial use only
Take da CONFIDENTIAL Page 163
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 3CMV GENETIC MUTATION S ASSOCIATED WITH RESISTANCE TO 
ANTI CMV DRUGS
Specific mutations in the UL 97 and/or UL54 human cy tomegalovirus (HCMV) genes are 
associated with resistance to certain anti -CMV drugs (ganciclovir/valganciclovir, foscarnet, or 
cidofovir). The UL97 gene encodes a viral protein kinase, while the UL54 gene encodes a viral DNA 
polymerase.
Ganciclovir (administered intravenously , orally , or through its oral prodrug valganciclovir) is a 
guanosine analog that acts as a chain terminator once incorporated into the elongating viral DNA 
chain. In order for the drug to be incorporated into the viral DNA chain, ganciclovir first needs to be 
monophosphory lated by  the UL97 HCMV protein kinase. Cellular kinases then di -and 
tri-phosphory late the drug into a form that can be incorporated into the viral DNA chain. Mutations 
in the UL97 gene that inactivate the UL97 kinase prevent the monophosphory lation step and result in 
resistance to ganciclovir/valganciclovir. Foscarnet is a py rophosphate analog that blocks the release 
of py rophosphate by  the UL54 viral poly merase. Cidofovir is a cy tosine monophosphate analog that 
is dependent on diphosphory lation by  cellular kinases for its inhibition of viral DNA sy nthesis.
The tables below list the mutations in UL97 that are proven to confer resistance to 
ganciclovir/valganciclovir and the mutations in UL54 that confer resistance to one or multiple anti -
CMV agents, mostly  based on the phenoty ping, except in the case of deletions, that do not need to be 
confirmed due to the location of the deleted residues.
Since foscarnet and cidofovir do not require phosphory lation by  the viral UL97 kinase for their 
activit y, they  are unaffected by  mutations in the UL97 gene. Mutations in the UL54 gene that 
inactivate the viral DNA p olymerase prevent incorporation of ganciclovir/valganciclovir and/or 
cidofovir into the elongating viral DNA chain, leading to resistance to the drug(s). Similarly , 
mutations in the UL54 gene can lead to foscarnet resistance.
The tables below are the reference for the investigators while the full list of reportable mutations 
should they be found in the clinical study  analy ses will be provided in the resistance analy sis plan.
The following mutations have been determined to confer resistance to ganciclovir/va lganciclovir or 
cross -resistance to foscarnet, cidofovir or maribavir ( Campanini et al., 2012 ; 
Cherrier et al., 2018 ; Chou, 2020 ; Chou and Bowlin, 2011 ; Fischer et al., 2016 ; 
Gilbert et al., 2011 ; Harada et al., 1997 ; Van Leer Buter et al., 2019 ;Viracor, n.d. ; 
Wong et al., 2019 ). The PRS and MRS populations will be defined by  the presence of one or more of 
these mutations at study  baseline genoty pic results performed by  the central specialty  laboratory .
For non-commercial use only
Take da CONFIDENTIAL Page 164
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A2 Known Ganciclovir/Valganciclovir Resistance Mutations
UL97 Mutation Ganciclovir/Valganciclovir
F342S R (also MBV-R) 
F342Y R (also MBV- R)
V356G R (also MBV-R) 
K359E R 
K359Q R
L405P R
D456N R (also MBV- R)
M460I R
M460T R
M460V R
M460L R*
V466G R (also MBV- R)
C480F R (also MBV- R)
C480R R (also MBV- R)
C518Y R
H520Q R
P521L R (also MBV- R)
A590T Ra
del590 to 600 Ra
del590 to 603 Ra
del591 to 594 R
del591 to 607 R
A591D Ra
A591V R
C592G Rb
C592F Ra
del594 to 601 Ra
A594E R
A594G R
A594P R
A594S R
A594T R
A594V R
For non-commercial use only
Take da CONFIDENTIAL Page 165
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A2 Known Ganciclovir/Valganciclovir Resistance Mutations
UL97 Mutation Ganciclovir/Valganciclovir
L595F R
L595S R
L595W R
L595T Ra
del595 R
del595 to 603 R
del596 R
E596G R
E596Y R
del597 to 598 R
del597 to 599 R
del597 to 600 Ra
del597 to 603 Ra
N597I Ra
G598S R
G598V Ra
del599 R
K599M Ra
K599T R
del599 to 603 Ra
del600 R
del601 R
del600 to 601 R
del601 to 602 R
del601 to 603 R
C603R R
C603S R
C603W R
C603Y Ra
A606D Ra
C607F R
C607S Ra
C607Y R
For non-commercial use only
Take da CONFIDENTIAL Page 166
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A2 Known Ganciclovir/Valganciclovir Resistance Mutations
UL97 Mutation Ganciclovir/Valganciclovir
I610T R
A613V R
del617 R (also MBV- R)
MBV=maribavir; R=resistance
aClinical isolates but unconfirmed by Marker transfer.
bAlone confers modest resistance. When found in conjunction with UL54 del 981 to 982, there is a much higher level of 
resistance.
Note: Mutations in bold letters are the most common mutations.
Table A3 UL54 Resistance Mutations, Including Cross -resistance
UL54 Mutation Cidofovir Foscarnet Ganciclovir
S290R S R S
D301N R S R
E303DaR S R
E303GaR S R
N408D R S R
N408K R S R
N408S R S R
N410K R S R
F412C R S R
F412L R S R
F412S R S R
F412V R S R
D413A R S R
D413E R S R
D413N R S R
D413YaR S R
P488R R S R
K493N R R R
N495K S R R
P497S R S R
K500N R S R
L501F R S R
L501I R S R
For non-commercial use only
Take da CONFIDENTIAL Page 167
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A3 UL54 Resistance Mutations, Including Cross -resistance
UL54 Mutation Cidofovir Foscarnet Ganciclovir
T503I R S R
A505VaR S R
K513N R S R
K513E R S R
K513R R S R
K513T R S R
D515E S S R
D515Y R S R
L516R R S R
L516P R S R
L516W R S R
I521T R S R
P522A R S R
P522S R S R
del524 R S R
V526L R S R
C539G R S R
C539R R S R
D542EaR S S
A543P R S R
L545S R S R
L545W R S R
T552N S R R
L565V R R R
Q578H R R R
Q578L S R S
S585A S R S
D588E S R S
D588N S R R
F595I S R S
T700A S R S
V715A S R S
V715M S R S
For non-commercial use only
Take da CONFIDENTIAL Page 168
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A3 UL54 Resistance Mutations, Including Cross -resistance
UL54 Mutation Cidofovir Foscarnet Ganciclovir
I726T S S R
I726VbR S R
E756K R or SbR R
E756D S R S
E756Q S R S
L773V R R R
L776M S R R
V781I S R Rb
V787A S R R
V787E R R R
V787L S R R
L802M S R R or Sb
K805Q R S S
A809V S R R
V812LaR R R
T813S R R R
T821I S R R
V823A R S R
P829S S S R
A834P R R R
T838A S R S
G841A R R R
G841S S R R
M844T S R S
M844V S R R
V946L S R S
E951D S R R
L957F S S R
del981 to 982 R R R
A987G R S R
A987V S R S
R=resistant; S=sensitive
aAlso confers resistance to brincidofovir.
bLow grade or variable resistance.
For non-commercial use only
Take da CONFIDENTIAL Page 169
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 4DEFINITIONS OF TISS UE INVASIVE CMV DISE ASE
The following definitions of CMV disease are based on a commonl y cited reference that was 
intended for application to transplant recipients ( Ljungman et al., 2017 ; please refer to the 
citation for full details on the definitions of CMV disease). Definitions often r equire clinical 
judgment regarding compatible sy mptoms or other factors. The investigator should utilize his/her 
best clinical judgment for this categorization, and apply  these definitions whenever possible for 
consistency . When reporting CMV disease, the presence of an y co-pathogens that may  be 
contributing to the organ disease must be reported as well.
Pneumonia: “CMV pneumonia” is defined b y the presence of signs and/or symptoms of 
pulmonary  disease combined with the detection of CMV in bronchoalveolar l avage fluid or lung 
tissue samples. Detection of CMV should be performed by  virus isolation, histopathologic 
testing, immunohistochemical anal ysis, or in situ hy bridization. Detection of CMV by  
polymerase chain reaction (PCR) alone may  be too sensitive for the diagnosis of CMV 
pneumonia and is therefore insufficient for this purpose. The presence of fungal copathogens, 
such as Aspergillus species, together with radiologic signs t ypical of Aspergillus pneumonia (eg, 
a halo sign or a crescent sign) indicates fungal pneumonia rather than CMV pneumonia. CMV 
documented b y culture from BAL might be used as the evidence in the absence of other 
preferred assay s.
Gastrointestinal disease: “CMV gastrointestinal disease” is defined by  the identification of a 
combinatio n of clinical symptoms from the upper or lower gastrointestinal tract, findings of 
macroscopic mucosal lesions on endoscopy , and demonstration of CMV infection (by  culture, 
histopathologic testing, immunohistochemical analy sis, or in situ hy bridization) in a 
gastrointestinal tract biopsy  specimen. Detection of CMV by  PCR alone is insufficient for the 
diagnosis of CMV gastrointestinal disease. Patients with CMV disease that involves the 
intestinal tract usually  have mucosal abnormalities that can be seen by  the endoscopist, but the 
appearance of some of these lesions is subtle. The spectrum of endoscopic lesions is variable and 
ranges from patch y erythema, exudates, and microerosions to diffusel y edematous mucosa, to 
multiple mucosal erosions, to deep ulcers and pseudotumors. The diagnostic y ield for CMV is 
higher when mucosal abnormalities are targeted for study . If CMV is detected in normal mucosa 
near a lesion consistent with those ty pical of CMV infection, this can be accepted as CMV 
gastrointestinal disea se.
Cytomegalovirus documented in blood by  PCR or antigenemia or CMV documented by  PCR 
from tissue biopsies might be used in the absence of other preferred methods of diagnosis.
For non-commercial use only
Take da CONFIDENTIAL Page 170
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Hepatitis: “CMV hepatitis” is defined by  the findings of elevated bilirubin and/or enzy me levels 
during liver function testing, absence of an y other documented cause of hepatitis, and detection 
of CMV infection (b y culture, histopathologic testing, immunohistochemical analysis, or in situ 
hybridization) in a liver biopsy  specimen. D etection of CMV by  PCR alone is insufficient for the 
diagnosis of CMV hepatitis because it can impl y the presence of transient viremia. 
Documentation of CMV (ie, by  immunohistochemical anal ysis) within the liver tissue is needed. 
Other pathogens, such as hepatitis C virus, may  be present without excluding the diagnosis of 
CMV hepatitis.
Central Nervous System disease: Cytomegalovirus “CNS disease” is defined by  the 
identification of CNS symptoms together with the detection of CMV in cerebrospinal fluid 
samples, by  culture or PCR, or in brain biopsy  specimens, by  culture, histopathologic testing, 
immunohistochemical analy sis, or in situ hy bridization.
Retinitis: The diagnosis of disease requires typical ophthalmological signs judged b y an 
ophthalmologist experienced with the diagnosis of CMV retinitis. I f the presentation is aty pical 
or an experienced ophthalmologist is not available, it is recommended that the diagnosis is 
supported by  CMV documented in vitreous fluid by  PCR. The images or retina taken du ring 
ophthalmological exam should be provided.
Nephritis : Cytomegalovirus nephritis can be defined by  the detection of CMV infection (by  
culture, immunohistochemical anal ysis, or in situ hy bridization) together with the identification 
of histologic feature s of CMV infection in a kidney  biops y specimen obtained from a patient 
with renal d ysfunction.
Cystitis : Cystitis is defined by  the detection of CMV infection (by  culture, 
immunohistochemical analy sis, or in situ hy bridization) together with the identifica tion of 
conventional histologic features of CMV infection in a bladder biops y specimen obtained from a 
patient with cy stitis.
Myocarditis: My ocarditis is defined by  the detection of CMV infection (b y culture, 
immunohistochemical analy sis, or in situ hy bridization) together with the identification of 
conventional histologic features of CMV infection in a heart biops y specimen obtained from a 
patient with my ocarditis.
Pancreatitis : The definition of CMV pancreatitis requires the detection of CMV infecti on (b y 
culture, immunohistochemical anal ysis, or in situ hy bridization) together with the identification 
of conventional histologic features of CMV infection in a pancreatic biopsy  specimen obtained 
from a patient with pancreatitis.
For non-commercial use only
Take da CONFIDENTIAL Page 171
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Other CMV disease categories : Cytomegalovirus can also cause disease in other organs, and 
the definitions of these additional disease categories include the presence of compatible 
symptoms and signs, and documentation of CMV by biops y (detection of CMV by PCR alone is 
insufficie nt), with other relevant causes excluded.
For non-commercial use only
Take da CONFIDENTIAL Page 172
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 5KARNOFSKY PERFORMAN CE STATUS SCALE
The Karnofsk y Performance Scale Index ( Table A4) a llows patients to be classified as to their 
functional impairment. This can be used to compare effectiveness of different therapies and to 
assess the prognosis in individual patients. The lower the Karnofsk y score, the worse the survival 
for most serious i llnesses.
Table A4 Karnofsky Performance Scale Index
Able to carry  on 
normal activity  and 
to work; no special 
care needed.100 Normal no complaints; no evidence of disease.
90 Able to carry  on normal activity ; minor signs or sy mptoms of 
disease.
80 Normal activity  with effort; some signs or s ymptoms of 
disease.
Unable to work; 
able to live at home 
and care for most 
personal needs; 
varying amount of 
assistance needed.70 Cares for self; unable to carry  on normal activit y or to do active 
work.
60 Requires occasional assistance, but is able to care for most of 
his personal needs.
50 Requires considerable assistance and frequent medical care.
Unable to care for 
self; requires 
equivalent of 
institutional or 
hospital care; 
disease may  be 
progressing rapidl y.40 Disabled; requires special care and assistance.
30 Severel y disabled; hospital admission is indicated although 
death not imminent.
20 Very  sick; hospital admission necessary ; active supportive 
treatment necessary .
10 Moribund; fatal processes progressing rapidl y.
0 Dead
Sources:
Crooks, V, Waller S, et al. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric 
outpatients. J Gerontol. 1991; 46: M139 -44.
de Haan R, Aaronson A, et al. Measuring quality of life in stroke. Stroke. 1993; 24:320 -7.
Hollen PJ, Gralla RJ, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapi es. 
Cancer. 1994; 73: 2087 -98.
O'Toole DM, Golden AM. Evaluating cancer patients for rehabilita tion potential. West J Med. 1991; 155:384-7.
Oxford Textbook of Palliative Medicine, Oxford University Press. 1993; 109.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin 
Oncology. 1984; 2 :187-93.
For non-commercial use only
Take da CONFIDENTIAL Page 173
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 6
For non-commercial use only
Take da CONFIDENTIAL Page 174
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 7ACUTE GRAFT -VERSUS- HOST DISEASE: CLINICAL STAGING AND 
GRADING
The clinical staging and grading of acute GVHD is done through evaluation of the s kin, liver, 
and gastrointestinal tract (upper and lower) ( Harris et al., 2016 ).
Table A6 GVHD Target Organ Staging
Stage Skin (Active Erythema Only) Liver
(Bilirubin)Upper GI Lower GI (stool 
output/day)
0No active (erythematous) GVHD 
rash<2mg/dL No or intermittent 
nausea, vomiting, 
or anorexiaAdult: <500 mL/day or 
<3episodes/day
Child: <10 mL/kg/day or 
<4episodes/day
1Maculopapular rash
<25% BSA2-3mg/dL Persistent nausea, 
vomiting or 
anorexiaAdult: 500 -999mL/day or 
3-4episodes/day
Child: 10 -19.9 mL/kg/day or 
4-6episodes/day
2Maculopapular rash
25-50% BSA3.1-6mg/dL Adult: 1000 -1500 mL/day or 
5-7episodes/day
Child: 20-30mL/kg/day or 
7-10episodes/day
3Maculopapular rash
>50% BSA6.1-15mg/dL Adult: >1500 mL/day or 
>7episodes/day
Child: >30 mL/kg/day or 
>10episodes/day
4Generalized erythroderma
(>50% BSA) plus bullous 
formation and desquamation >5% 
BSA>15mg/dL Severe abdominal pain with 
or without ileus or
grossly bloody stool 
(regardless of stool volume)
BSA=body surface area; GI=gastrointestinal; GVHD=graft -versus -host disease
Overall clinical grade (based on most severe target organ involvement):
Grade 0: No stage 1 -4 of any organ.
Grade I: Stage 1-2 skin without liver, upper GI, or lower GI involvement.
Grade II: Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI.
Grade III: Stage 2 -3 liver and/or stage 2 -3 lower GI, with stage 0 -3 skin and/or stage 0 -1 upper GI.
Grade IV: Stage 4 skin, liver, or lower GI involvement, with stage 0 -1 upper GI.
Source: Table 1, Harris et al., 2016
The differences in GVHD diagnosis make it challenging to conduct multicenter trials because of 
the dif ﬁcult y determining whether a patient trul y experienced GVHD. To address these varying 
practices, Harris et al. ( 2016 )developed a structure for collecting granular GVHD data and 
assigning con ﬁdence levels for the attribution of sy mptoms to GVHD based on the treatment 
decisions made b y the clinician.
For non-commercial use only
Take da CONFIDENTIAL Page 175
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A7 Confidence Level Criteria
Confidence 
LevelPathologic 
EvidenceClinical Assessment Treatm ent for 
Acute GVHDComments
Confirmed Unequivocal 
pathologic 
evidence of GVHDGVHD is the 
etiology for 
symptomsNot applicable GVHD is clearly present even 
if other etiologies may coexist 
simultaneously.
Probable Not required GVHD most likely 
etiology for 
symptoms (as 
evidenced by 
treatment being 
provided)Yes GVHD is most likely present, 
but other etiologies may also 
explain the symptoms, and 
there is insufficient evidence to 
make a confirmed diagnosis.
Possible Not required GVHD in 
differential diagnosis
(but no treatment is 
being provided)No GVHD may be present, but 
other etiologies are favored to 
the degree that GVHD 
treatment is not initiated.
Negative Unequivocal 
evidence of a 
diagnosis other 
than GVHD (eg, 
drug rash)GVHD is not 
considered as an 
explanation for the 
symptomsNo and the 
symptoms 
resolve without 
GVHD 
treatmentA “negative” biopsy (eg, 
norm al skin) is not unequivocal 
evidence of a diagnosis other 
than GVHD.
Source: Table 2, Harris et al., 2016
For non-commercial use only
Take da CONFIDENTIAL Page 176
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 8RECOMMENDATIONS FOR CHRONIC GVHD DIAGNO SIS AND 
GRADING
A. Organ Scoring of Chronic GVHD as published in NIH GVHD Consensus for GVHD 
Consensus for Clinical Trials: I . The 2014 Diagnosis and Staging Working Group Report, 
Jagasia et al., 2015 (Figure 1).
Figure A-1. Organ Scoring of Chronic GVHD
For non-commercial use only
Take da CONFIDENTIAL Page 177
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Figure A-1. Organ Scoring of Chronic GVHD (continued)
For non-commercial use only
Take da CONFIDENTIAL Page 178
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Figure A-1. Organ Scoring of Chronic GVHD (continued)
ADL=activities of daily living; ALT=alanine aminotransferase; AP=alkaline phosphatase ; BSA=body surface area; 
ECOG=Eastern Cooperative Oncology Group; FEV1=forced expiratory volume in 1 second; GVHD= graft -versus -host -
disease ; 
KPS=Karnofsky Performance Status; LFTs=liver function tests; LPS=Lansky Performance Status; ULN=normal upper limit.
* Weight loss within 3 months.
† Skin scoring should use both percentage of BSA involved by disease signs and the cutaneous features scales. When a 
discrepancy exists between the percentage of total body surface (BSA) score and the skin feature score, OR if 
superficial sclerotic features are present (Score 2), but there is impaired mobility or ulceration (Score 3), the higher 
level should be used for the final skin scoring.
‡ To be completed by specialist or trained medical providers (see Supplementary Fig ure: Figure A-2).
** Lung scoring should be performed using both the symptoms and FEV1 scores whenever possible. FEV1 should be used 
in the final lung s coring where there is discrepancy between symptoms and FEV1 scores.
For non-commercial use only
Take da CONFIDENTIAL Page 179
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Figure A-2. Supplemental Genital Tract Chronic GVHD Scoring and Supplemental Skin 
GVHD Scoring (supplemental material for Jagasia et al. [ 2015 ], Figure 1.)
For non-commercial use only
Take da CONFIDENTIAL Page 180
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
B. NIH Severity Grading of Chronic GVHD as published in NIH GVHD Consensus for 
GVHD Consensus for Clinical Trials: I. The 2014 Diagnosis and Staging Working Group 
Report (Table 2 in the supplemental material for Jagasia et al. [ 2015])
Table A8 NIH Global Severity of Chronic GVHD
Mild chronic GVHD
1 or 2 organs involved with no more than score 1 plus
Lung score 0
Moderate chronic GVHD
3 or more organs involved with no more than score 1
OR
At least 1 organ (not lung) with a score of 2
OR
Lung score 1
Severe chronic GVHD
At least 1 organ with a score of 3
OR
Lung score of 2 or 3
Key points:
In skin: higher of the 2 scores to be used for calculating global severity.
In lung: FEV1 is used instead of clinical score for calculating global severity.
If the entire abnormality in an organ is noted to be unequivocally explained by a non -GVHD 
documented cause, that organ is not included for calculation of the global severity.
If the abnormality in an organ is attributed to multifactorial causes (GVHD plus ot her 
causes) the scored organ will be used for calculation of the global severity regardless of the 
contributing causes (no downgrading of organ severity score).
Source: Table 2, Jagasia et al., 2015
For non-commercial use only
Take da CONFIDENTIAL Page 181
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
APPENDIX 9DIAGNOSTIC CRITERIA FOR CHRONIC GVHD
A. Signs and Symptoms of Chronic GVHD (Table 1 in Jagasia et al., 2015)
Table A9 Signs and Symptoms of Chronic GVHD
Organ or Site Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
Chronic GVHD)Distinctivea(Seen in 
Chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)Other Features or 
Unclassified EntitiesbComm onc(Seen 
with Both Acute 
and Chronic 
GVHD)
Skin Poikiloderma
Lichen planus –like 
features
Sclerotic features 
Morphea- like 
features
Lichen sclerosus –
like featuresDepigmentation
Papulosquamous lesionsSweat impairment
Ichthyosis
Keratosis pilaris
Hypopigmentation
HyperpigmentationErythema
Maculopapular 
rash
Pruritus
Nails Dystrophy
Longitudinal ridging, 
splitting or brittle features
Onycholysis
Pterygium unguis
Nail loss (usually 
symmetric, affects most 
nails)
Scalp and body 
hairNew  onset of scarring or 
nonscarring scalp 
alopecia (after recovery 
from chemoradiotherapy)
Loss of body hair
ScalingThinning scalp hair, 
typically patchy, coarse 
or dull (not explained 
by endocrine or other 
causes)
Prem ature gray hair
Mouth Lichen planus –like 
changesXerostomia
Mucoceles
Mucosal atrophy
Ulcers
PseudomembranesGingivitis
Mucositis
Erythema
Pain
Eyes New  onset dry, gritty, or 
painful eyes
Cicatricial conjunctivitis
KCS
Confluent areas of 
punctate keratopathyPhotophobia
Periorbital 
hyperpigmentation
Blepharitis (erythema of 
the eyelids with edema)
For non-commercial use only
Take da CONFIDENTIAL Page 182
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A9 Signs and Symptoms of Chronic GVHD
Organ or Site Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
Chronic GVHD)Distinctivea(Seen in 
Chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)Other Features or 
Unclassified EntitiesbComm onc(Seen 
with Both Acute 
and Chronic 
GVHD)
Genitalia Lichen planus –like 
features
Lichen sclerosus –
like featuresErosions
Fissures
Ulcers
Females Vaginal scarring or 
clitoral/labial 
agglutination
Males Phimosis or 
urethral/meatus 
scarring or stenosis
GI Tract Esophageal web
Strictures or stenosis 
in the upper to mid 
third of the 
esophagusExocrine pancreatic 
insufficiencyAnorexia
Nausea
Vom iting
Diarrhea
Weight loss
Failure to thrive 
(infants and 
children)
Liver Total bilirubin, 
alkaline 
phosphatase 
>2×upper limit of 
norm al
ALT >2 ×upper 
limit of normal
Lung Bronchiolitis 
obliterans diagnosed 
with lung biopsy
BOSdAir trapping and 
bronchiectasis on chest 
CTCryptogenic organizing 
pneumonia
Restrictive lung 
diseasee
Muscles, 
fascia, jointsFasciitis
Joint stiffness or 
contractures 
secondary to 
fasciitis or sclerosisMyositis or polymyositisfEdema
Muscle cramps
Arthralgia or arthritis
For non-commercial use only
Take da CONFIDENTIAL Page 183
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A9 Signs and Symptoms of Chronic GVHD
Organ or Site Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
Chronic GVHD)Distinctivea(Seen in 
Chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)Other Features or 
Unclassified EntitiesbComm onc(Seen 
with Both Acute 
and Chronic 
GVHD)
Hem atopoietic 
and ImmuneThrombocytopenia
Eosinophilia
Lymphopenia
Hypo-or hyper -
gammaglobulinemia
Autoantibodies (AIHA, 
ITP)
Raynaud's phenomenon
Other Pericardial or pleural 
effusions
Ascites
Peripheral neuropathy
Nephrotic syndrome
Myasthenia gravis
Cardiac conduction 
abnormality or 
cardiomyopathy
AIHA=autoimmune hemolytic anemia; ALT=alanine aminotransferase; BOS=bronchiolitis obliterans syndrome; 
GVHD=graft -versus -host disease; ITP=idiopathic thrombocytopenic purpura.
aIn all cases, infection, drug effect, malignancy, or other causes must be excluded.
bCan be acknowledged as part of the chronic GVHD manifestations if diagnosis is confirmed.
cCommon refers to shared features by both acute and chronic GVHD.
dBronchiolitis obliterans syndrome can be diagnostic for lung chronic GVHD only if dis tinctive sign or symptom 
present in another organ (see text).
ePulmonary entities under investigation or unclassified.
fDiagnosis of chronic GVHD requires biopsy.
Source: Table 1, Jagasia et al., 2015
For non-commercial use only
Take da CONFIDENTIAL Page 184
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
B. Histological Criteria for GVHD by Organ System according to NIH Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft -versus -Host 
Disease: II. The 2014 Pathology  Working Group Report (Table 1 in 
Shulman et al., 2015 ). Chronic GVHD is supported by  histologic evidence of GVHD 
from an y affected site. Investigators are expected to consider recommendations for 
chronic GVHD diagnosis including not only  clinical but histological evidence.
Table A10 Histological Criteria for GVHD by Organ System
Organ or SystemMinim al Criteria for 
Acute/Active GVHDa Specific Criteria for Chronic GVHDb
LiverGlobal assessment of 
dysmorphic or destroyed small 
bile ducts ±cholestasis, lobular 
and portal inflammationDuctopenia, portal fibrosis, chronic 
cholestasis reflect chronicity but are not 
specific for chronic GVHD
GIVariable apoptotic criteria 
(≥1/piece) in cryptsDestruction of glands, ulceration or 
submucosal fibrosis may reflect severe or 
long-standing disease but are not specific for 
chronic GVHD
Skin, in generalApoptosis in epidermal basal 
layer or low er Malphigian layer 
or infundibulum/outer root 
sheath/hair bulge of hair follicle 
or acrosyringium/sweat 
ducts ±lichenoid 
inflammation ±vacuolar 
change ±lymphocytic satellitosis
Skin, lichen 
planus –likeCom bination of epidermal 
orthohyperkeratosis, hypergranulosis and 
acanthosis resembling lichen 
planus ±lichenoid inflammation and/or 
vacuolar changes of eccrine units
Skin morpheic 
(localized or 
diffuse)Thickening and homogenization of collagen 
bundles throughout reticular dermis or 
pandermal sclerosis with overlying interface 
changes ± thickening and homogenization of 
subcutaneous septa
Skin, lichen 
sclerosus –likeHom ogenization ±sclerosis of papillary 
dermal collagen with overlying interface 
changes including melanophages in the 
papillary dermis and sparse lymphocytic 
infiltrate
Skin, fasciitisThickening of fascial septa with adjacent 
inflammation ±sclerosis of subcutis
For non-commercial use only
Take da CONFIDENTIAL Page 185
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Table A10 Histological Criteria for GVHD by Organ System
Organ or SystemMinim al Criteria for 
Acute/Active GVHDa Specific Criteria for Chronic GVHDb
Oral/oropharyngeal
mucosa and 
conjunctivaLichenoid interface lymphocytes 
with infiltration of mucosa 
(exocytosis) and variable 
apoptosisc
Minor salivary or 
lacrimal glandPeriductal lymphocytic infiltrate w ith 
infiltration and damaged intralobular ducts, 
fibroplasia in periductal stroma, mixed 
lymphocytic and plasmacytic inflammation 
with destruction of acinar tissued
LungCBO: dense eosinophilic scarring beneath the 
respiratory epithelium, resulting in luminal 
narrow ing or complete fibrous obliteration. 
May be preceded by lymphocytic bronchiolitis 
without intraluminal fibrosise
KidneyMem branous nephropathy, minimal change 
disease
Lesions of Uncertain Pathogenesis
Lung COP
Skeletal Muscle Myositis
CBO=constrictive bronchiolitis obliterans; COP=cryptogenic organizing pneumonia; 
GVHD= graft -versus -host -disease
aConditions that result in lesser degrees of change include immunosuppressive treatment, biopsy very soon after 
onset of signs, suboptimal or small tissue sample, insufficient serial sectioning, confounding infection, drug 
reaction, or inflammatory conditions.
bAfter the diagnosis of chronic GVHD has been established or following immunosuppressive treatment, the 
histological manifestations of active disease may meet only minimal diagnostic criteria for activity. Different 
manifestations of cutaneous chronic GVHD may all be present together in 1 biopsy or in separate but concurrent 
biopsies.
cInflammation of the oral mucosa and within the minor salivary glands may persist from prior chemo -irradiation or 
prior inflammation. The distinction between acute and chronic GVHD requires the addition of distinctive oral 
manifestations.
dThe distinction of past acinar destruction and fibrosis from ongoing chronic GVHD activity can be difficult and 
relies on assessing lobules that are not completely fibrotic. Acinar and periductal inflammation with features of 
damage to ducts, such as vacuolar change, lymphocytic exocytosis nuclear dropout, dyspolarity or ap optosis, and 
resultant fibroplasia indicate chronic GVHD activity.
eConstrictive bronchiolitis obliterans should be distinguished from cryptogenic organizing pneumonia, which is 
also associated with GVHD but has a different clinicopathologic presentation and a more favorable outcome.
Source: Table 1, Shulman et al., 2015
For non-commercial use only
Take da CONFIDENTIAL Page 186
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
C. Recommendations for Final Diagnosis Categories of GVHD (Table 2 in 
Shulman et al., 2015 )
Table A11 Recommendation for Final Diagnosis Categories
Category Definition Examples Comments
Not GVHD No evidence for GVHD
Possible 
GVHDEvidence of GVHD but other 
possible explanationsObvious CMV enteritis with 
inclusions near the apoptotic changes
Focal colonic ulcers with marked 
apoptotic cryptitis and destruction of 
crypts associated with use of MMF
Coinfection with known active viral 
hepatitis
Clinical features which suggest or 
favor a drug reactionIndicate possible 
alternate 
diagnoses and 
reasons for 
suspicion
Likely 
GVHDClear evidence of GVHD 
without a competing cause of 
injury
OR
Clear evidence of GVHD with 
mitigating factors
OR
GVHD most likely diagnosis but 
relevant clinical information is 
limited
OR
GVHD is validated by 
sequential biopsy or by absence 
of competing diagnosisAbundant epithelial apoptosis 
without clinical or histological 
evidence of drug injury or infection
Evidence of CMV yet abundant 
apoptotic epithelial changes that are 
not associated with CMV infected 
cells by immunostaining
Single or rare apoptotic epithe lial 
changes without other features of 
active GVHD and no alternative 
explanations
Limited sample or minimal or focal 
findings
Proximity to recent chemotherapy or 
radiotherapyIncluded old 
categories of 
“consistent with” 
and 
“unequivocal” 
GVHD
CMV=cytomegalovirus; GVHD= graft -versus -host -disease ; MMF=mycophenolate mofetil
Source: Table 2, Shulman et al., 2015
For non-commercial use only
Take da CONFIDENTIAL Page 187
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Am endment 9 15 Sep 2021
APPENDIX 10BACTERIAL AND FUNGA L INFECTIONS ASSESSM ENT
In Hematopoietic Stem Cell Transplant (HSCT) population post -transplant infection remains a 
significant cause of morbidity  and mortality, particularly  after allogeneic transplantation. While 
the expected period of profound neutropenia after HSCT usually  occurs during the pre -
engraftment stage, normal neutrophil recovery  is not alway s possible as neutrophil count is 
adversel y affected b y other risk factors and comorbidities, such as graft failure or rejecti on, 
GVHD, relapse of the underly ing neoplasm, drug -induced my elosuppression and concomitant 
infections ( Klumpp, 1993).
Due to the gradual immune sy stem reconstitution HSCT recipients are vulnerable to various 
opportunistic viral, bacterial or fungal pathogens at different stages after the transplant 
(Tombly n et al., 2009 ). Opportunistic infection is defined as an y infection that occurs with 
increased frequency  or severity  in HSCT population ( Dykewicz, 2001 ).
Figure A-3. Phases of Opportunistic Infections Among Allogeneic HSCT Recipients
EBV=Epstein -Barr virus; HHV=human herpes virus; HSCT=Hematopoietic Stem Cell Transplant; 
PTLD=post- transplant lympho -proliferative disease
Phase I: <15 -45 days post -transplant; Phase II: 30 -100 days post- transplant; Phase III: >100 days after HSCT.
Source: Figure 1, Tomblyn et al., 2009 .
For non-commercial use only
Take da CONFIDENTIAL Page 188
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Infectious complications are most frequent in the pre -engraftment period due to cy topenias and 
immune ablation and immune suppression but may continue for months or years in HSCT 
recipients with delay ed immune reconstitution ( Majhail et al., 2012 ). During the earl y 
post-transplant period HSCT recipients are susceptible to bacteremia and fungal infections with 
Candida and Aspergillus species, along with herpes simplex virus (HSV) reactivation. Candida 
often causes superficial skin infection (thrush), with rare occasions of invasive disease 
manifested as esophagitis, endocarditis or hepatosplenic dis ease.
During the early  postengraftment phase infections relate primarily  to impaired cell -mediated 
immunity , which is influenced b y a history  of GVHD and the requirement for ongoing 
immunosuppression. The predominant organisms in this phase are herpesvirus es, along with 
Pneumocystis jiroveci and Aspergillus species. In the late postengraftment period common 
pathogens include CMV, VZV and infections with encapsulated bacteria, such as Streptococcus 
pneumonia, Haemophilus influenzae (Tombly n et al., 2009 ; Majhail et al., 2012 ).
Prolonged neutropenia in the pre -engraftment phase results is a substantial risk for bacterial and 
fungal infections, and has been the most important risk factor for invasive aspergillosis 
(Schwartz et al., 1984 ; Salzberger et al., 1997; Marr et al., 2002 ).
The most common bacterial infections in neutropenia are provided in the table below.
Table A12 Common Bacterial Pathogens in Neutropenic Patients
Comm on gram -positive pathogens Coagulase -negative staphylococci
Staphylococcus aureus , including methicillin -resistant strains
Enterococcus species, including vancomycin -resistant stains
Viridans group streptococci
Streptococcus pneumoniae
Comm on gram -negative pathogens Escherichia coli
Klebsiella species
Enterobacter species
Pseudomonas aeruginosa
Citrobacter species
Acinetobacter species
Stenotrophomonas maltophilia
Source: Table 1; Freifeld et al., 2011
For non-commercial use only
Take da CONFIDENTIAL Page 189
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
Fever during neutropenia in immunocompromised patients may  be the onl y indication of a 
severe underl ying infection, because signs and symptoms of inflammation ty picall y are 
attenuated; pulmonary  infection may  have no signs on infiltrates on radiographs, CS F 
pleocy tosis might be low or absent in the setting of meningitis. The guidance document for 
management of neutropenic patients with fever ( Freifeld et al., 2011) also provides the details of 
the evidence to be used for the confirmation of the relevant bacterial or viral infection.
In this stud y, a history of infections, including ongoing infections at baseline, will be 
documented as part of the subject’s medical history . Any  new infections that occur during the 
course of the stud y will be recorded as adverse events. I t is recommended that bacterial and 
fungal infections diagnosed as possible/probable or proven per the criteria described b y 
Boeckh et al. ( 2015)
 are reported.
FUNGAL INFECTIONS
A.Aspergillus spp. or other mold infection:
Proven: Clinical signs and symptoms plus a tissue biopsy  revealing growth of an 
organism or positive histopathology .
Probable : Clinical signs and sy mptoms with bronchoalveolar lavage (BAL) y ielding 
positive growth or positive histopathology .
Possible : at least 3 clinical signs or s ymptoms and growth of an organism from 
nonsterile fluid (ie, sputum).
B.Candida spp. or other yeast (eg, T. glabrata):
Proven fungemia : Any  single positive blood culture that is culture positive for 
Candida spp. or T.glabrata. [Not e: Removal of indwelling catheters is strongl y 
encouraged.]
Tissue documented : Clinical signs and s ymptoms compatible with invasive y east 
infection and a positive culture from a normally  sterile site with histologic evidence of 
tissue invasion (definite) or positive culture from sterile site without histologic 
evidence of invasion (probable).
BACTERIAL INFECTIONS
A.Bacteremia:
Any single positive blood culture that is culture positive for bacterial pathogens 
consistent with a serious bloodstream infection.
Urinary  tract infections will not be captured as opportunistic infections of interest.
For non-commercial use only
Take da CONFIDENTIAL Page 190
Maribavir 
Clinical Study Protocol: SHP620 -302 Protocol Amendment 9 15 Sep 2021
B.Invasive Bacterial Tissue Infection:
Clinical signs and s ymptoms compatible with disease (sinusitis, pneumonia, 
intra-abdominal abscess)
and
Radiographic evidence of dis ease and pure or predominant culture or pathogen 
detection from a sterile site biopsy .
Pathogen detection in respiratory  secretion or sinus aspirates or CSF specimens will be 
considered if they  are predominant and compatible with the clinical picture.
For non-commercial use only